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ABSTRACT
Diseases affecting the cartilage and/or bone, including osteoarthritis (OA), are the
most prevalent musculoskeletal tissue pathologies. OA is the result of cartilage
degradation, altered sub-chondral bone, impaired joint mobility and severe pain - making
it one of the leading causes of disability worldwide. While OA is stereotypically
described as a physical wear and tear disease, mounting evidence suggests that synovial
inflammation significantly contributes to its pathogenesis. In OA, macrophages infiltrate
the synovium and secrete supra-physiological levels of pro-inflammatory cytokines,
which create a caustic joint environment promoting articular cartilage degradation. Due
to the pro-inflammatory characteristics of OA, the immunomodulatory potential of stem
cells likely represents an under investigated therapeutic alternative.
The purpose of this research was to investigate if stem cells from the amniotic
membrane (a tissue routinely discarded after the birth of term pregnancies) represent an
efficacious alternative cell source for future OA therapies. This was achieved by directly
comparing the abilities of human amniotic membrane derived stem cells and a commonly
employed stem cell, human adipose derived stem cells, with regards to osteogenic and
chondrogenic differentiation potential as well as the ability to mitigate OA disease
progression both ex vivo and in vivo.
Our results demonstrate stem cells from the amniotic membrane exhibit
heightened differentiation potential, higher yields, enhanced immunomodulatory
properties, and the ability to induce pro-regenerative (M2) phenotypes within
macrophages, in OA experimental models. Additionally, amnion stem cells appeared to
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offer accelerated treatment time lines compared to adipose derived stem cells. For these
reasons, we believe amnion membrane derived stem cells are an efficacious stem cell
source for OA therapeutic approaches.
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CHAPTER ONE
Background & Significance
1.1 Stem Cells & Orthopedic Regenerative Medicine
Musculoskeletal disorders represent the largest disease subset in the U.S.
population, as recent reports estimate that 50% of the U.S. population (approximately 110
million individuals) suffers from at least one musculoskeletal tissue pathology.1 Due to
increases in life expectancy these estimates are expected to rise.1,2 Direct costs associated
with musculoskeletal disease management have been estimated upwards of $510 billion.1
Additionally indirect costs, including lost wages, are estimated near $350 billion.1
Moreover, the societal costs covering the care of such conditions (hospitals, physicians,
therapists, caregivers, etc.) near $1 trillion.1 Though physical therapy and non-invasive
treatment options are often initially pursued, many patients require further intervention.
Orthopedic surgical intervention typically occurs when the conservative
management of musculoskeletal tissue pathologies has failed. Such surgeries usually
involve the replacement of native tissue(s) with biological or metal implants.3,4
Musculoskeletal tissue grafts have demonstrated only limited success.3 Metal-based
orthopedic replacements fail prematurely with the potential for biological incompatibility
due to the generation of metal wear debris particles.3,4 In light of these shortcomings,
recent research in the field of orthopaedic regenerative medicine has turned to the use of
biologic therapies, including stem cell-based therapies.3–7 Clinically, these cells could be
used alone or in combination with either synthetic or natural scaffolds in order to mitigate
progression of disease or to promote the repair or regeneration of damaged
musculoskeletal tissues. Numerous stem cell sources have been evaluated, yet currently
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no single stem cell source has been identified as being ideal for any specific orthopaedic
application (i.e. regeneration of bone, cartilage, muscle, tendon, etc.…).
However, evidence is starting to emerge which may suggest preferential tissuespecific lineage differentiation of adult and perinatal stem cells.6,8,9 While it may stand to
reason that adult stem cells derived from the target tissue (i.e. the tissue to be repaired /
regenerated) may be optimal; the possibility that these stem cells have 1) also succumb to
damage or disease and 2) are only available in limited quantities make them less than
ideal for clinical use.5,10–12 It has been widely accepted that stem cells must be
administered in large quantities to demonstrate clinical efficacy. However, only recently
has clinical evidence emerged from the orthopedic community suggesting therapeutic
benefit is only achieved when stem cell are administered in high doses.13 In light of this
need for large quantities of cells, it has been suggested that the ex vivo expansion of
mesenchymal stem cells (MSCs) makes them suited for orthopedic applications.4,5,14
However, ex vivo expansion exposes cells to increased possibilities of contamination,
alterations to their phenotype and differentiation potentials, and a potentially delayed
administration.15–17 Thus, a stem cell source requiring limited (or no) ex vivo expansion
in order to achieve clinically significant numbers would be preferred. Accordingly, stem
cells with both demonstrated orthopedic applications and high yield isolations, both
discussed herein, would be most clinically relevant.
1.1.1 The Need For Orthopedic Regenerative Medicine
According to the American Academy of Orthopedic Surgeons, over 2 million
musculoskeletal tissue repairs are performed in the US, annually.18 Many of these repairs
rely on tissue grafts or metal implants in order to reduce pain and restore tissue function.
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Tissue grafts have been shown to fail due to incomplete filling of the defect, failed
resorption (bone), or lack of host tissue integration.3,19 Tendon grafts, specifically, do not
adequately reproduce the tendon-bone interface, limiting the strength and functionality of
the graft.4 Additionally, there have been reports of allogeneic musculoskeletal tissue graft
rejection.3,4 Implanted biomaterials have finite lifespans, increasing patient morbidity
through the resulting necessary re-operation.4 Metal implants in particular, have the
potential to elicit an immune response through metal debris particles and metal implant
infection typically necessitates a re-operation to remove the implant.3,4
Alternative methods address not only the restoration of musculoskeletal tissue
function but also aim towards host tissue integration and regeneration. For example, in
osteochondral defect repair, the micro-fracture technique punctures the sub-chondral
bone allowing bone marrow to leak into the repaired area, accelerating healing.4,5
Autologous cartilage transplantation has also been utilized for enhanced cartilage defect
repair.4 Additionally, tissue-engineered materials (ex. calcium sulfate pellets, methyl
methacrylate, collagen and hydroxyapatite (HA) have been utilized as bone fillers in bone
defect repair.19 A developing area of research over the past twenty years has been
platelet-rich plasma (PRP). PRP therapies involve the autologous administration of the
patient’s own concentrated plasma.20,21 As platelets play a significance role in natural
wound healing (via cell recruitment and growth factor secretion), the administration of
PRP has the potential to enhance healing of various orthopedic injuries.21 Growing
evidence supports accelerated healing and/or enhanced tissue regeneration in bone,
muscle and tendon injuries after PRP injection therapy.20,21
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1.1.2 Stem Cells: The Future for Orthopedic Regenerative Medicine?
Stem cells have been proposed as an intriguing alternative for orthopedic
regenerative medicine due to their musculoskeletal tissue differentiation and
immunomodulatory capacities. Most musculoskeletal tissues have limited capacity for
self-renewal.6 Therefore, stem cells could be considered as alternative healthy cells
within target tissues, potentially leading to replenished host cell populations and tissue
regeneration. Additionally, as some musculoskeletal tissue disorders, such as arthritis,
have an identified immune component; paracrine or juxtacrine stem cell effects could
assist in disease modulation.4,7,11
In addition to the hypothesized benefits of stem cell therapies, experimental
evidence supports their beneficial use in orthopedics. As previously mentioned, the
micro-fracture technique in osteochondral defect repair introduces bone marrow to the
defect repair area, promoting tissue healing by exposing the area to bone marrow stem
cells.4,5 MSCs have also been used successfully as a therapy for delayed fracture union,
non-unions, arthrodesis, and bone defects.6 The autologous chondrocyte transplantation
technique has been employed with not only autologous chondrocytes, but chondrocyte
precursor cells, periosteum and stem cells, as well.4 Preliminary cohort studies have
demonstrated that MSC administration is at least as effective as autologous chondrocyte
transplantation.22 High dose stem cell therapies have also been employed in the treatment
of rheumatoid arthritis and other rheumatic diseases, with positive outcomes.4 Though
beyond the scope of our review, there are also numerous animal studies employing stem
cells that show mitigation of musculoskeletal disease progression and/or tissue
regeneration.3–6 Interestingly, animal studies comparing the efficacy of current orthopedic
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regenerative medicine techniques (periosteal graft, mosaicplasty, and autologous
chondrocyte transplantation) to stem cell therapy, show stem cell therapy is superior to
periosteal grafts and mosaicplasty.23

1.2 Basic Stem Cell Characteristics
Stem cells, by definition, must demonstrate potency (the ability to differentiate
into target tissue cell types) and self-renewal (the ability to both proliferate and generate
progeny stem cells).9,24 The minimal criteria defining MSCs was determined by the
International Society for Cellular Therapy in 2006. MSCs must: 1) demonstrate plastic
adherence, 2) test positively (>95%) for CD105, CD73, and CD90 and negatively (<2%
positive) for CD45, CD34, CD14 or CD11b, and CD79 or CD19, and 3) be capable of
differentiating into adipogenic, chondrogenic and osteogenic lineages.25 To ensure
isolated cells meet such requirements, experiments are conducted demonstrating 1)
plastic adherence through serial passaging on plastic tissue culture flasks, 2) appropriate
cell phenotype through flow cytometric analysis (cell marker identification via antibody
tagging) with serial passaging, and 3) in vitro (and in some cases in vivo) differentiation
experiments where cells are exposed to signals (ex. exogenous growth factors or other
chemicals, mechanical stimulation) and evaluated for morphologic and gene/protein
phenotypic likeness to target cells.
Large variability in MSC isolation, propagation and characterization techniques
exist.7,9,14,24–26 Some authors have attributed such variability to the noted discrepancy
between in vitro experiment success and in vivo experiment (or clinical trial) failure.7,14
As such, there has been a push to employ more than “minimal” criteria when proposing
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to use MSCs.14,24 Additional suggested criteria include in vivo (as opposed to the
common practice, in vitro) differentiation potential, the ability to form colonies in vitro
and evaluation of teratoma formation in vivo. It has also been suggested that the
definitions of potency and self-renewal should reflect the overarching goal of use in
human; thus restricting MSC criteria to in vivo (not in vitro) demonstrations.24,27
Bone marrow derived stem cells (BMSCs), adipose derived stem cells (ADSCs),
amniotic fluid stem cells (AFSCs), amniotic mesenchymal stem cells (AMSCs), and
chorionic mesenchymal stem cells (CMSCs), have been previously evaluated and meet
the minimal MSC criteria defined by the International Society for Cellular Therapy.28–42
Table 1 reports the verified stem cell criteria for each cell type, including reports of cell
surface marker expression (phenotype). Cell phenotype is passage dependent and can also
vary depending on the isolation method employed.9 Though ≥95% and ≤2% are the
threshold values assigned to positive and negative surface marker expression, variable
expression has been reported with positive values as low as 80%.9

1.3 Review of Common MSC Isolation Techniques
1.3.1 BMSC Isolation Techniques
Bone% marrow% (BM)% aspiration% is% typically% required% for% BMSC% isolation.% For% several%
decades,% the% most% common% site% of% aspiration% has% been% the% iliac% crest,% though% the% femoral%
shaft% has% also% been% utilized.43,44% As% illustrated% in% figure% 1,% BM% is% collected% through% an%
aspiration%needle%system%at%varying%depths%of%insertion%into%the%iliac%crest.%Typically,%the%BM%
aspirate% is% separated% into% its% constituent% components% using% Ficoll% gradient% centrifugation.%
This%technique%employs%centrifugation%to%separate%BM%components%by%density,%resulting%in%
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47

Yes

AFSC

45,48,49

Yes34,39,41,45–

47

Yes34,39,41,45–

Plastic
Adherence

ADSC

BMSC

Stem
Cell

Yes

Yes

45,48,49

34,51,52

Yes34,47,51,52

Positive for
CD105,
CD90,
CD73

Yes

Yes

45,48,49

34,51,52

Yes34,47,51,52

Negative for
CD45, CD34,
CD14 (or 11b),
CD79 (or19)

Osteogenic45,49
Chondrogenic45
Adipogenic45,49

Osteogenic34,41,46,51
Chondrogenic34,41,46,51
Adipogenic41,46

Osteogenic34,41,46,51
Chondrogenic34,41,45,47
Adipogenic41,46

Differentiation Capacity

Table 1: Verified Stem Cell Criteria

HLA-DR(-)34,47

CD29(+)45,48,49
CD44(+)45,48
CD49(+)48
CD166(+)48
CD117(+)50

CD10(-)49
HLA-DR(-)49

CD9(+)41
CD14(-)46
41
CD117(-)34
CD13(+)
41,46
HLA-DR(-)34,41
CD29(+)
34,41,46
CD44(+)
CD49(+)41
CD54(+)41
CD106(+)41
CD146(+)41
CD166(+)34,41
HLA-ABC(+)41

HLA-ABC(+)34,47

CD13(+)41,45
CD106(+/-)41
40,45,46
CD14(-)46
CD29(+)
34,41,45–47
CD117(-)34
CD44(+)
34,41,45,47
CD133(-)46
CD166(+)

Other Marker Expression
(+)
(-)

Table 1: Verified Stem Cell Criteria for human BMSCs, ADSCs, AFSCs, AECs, AMSCs, CVSCs and CMSCs.
Criteria selections have corresponding references supporting the stem cells’ ability to meets each specific criterion. The
far right column represents additional phenotypic analysis for each stem cell type.
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CMSC

CVSC

AMSC

AEC

52,55,56

Yes29,41,45,49,

Yes

41,55

45,46,48,50,52,53

Yes29,34,37,41,

Yes

54,58

6,57

Yes41,48,51,54,5

Yes

55

8,52–54

Yes29,34,41,45,4

Yes

54,58

Yes

Yes

54

41,48,51,54,56,57

55

Yes29,34,41,45,48,52–

Yes

54,58

Osteogenic29,41,48,51,56,57
Chondrogenic29,41,48,51,56,57
Adipogenic45,47,52,54

Osteogenic41,45,55
Chondrogenic41,45,55
Adipogenic41,45,55

Osteogenic29,34,41,45,51–54
Chondrogenic29,34,41,45,51–54
Adipogenic29,41,45,52–54

Osteogenic4,58
Chondrogenic4,58
Adipogenic4,58

CD31(-)55
HLA-DR(-)55

CD13(+)45
CD3(-)45
45,52
CD117(-)34
CD29(+)
CD44(+)34,45,47,52,54 HLA-DR(-)
29,34,47
CD49(+)52
45
CD54(+)
CD166(+)34,45,47,52
HLA-ABC(+)29,47

CD13(+)55
CD44(+)55
HLA-ABC(+)55

CD29(+)45,52,53
CD31(-)37
34,47,52–54
CD117(-)34
CD44(+)
HLA-DR(-)29,34,47
CD49(+)52
29
CD71(+)
CD166(+)34,47,52,53
HLA-ABC(+)29,47

the separation of solid components.
The BMSCs are located within the
resulting cell pellet, which is known
as the mononuclear cell (MNC)
fraction. The MNC contains not only
BMSCs but populations of cells with
phenotypic

expression

profiles

dissimilar to those of a defined stem
cell.33,43,59 The BMSCs can be
isolated from the other cells of the
MNC by re-suspending (i.e. adding
media and gently mixing to redistribute the cells throughout the
suspension) the MNC pellet and
culturing

on

overnight),

plastic

with

(at

BMSCs

least
found

amongst the adherent cells. Flow
cytometric
multipotency

analysis
assays,

like

and
those

previously described, to confirm the
Figure 1: Left, Pictorial Representation of
BMSC Isolation beginning at the top with bone
marrow aspiration from the iliac crest, followed
by centrifugation to separate the MNC,
supernatant aspiration, re-suspension in media
and plating, where the adherent cells are termed
BMSCs.
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presence of mesenchymal stem cells
are also suggested.59
1.3.2 ADSC Isolation Techniques
Adipose tissue is relatively
abundant, and it is typically removed
in large quantities through gross
resection, conventional liposuction
and ultra-sound assisted liposuction
procedures.60
liposuction

Laser-assisted
is

less

commonly

employed.61 Adipose tissue is most
commonly

removed

from

the

abdomen, and there does not appear
to be a relationship between body
mass index or gender and ADSC
yield.62 To obtain the ADSCs, the
adipose tissue is usually washed,
minced, and enzymatically digested
(typically in collagenase) to obtain
what is commonly referred to as the
Figure 2: Left, Pictorial Representation of
ADSC Isolation beginning at the top, human
lipoaspirate is washed and minced prior to
centrifugation to separate the SVF, supernatant
aspiration, re-suspension in media and plating,
where the adherent cells are termed ADSCs.
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stromal vascular fraction (SVF).7,9,60,63 The SVF is comprised of stromal and stem cells
(<0.1%),

endothelial

cells

(10-20%),

lymphocytes

(10-15%),

monocytes

and

macrophages (5-15%), pericytes (3-5%), among other cell types.9 ADSCs can be
separated from the SVF via Ficoll gradient centrifugation.7,9 As with BMSCs, in vitro
culture (at least overnight) and flow cytometric analyses for the previously mentioned
surface markers are commonly employed to ensure stemness of the isolated cells.
1.3.3 AFSC Isolation Techniques
Amniotic fluid (AF) is typically obtained during the second trimester by
ultrasound-guided needle puncture (trans-abdominal or trans-cervical) during an
amniocentesis procedure, though it can be obtained with minimal risk from week 14
through the duration of the pregancy.34,57 In’t Anker et al collected AF via transabdominal and trans-cervical amniocentesis from second and third trimester pregnancies.
AFSCs free of maternal contamination were successfully isolated in n=10/10 transabdominal and in n=4/10 trans-cervical second trimester amniocentesis samples (mean
AF volume: 8.7±1.7mL trans-abdominal; 32.3±13.9mL trans-cervical). AFSCs free of
maternal contamination were successfully isolated in only n=2/10 third trimester samples
(mean AF volume: 10.7±4.8mL).57 This highlights the utility of trans-abdominal
amniocentesis and the known change (decrease in AFSC) in the AF cellular profile
throughout pregnancy. Higher volumes of AF can be obtained via trans-cervical
amniocentesis, but these samples do not reliably yield pure AFSC populations. Transabdominal amniocentesis seems to routinely yield pure AFSC populations throughout the
second trimester, but lower volumes of AF are typically taken using this procedure.
Though groups such as Kaviani et al describe taking as much as 22mL of AF during
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amniocentesis, it has been reported
that as little as 1-2mL of AF is
required

to

successfully

isolate

AFSCs.39,51 As illustrated in figure
3, the AF is centrifuged, the resultant
cell pellet is re-suspended and
cultured

on

plastic

(at

least

overnight), with the adherent cells
termed AFSCs.38,40,52,64 The danger
of plastic adherence-based isolation
of AFSCs is the known plastic
adherence exhibited by three distinct
AF cells types: E-type, F-type, and
AFSCs.65 Thus stem cell yields
calculated from plastic adherencebased isolation are likely inflated
values.
isolation

Plastic

adherence-based

followed

by

flow

cytometric analysis for CD117, a

Figure 3: Left, Pictorial Representation of
AFSC Isolation beginning at the top, human AF
is typically obtained via amniocentesis prior to
centrifugation (to obtain the cell pellet),
supernatant aspiration, re-suspension in media
and plating, where the adherent cells are either
AFSCs, E-Type or F-type cells. Flow cytometric
analyses are typically required to further separate
AFSCs.
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tyrosine kinase receptor of stem cell
factors,

is

preferred.34,40,50,66

However, more meticulous isolation
methods such as that described by
Phermthai et al would also remove
this bias in yield reporting.67
1.3.4 AMSC Isolation Techniques
Amniotic

membrane

typically

obtained

(AM)
after

is
term

cesarean section.54 The AM contains
two distinct populations of cells that
exhibit

stem

cell

markers:

1)

amniotic epithelial cells (AECs) and
2) amniotic mesenchymal stem cells
(AMSCs).
characterization,

The
and

isolation,
potential

application of amniotic cells have
been previously reviewed by our
group.68 In’t Anker et al successfully

Figure 4: Left, Pictorial Representation of
AMSC Isolation beginning at the top, human
AM is mechanically peeled from the CM and
digested in trypsin/EDTA (to selectively remove
AECs) followed by digestion in collagenase (to
remove AMSCs). Similar processing steps are
utilized as previously described. Adherent cells
from the trypsin digest are termed AECs while
adherent cells from the collagenase digest are
termed AMSCs.
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isolated AMSCs from n=8/10 second trimester and n=7/10 term AMs.57 The most
traditional method to isolate out each amniotic cell population is via serial digestion with
trypsin/EDTA (to selectively remove the AECs from the epithelial layer) followed by
collagenase or dispase digestion (to liberate the AMSCs from the stromal tissue
layer).41,54 To obtain AMSCs, the collagenase-digested sample is centrifuged; the
resultant cell pellet is re-suspended and cultured on plastic (at least overnight), with the
adherent cells termed AMSCs. It should be noted that initial collagenase digestion of the
amniotic membrane (without a trypsin digestion step) results in a mixed (AEC+AMSC)
population of cells. In our experience, similar results can be obtained by using diluted
volumes of trypsin during the initial digestion step, resulting in only the partial removal
of AECs and consequent removal of the remaining AECs and AMSCs during collagenase
digestion. Yields reported using such methods are thus inflated, as they do not depict a
pure AMSC population. Flow cytometry for epithelial markers (to ensure no AEC
contamination) and mesenchymal stem cell markers are suggested employed to further
distinguish AMSCs. In fact, Marongiu warns that standard trypsin isolation
concentrations (0.05% weight/volume) do not reproducibly yield pure AMSC populations
and recommends purification through a density separation method.47
1.3.5 CMSC Isolation Techniques
The chorionic membrane contains two primary stem cell populations that retain
mesenchymal stem cell characteristics: 1) chorionic mesenchymal stem cells (CMSCs)
harvested from the stromal chorionic layer and 2) chorionic villous stem cells (CVSCs)
isolated from the trophoblastic chorionic villi (As such, CVSCs are also referred to as
chorionic trophoblastic cells). Placentas for CMSC isolation are typically obtained after
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term cesarean section. Nazarov et al
reported the ability to isolate plasticadherent CMSCs in all n=10/10 and
Ba"enková et al reported success in
all n=6/6 isolation attempts under
such conditions.46,69 Jones et al
compared first and third trimester
CMSCs, finding similar phenotypes
and differentiation potentials despite
the

developmental

discrepancy.

Additionally, first trimester CMSCs
exhibited

heightened

kinetics,

smaller sizes and unique surface
expression

profiles

more

characteristic of embryonic stem
cells.70 However, as the author
acknowledged, therapeutic use of
first trimester CMSCs would require
pregnancy termination.

Figure 5: Left, Pictorial Representation of
CMSC Isolation beginning at the top, human
CM is removed form the maternal decidua and
digested in trypsin/EDTA (to selectively remove
CVSCs) followed by digestion in collagenase (to
remove CMSCs). Similar processing steps are
utilized as previously described. Adherent cells
from the trypsin digest are termed CVSCs while
adherent cells from the collagenase digest are
termed CMSCs.
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These authors could find no report of CVSC use in orthopedic regenerative
medicine, though there are reports of using general chorionic (CMSCs+CVSCs) stem
cells in musculoskeletal tissue engineering and regenerative medicine investigations.
Additionally, as previously indicated their removal is necessary to ensure pure CMSC
populations and we have thus briefly included them in our review. CVSCs can be
obtained throughout pregnancy through trans-cervical chorionic villous samplings.34 The
primary concern in CVSC isolation is maternal contamination, which is frequently
reported.54,71 The most traditional methods by which to isolate out each chorionic cell
population is via serial digestion with trypsin (to selectively remove the trophoblastic
cells) followed by collagenase and or dispase digestion (to liberate the CMSCs from the
stromal tissue layer), and subsequent in vitro culture to confirm plastic adherence.31,70–72
There are also reports of CVSC isolation by the explant culture method.35,73 Briefly,
chorionic villi are attached to plastic culture dishes maintained in culture medium for
approximately 14-20 days, at which time the migrated cells (CVSCs) are harvested.

1.4 Review of MSC Yields
Beyond orthopedics, the importance of high dose stem cell administration has
been established in therapeutic strategies combating wound healing, fistula and heart
failure.74–76 Moreover, in recent proof of concept clinical trials examining the potential
therapeutic efficacy of using stem cells to mitigate musculoskeletal tissue pathologies (in
this instance osteoarthritis), it has been demonstrated that only study groups receiving
high doses (10x107 autologous ADSCs) show statistically significant improvement
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compared to low dose stem cell administration and non-stem cell treated controls.13 Such
reports further the relevance of stem cell yields in musculoskeletal regenerative medicine
approaches, as sources exhibiting the highest yields represent the most practical (readily
useable) stem cell.
1.4.1 BMSC Yields
Pittenger suggests that only 0.001 – 0.01% of isolated MNCs are stem cells.59
This was corroborated by Pasquinelli et al who reported 0.001 – 0.1% of MNC
suspensions were BMSCs as indicated by stem cell surface marker profiles.33 Recently,
Li et al evaluated the number of colony forming unit fibroblasts (CFU-F; i.e. BMSCs)
from repeated BM aspirations in healthy patients and those with leukemia.77 On average
after the first aspiration, the mean number of CFU-F’s per 1 x 106 MNC’s was 84; this
indicates roughly a 0.008% yield, which is within the range established by Pittenger’s
findings. Furthermore, Li found the average number of MNC’s isolated during the first
aspiration was 12 x 106/ mL BM, resulting in an average normalized stem cell yield of
approximately 1 x 103 BMSC/mL of BM aspirate.77 Wexler et al had previously assessed
the frequency of stem cells in the CFU-F population to be one BMSC in every 3.4 x 104
cells.44 Baer et al cites that “a bone marrow transplant contains approximately 6 x 106
nucleated cells per mL.”78 Taken together with the percentage range (0.01-0.001%) of
BMSCs per nucleated cell established by Pittenger et al; 60 - 600 BMSCs can be
theoretically obtained per milliliter of BM aspirate, which is in accordance with the
values determined by Li et al. Lannert et al found no significant difference in BMSC
yield when varying bone marrow aspiration methods, resulting in an average of 0.11 0.34 x 108 total nucleated cells per liter of BM.43 Considering that only a small portion of
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these cells are actually BMSCs; the theoretical stem cell yield per mL aspirate would be
11 - 340 BMSC/mL, which represent slightly lower values than those determined by
other authors.
1.4.2 ADSC Yields
Chung et al determined that traditional suction assisted liposuction yields a mean
stem cell count of 5.4 x 105 cells per mL with roughly 81% cell viability (i.e. 4.4 x 105
viable ADSCs/mL processed lipoaspirate).61 Baer et al cite that the SVF of adipose tissue
contains approximately 0.5 – 2 x 106 cells per gram.78 Jurgens et al suggest that
approximately 5% of the total cell count found in the SVF from liposuction of the
abdomen is ADSCs, though Bourin suggests it can be as low as 0.1%.9,79 In line with this
finding, Baer cites others who indicate that 1-10% of the cells in the SVF are stem cells.78
Using a conservative estimate of 5% and provided the total number of cells estimated per
gram of SVF by Baer, the calculated theoretical ADSC yield is 2.5 x 104 – 1 x 105
ADSCs/g adipose tissue (or 5 x 103 – 2 x 105 ADSCs/g, if you assume 10% of the SVF
are stem cells). Oedayrajsingh-Varma et al compared whole tissue resection, tumescent
liposuction, and ultrasound-guided liposuction to determine if there was a difference in
cell yields between these methods. These methods yielded 7 x 105, 5 x 105, and 6 x 105
SVF cells (+/- 1 x 105)/g of harvested tissue, respectively.60 Using the 5% estimate, the
total ADSC yield by these methods was approximately 3.5 x 104, 2.5 x 104, and 3 x 104
(+/- 1 x 105) ADSC/g. This suggests similar effectiveness between isolation methods, and
is in accordance with previously calculated ADSC yield values. Christodoulou et al
isolated a mean SVF yield of 312 x 106 cells from 173.8g of adipose tissue.80 Applying
the 5% estimate, approximately 8.9 x 104 ADSC/g were obtained, again in accordance
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with previously predicted values. However, it is noteworthy that all of these calculated
values are larger than the 5 x 103 ADSCs/g cited by Hass et al.32 Zuk et al suggests that 2
– 6 x 108 nucleated cells can be found in the SVF obtained from 300 mL of raw
lipoaspirate, which would yield 6.7 x 105 – 2 x 106 cells per mL.63 Again, assuming 5%
of these cells are stem cells (in accordance with Jurgen et al79) this would result in
approximately 3.4 x 104 – 1 x 105 ADSCs/ mL of lipoaspirate, which is in agreement with
Baer’s citations (which includes Zuk et al and others).
1.4.3 AFSC Yield
Though the cellular profile of AF has been shown to change with fetal age, the
majority of cells isolated from AF are terminally differentiated and do not have the
proliferative capacities characteristic of mesenchymal stem cells.48,52 It is estimated that
only 1% of the cells obtained during amniocentesis are AFSCs.34,40 It has been reported
that the mean AF volume is relatively constant (207±92mL at 16 weeks, 258±97mL at 18
weeks and 365±88mL at 20 weeks), but during the second trimester the number of cells
within the AF varies from 10-1,000 cells/µL.65 Based on these reports, the theoretical
number of cells in the total volume of AF at 20 weeks is between 3.65 x 106 – 3.65 x 108
cells. Following reports that AFSCs constitute only 1% of the overall AF cell population;
the theoretical number of AFSCs in the entire AF at 20 weeks is 3.65 x 104 – 3.65 x 106
AFSCs (or 100-10,000 AFSCs/mL AF). However, it must be noted that the entire AF
volume could never be utilized without compromising pregnancy. Pappa et al reported an
average of 0.9-1.5% AFSCs isolated from 10-15mL of AF taken at 15-18 gestational
weeks, which resulted in 2.7 x 105 total AFSCs (or 1.8 x 104 – 2.7 x 104 AFSCs/mL AF),
within the previously calculated theoretical range.29 Unpublished observations by Ekblad

19

also fall within this theoretical range, as 1,500±3,250 AFSCs/mL were obtained by
pooling 2-3 AF samples (mean sample volume: 6.7mL) and combining n=7 pooled
samples together.
1.4.4 AMSC Yields
Expected yields using the previously described serial enzymatic digestion
technique are 4-5 x 106 AMSCs/AM.55 Soncini et al reports a typical isolation of 24 ± 10
x 106 AMSCs/AM.71 Using a similar method, Casey et al isolated 1 x 106 AMSCs/g of
AM (mass of amnion tissues: 5-15 grams).53 Published data by Bilic et al states that a
mean of 1.7 x 106 AMSCs/g could be harvested.49 Unpublished results by Bilic et al
(reviewed by Parolini et al54) state that “typically 4 x 106 AMSCs per 100 cm2 of starting
material” can be isolated from the term amnion. While Alviano et al noted 1.3-1.5 x 106
AMSC/4cm2 AM (3.2-3.75 x 105 AMSC/cm2). They extrapolated that with an average
amnion area of 1300cm2, 4 x 108 AMSCs can be isolated/AM.37 Unpublished data by our
group seems to align with previous reports, as we routinely isolate an average of 1.6 x 106
AMSCs/mL and as many as 3 x 108 AMSC/AM.
1.4.5 CMSC Yields
We are not the only authors to remark at the extremely limited information
available regarding CMSCs.34,46,81 Witkowska-Zimny et al cite Soncini et al who report
that 21 x 106 CMSCs can be isolated from the enzymatic digestion of a single chorionic
membrane.34,71 While Bačenková reported 11 x 106 CMSCs were isolated from 6-pooled
10x10cm chorion segments (11 x 104 CMSC/cm2).31 Abumaree successfully isolated
11.55 ± 1.23 x 103 CVSCs/40mg chorion (wet weight) when employing the standard
explant culture technique (2.89 x 102/mg) and 24.66 ± 2.67 x 103 CVSCs/40mg chorion
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(wet weight) when employing trypsin (6.17 x 102/mg), with confirmation that the CVSCs
were free of maternal contamination.73 Both Zhang and Igura et al reported 1 x 104
CVSCs/5mm3 chorion using the explant culture method (2 x 103/cm2).35,81 All of the
previously reviewed stem cell yields are succinctly reviewed below in table 2.

Stem
Cell
BMSC

ADSC

AFSC

AMSC
CVSC
CMSC

Table 2: Calculated and Reported MSC Yields
% Stem Cells
[Stem Cells/
[Stem Cells/
in Cellular
Other
mL tissue]
g tissue]
Fraction
1x103,
0.001-0.01%,
NA
NA
60-600,
0.001-0.1%,
11-340
0.008%
2.5x104-1x105,
3.5x104,
5
4.4x10 ,
2.5x104,
5%,
NA
4
5
3.4x10 -1x10
3x104,
1-10%
4
8.9x10 ,
5x103
2
4
1x10 -1x10 ,
1.8x104-2.7x104,
NA
1%
NA
1.5x102-3.25x102
4-5x106/AM,
24±106/AM,
6
1.7x10
NA
NA
4x108/AM,
4x104/cm2,
3.2-3.75x105/cm2
5
NA
6.17x10
NA
2x103/cm2
21x106/CM,
NA
NA
NA
11x104/cm2

Reference(s)
33,43,59,78,79

48,56,59,60,
62,78,79

29,34,40

37,53,54,72,81

77
31,34,72

Table 2: Reported and Extrapolated MSC Yields reviewing the previously described yields obtained or calculated
(underlined values) based on the current literature. This table highlights the numerous ways stem cell yields are
reported, limiting immediate cross-comparisons between MSC types. Underlined data points indicate calculated values
based on the 0.001-0.01% (BMSC), 5% (ADSC) and 1% (AFSC) ranges

1.5 Obtaining “Clinically Relevant” Stem Cell Populations
It has been widely accepted that stem cells must be administered in large
quantities to demonstrate clinical efficacy.4,5,14 Commonly, this is expressed as needing to
obtain “clinically relevant” stem cell populations, presumably through ex vivo
expansion.82,83 With limited past precedence within orthopedics, we define clinically
relevant populations as those commonly employed in orthopedic clinical trials. Upon
21

Figure 6: Calculated AFSC, AMSC and CMSC Yields with the dashed lined indicating the mean reported dose of
current orthopedic clinical trials employing MSCs.

review of the United States National Institutes of Health clinicaltrials.gov website,
between 1 x 106 -1 x 109 stem cells are commonly employed in various clinical trials for
orthopedic applications, seeming to imply that 1 x 106 is the minimum number of stem
cells required for clinical relevance in stem cell-based orthopedic therapies. Of note, no
orthopedic trials were discovered utilizing AFSCs, AMSCs, CMSCs or CVSCs. (Note:
The reported range excludes studies with dosages reported as mL BM aspirate. The
lowest BM aspirate reported is 6mL, which based on our calculations would yield 3.6 x
102 - 3.6 x 103). However, this claim can only be verified upon study conclusion and
evaluation of ongoing trials.
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Figure 7: Largest Reported BMSC, ADSC, AFSC and AMSC Yields highlighting the exponentially greater yields
of AMSCs compared to more standard stem cell sources.

Based on our summation of the literature and extrapolation of stem cell yields,
AMSCs yields are the highest of all stem cell types examined. An averaged size AM can
yield up to 4 x 108 AMSCs, whereas the largest yield reported from the chorionic
membrane is only 21 x 106 CMSCs, approximately 20x less than the amniotic membrane.
AFSC isolation using the entire AF volume at 20 gestational weeks yields 3.65 x 104 –
3.65 x 106, approximately 100x less mesenchymal stem cells than the amniotic
membrane. These relative yields are represented in figure 6. Additionally, it cannot be
ignored that being able to utilize the entire AF volume represents an unrealistic
therapeutic scenario. We were unable to determine average lipoaspirate or BM aspirate
volumes removed during standard procedures from the literature, but calculated yields
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indicate 3.4 x 104 – 1 x 105 ADSCs/mL lipoaspirate, nearly 500x greater than the
calculated BMSC yield of 60-600BMSC/mL BM aspirate, can be obtained. Still,
hAMSCs can be isolated in as much as 40x greater quantities than ADSCs (1.6 x 106
AMSC/mL AM vs. 3.4 x 104 – 1 x 105 ADSCs/mL lipoaspirate). These relative yields
are represented in figure 7.
In order to obtain the previously identified (minimal) number of stem cells
required for clinical relevance (1 x 106 stem cells) without ex vivo expansion of cells, at
least 1.6L BM, 10mL lipoaspirate, 55mL AF, 0.625mL AM, or 500cm2 CM would be
required (illustrated in figure 8). This highlights the utility of stem cell sources such as
the amnion, as one amnion would be substantial to obtain multiple therapeutic doses.
The highest reported clinical trial dosage of 1 x 109 is not possible without ex
vivo expansion of any of the listed cell types. However, the mean reported dosage (2 x
108 stem cells, also the dosage termed “clinically relevant” by Schallmoser et. al.83) could
only be accomplished without ex vivo expansion through using AM. As previously
indicated, ex vivo expansion exposes cells to increased possibilities of contamination as
well as alterations to their phenotype and differentiation potentials.15–17 Thus, AMSCs
may be an under-used stem cells source in orthopedic regenerative medicine.
It should be noted that reported values for stem cell yields vary within each tissue
due to the differing isolation techniques employed. Furthermore, it is difficult to make
direct comparisons between stem cell yields within the same tissue as different
investigators utilize varying techniques for quantification. The dosage range of current
orthopaedic clinical trials employing stem cell therapies seems to indicate that at least 1 x
106 stem cells are required for clinical significance. Based on our summation of the
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literature and extrapolation of stem cell yields, AMSCs yields are the highest of all stem
cell types examined. AMSCs are also the only cell type examined that can be isolated in
quantities equal to the mean dosage of stem cells currently employed in orthopedic
clinical trials.

Figure 8: Tissue Required To Obtain 1x106 Stem Cells, the minimum number of stem cells required for clinical
significance, without ex vivo expansion.

1.6 FDA Regulation of Stem Cells
MSCs currently fall under the jurisdiction of the U.S. FDA’s Center for Biologics,
Evaluation and Research’s (CBER) Office of Cellular, Tissue and Gene Therapies
(OCTGT). Stem cells are considered as human cells, tissues or cellular and tissue-based
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products. As such, their use must meet current FDA regulatory codes and good
manufacturing practices, specifically Title 21, Part 1271.7,68 The FDA has two clinical
regulatory pathways governing the use of MSCs and MSC-based products. It is possible,
but not likely, for an MSC-based product to be regulated under Section 361 of the Public
Health System’s Act if the product meets the following criteria: 1) the product has been
minimally manipulated, 2) the product is intended for homologous use only, 3) the
product was not combined with any other biologic or synthetic article, 4) the product
does not have a systemic effect or depend on the activity of living cells for its primary
function and 5) the product is for autologous use.7,68 Regulation by Public Health system
Act Section 361 grants products sanctioned use for investigational trials without formal
FDA approval. While MSCs are HCT/Ps, to the best of the authors knowledge they do
not meet the criteria listed above an accordingly are regulated the PHS act under Section
351 as a biologic drug which must follow current good manufacturing and tissue
practices (cGMP and CGTP, respectively) and require investigational device exemptions
and clinical trial data to provide evidence of safety and efficacy to gain approval prior to
marketing. To date are no FDA approved MSC-based products for orthopaedic
applications. For more information on FDA regulations, please see our previous review.68
1.7 Stem Cell Differentiation
Stem cells, especially stem cells combined with biomaterial scaffolds, have the
potential to differentiate into target cells, establishing new populations of healthy, tissueforming, cells in diseased areas.11,84,85 In some instances it has been demonstrated that
stem cell differentiation can occur “spontaneously.” That is, differentiation can occur
without the addition of exogenous growth factors. In such instances the stem cells are
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typically seeded onto a scaffold. It is hypothesized that the physical and/or chemical
properties of the scaffold provides the stimulatory cues necessary to promote stem cell
differentiation, though the exact mechanisms behind such differentiation are not yet fully
understood.86–88
However the primary means to achieve stem cell differentiation involves
manipulation not currently allowed by FDA regulation, the addition of exogenous growth
factors to culture media (see figure 9).32,86,89–97 As different cell types require different

Figure 9: Growth Factor-Induced Stem Cell Differentiation is the most common technique to achieve stem cell
differentiation into desired tissue types. This involves the supplementation of cell culture media with growth factors.
Individual growth factors are best suited to specific lineages of differentiation.

growth factors to sustain their phenotype and functionality, a variety of chemical
cocktails are employed to achieve stem cell differentiation into multiple cell lineages. As
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previously indicated, osteogenic, adipogenic and chondrogenic differentiation are
necessary characteristics to be defined as a stem cell.25 Therefore, these lineages are the
most widely investigated. For the purposes of this review, only those with
musculoskeletal tissue relevance (osteogenic and chondrogenic) will be explained in
further detail.
Osteogenic differentiation has been achieved through the addition of
dexamethasone, #-glycerophosphate, ascorbic acid or bone morphogenic proteins (BMPs)
to culture media.32,49,89,90,92–95,98 Differentiation is typically evaluated through enhanced

Figure 10: Osteogenic Differentiation is typically accomplished via media supplementation with dexamethasone, #glycerophosphate, ascorbic acid or bone morphogenic proteins (BMPs). Differentiation is confirmed through gene
expression of key osteogenic markers and through protein deposition of bone matrix elements, notably, calcium. 1Photo
credit: OrthoX colleague, Sandra Siatkowski
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gene expression of master osteogenic transcription factor, runx-2, and other osteogenic
markers: osteocalcin, osteonectin, osteopontin and osteoprotegrin.32,89,94,98 At the protein
level, differentiation is also evaluated through alkaline phosphatase expression and
calcium

deposition

(visualized

through

von

Kossa

or

Alizarin

Red

staining).32,49,89,90,92,93,95,98,99
Chondrogenic differentiation has been achieved through the addition of
transforming growth factor #1, ascorbate-2-phosphate and dexamethasone.32,93–97 Growth

Figure 11: Chondrogenic Differentiation is typically accomplished via media supplementation with transforming
growth factor #1, ascorbate-2-phosphate and/or dexamethasone. Differentiation is confirmed through gene expression
of key chondrogenic markers and through protein deposition of cartilage matrix elements, notably, glycosaminoglycans
(GAGs). 1Photo credit: OrthoX colleague, Sandra Siatkowski
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and differentiation factor-5, fibroblastic growth factor-2 and BMP-6 have also been
described.32 Studies requiring the use of serum-free media (typically those aiming to
achieve clinical relevance of results through the use of human cells without animal serum
effects), typically employ insulin transferrin selenium (ITS).86,94,97 Differentiation is
typically evaluated through enhanced gene expression of master chondrogenic
transcription factor, sox-9, and other chondrogenic markers: aggrecan and collagen2.32,93,95–97 At the protein level, differentiation is also evaluated through matrix staining of
glycosaminoglycans (GAGs; visualized through Alcian Blue staining).32,95
In addition to plated culture, chondrogenic differentiation of MSCs is
accomplished through pellet culture. In this approach, stem cells remain in a pellet after
centrifugation (as opposed to being re-suspended in culture media and plated). This
provides the cells a 3D environment, allowing cell-to-cell interactions that more
accurately mimic the natural condensation of MSCs during chondrogenesis to
occur.100,101
1.8 Bone and Cartilage Formation: Endochondral Ossification
Bone formation (osteogenesis) can occur through mesenchymal condensation
differentiation into osteoblasts; this process forms the membranous elements of the
vertebral skeleton during development.102 However, most of the vertebral skeleton forms
through endochondral ossification100,102, the central biochemical pathway responsible for
both chondrogenesis and osteogenesis. In endochondral ossification, cells differentiate
into chondrocytes, proliferate and undergo hypertrophy until they reach terminal
differentiation (ossification).87,100,102–104 Simultaneously some cells differentiate into
osteoblasts and osteoclasts.102,103 Together these cells degrade the cartilage matrix
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(osteoclasts) and replace it with newly formed bone matrix (osteoblasts) through a
process known as remodeling.

Figure 12: Endochondral Ossification is the primary pathway through which osteogenesis and chondrogenesis
occurs; it is also the pathway of MSC differentiation into cells of chondral and osteo lineages. Initially, MSCs
condense, forming either osteoblasts/clasts or chondrocytes. These chondrocytes proliferate, ultimately undergo
hypertrophy and terminally differentiate through ossification.

Master chondrogenic transcription factor, sox-9, is required for mesenchymal cell
condensation formation.102,103 All chondroprogenitor cells but not all chondrocytes
express sox-9.102 Hypertrophic chondrocytes, in particular, and osteoblasts do not express
sox-9, further implicating sox-9 in the proliferative as opposed to the later phases of
endochondral ossification.102,103
Sox-5 and sox-6 are regulators of key chondrocyte matrix components, collagen 2
and aggrecan.102,103 Sox-5 and sox-6 are not required for mesenchymal cell condensation
but are required immediately following chondrocyte maturation where high levels of
surrounding matrix are produced.102 There does seem to be a redundancy in this pathway
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whereby mice deficient in either sox-5 or sox-6 mature with limited skeletal
abnormalities.102 However, mice deficient in both sox-5 and sox-6 die in utero.102
As previously indicated, runx-2 is a transcription factor controlling the rate of
expression of osteocalcin and other osteogenic matrix components. Runx-2 is required for
osteogenic differentiation. Through chemical induction, mesenchymal stem cells can upregulate runx-2 in order to promote osteogenic differentiation.102 Natively, runx-2 is
expressed by hypertrophic chondrocytes and osteoblasts.102

Figure 13: Sox-9 & Runx-2 Involvement in Endochondral Ossification is extensive. Sox-9 is primarily responsible
for condensation and chondrocyte proliferation. Runx-2 is primarily implicated in condensation of terminally
differentiated osteoblasts/clasts and the transition from proliferative to hypertrophic chondrocytes.

The TGF superfamily is another group of regulators influencing cell growth,
differentiation and apoptosis in many cell types, including chondrocytes and
osteoblasts.103 The TGF superfamily includes the BMPs 2-8 as well as the TGF-"s.103,105
TGF binding has been shown to influence chondrogenesis through two primary
molecular interactions, MAPK and SMAD pathways.103
As previously indicated, many members of the TGF superfamily are used as
exogenous growth factors to induce differentiation in stem cells. Previously it has been
demonstrated that TGF-" supplemented medium induces chondrogenesis more
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effectively in adult but not fetal BMSCs; conversely, medium supplemented with BMP-2
induces chondrogenesis more effectively in fetal but not adult BMSCs.95 TGF-β receptor
binding leads to the phosphorylation of SMAD2 and SMAD3.95,105–107 Whereas, BMP-2
receptor binding leads to the phosphorylation of SMAD1 and SMAD5.95,105–107 Each of
these SMADs serve specific (though not currently completely defined) functions. BMPpathway deficient mice have underdeveloped growth plates due to inhibition of
chondrocyte proliferation.106 Whereas, TGF-β-pathway deficient mice tend to develop
elongated growth plates due to maintenance of chondrocytes in the proliferative phase.106
TGF-β-related SMAD signaling has also been correlated with increased likelihoods of
osteoarthritis and osteophyte formation throughout cartilage.106 While it has been
established that both signaling pathways are necessary for proper development106, there
appear to be chondrogenic advantages (less potential for bone formation and maintenance
of chondrocytes in the proliferative phase) in BMP-induced chondrogenesis. The
biochemical process of endochondral ossification describes the formation of cartilage and
bone cells. These cells, together with specified matrix components, create the distinctive
tissue structures known as cartilage and bone.

1.9 Articular Cartilage: Structure & Function
Cartilage is a roughly 2-4 mm thick connective tissue composed of a unique host
cell type, chondrocytes, and the extracellular matrix (primarily composed of water,
collagen and proteoglycan) surrounding the chondrocytes.108–110 Despite having minimal
components, cartilage is a complex tissue with the cells and matrix fibers organized in
multiple patterns (referred to as zones). This heterogeneous structure results in varying
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cell phenotypes, gene and protein expression.108,109 Therefore each individual zone offers
a unique function to the cartilage unit.

Figure 14: Cartilage Structure is heterogeneous; the variable composition (cellular shape/phenotype and matrix) of
each zone yields specific functions. These zones combine together to serve one primary function: the absorption and
dissipation the mechanical loads of the joint. Cartilage lines the surface of joints, including the knee joint (pictured at
left).

In the superficial zone (figure 14), flattened chondrocytes arrange with their
lacunae oriented parallel to the cartilage surface.108 In a similar manner, type II and IX
collagen fibers align parallel to the surface.109 Type II collagen is the most abundant
extracellular matrix component (approximately 90-95% dry weight).109,111 Collagens I,
IV, V, VI and XI are also present, but in much lower proportions; these collagens
function primarily to stabilize the type II collagen network.109 Though this zone is the
thinnest cartilage layer (roughly 15% of total cartilage thickness), this parallel orientation
functions to protect deeper cartilage layers from mechanical stresses.109 Thus, the
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integrity of the superficial layer is paramount to overall cartilage function.112 This zone
also exhibits high levels of lubricin and hyaluronic acid (HA) secretion, lubricating the
joint surface (allowing fluid, pain-free movement).108 Water is also most abundant in the
superficial zone (approximately 80% wet weight), filling intrafibrilar spaces and
facilitating nutrient exchange.109
In the intermediate zone (figure 14), a combination of more rounded chondrocytes
can be found sparsely thought an oblique network of extracellular matrix fibers.109 These
fibers, primarily thicker collagen segments and proteoglycans, function to resist
compressive forces.109 Proteoglycans (up to 15% wet weight) are crucial to the
compressive resistance exhibited by cartilage. Aggrecan, the most abundant cartilage
proteoglycan, has unique osmotic properties, making it specially suited to resist
compressive loading.109
The deep zone (figure 14) provides the primary resistance to compressive
forces.109 In the deep zone, chondrocytes arrange in a columnar orientation perpendicular
to the cartilage surface. Dense networks of large diameter collagen fibers and
proteoglycans arrange parallel to chondrocyte columns (perpendicular to the surface).
The deep zone contains the highest proteoglycan and lowest water contents.109
Together the superficial, intermediate and deep zones make up the nonmineralized portion of cartilage.108 These non-calcified zones do not contain blood
vessels. Thus the chondrocytes in these regions live under hypoxic conditions, absorbing
nutrients from neighboring joint tissues.108,109,113 Though the exact mechanism is not
understood, it has been suggested that the high levels of collagen-2 and aggrecan
observed in these zones are a result of the hypoxic environment, as chondrocytes cultured
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under normoxia do not display the appropriate biochemical profile.108 Additionally,
hypoxia produces a more chondroprotective environment, reducing synthesis rates of
matrix metalloproteinases one and thirteen (MMP-1 and MMP-13, respectively; both
responsible for cartilage extracellular matrix degradation and fragmentation).108 These
regions are separated from the deep calcified cartilage by the tide mark (a line roughly
parallel to the cartilage surface visualized through hematoxylin staining).108
Calcified cartilage (figure 14) has a particularly unique composition that
drastically changes with age. Over time, nerves and blood vessels arise from the
subchondral bone, infiltrating the calcified cartilage.108 Additionally, the chondrocytes in
this zone express markers of hypertrophy (ex. runx-2, MMP-13 and type X
collagen).104,108,112
Together, the primary functions of cartilage are to absorb and dissipate
mechanical loads.108 In fact, mechanical stresses are required to maintain cartilage
homeostasis, as loading produces fluid movement within the joint.108,113 This (synovial)
fluid facilitates nutrient exchange as well as lubrication and will be addressed in more
detail in the subsequent section entitled, “Introduction to Osteoarthritis.” Biochemically,
mechanical loading decreases matrix metalloproteinase 3 (MMP-3; a cartilage
extracellular matrix degrading enzyme) and increases aggrecan expression in
chondrocytes.108 There is also evidence that mechanical loading prevents the secretion of
inflammatory mediators, including interleukin 1 (IL-1) and tumor necrosis factor alpha
(TNF-α).108
In normal adults cartilage is in a quiescent state.108,109,112,113 This is largely
possible due to the extremely long turn over rates of the primarily components: collagen
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(400 years) and proteoglycans (25 years).109 Chondrocytes, themselves, do not routinely
proliferate.108–110,113 Each chondrocyte is responsible for the turnover of the extracellular
matrix in its immediate vicinity. This essentially traps the chondrocytes in place,
preventing cell clustering and cell-to-cell signal transduction.109 Additionally, the
extracellular matrix does not repair and replenish the previously described collagen and
proteoglycan networks.108,109,114 Numerous pathologies, including osteoarthritis, disrupt
this previously described homeostatic regulation through the activation of chondrocytes.

1.10 Introduction to Osteoarthritis (OA)
1.10.1 Prevalence & Pathogenesis
OA is the most common form of arthritis, affecting over 30% of the U.S.
population over the age of 65.11,12,110,111,113–118 OA is the result of degraded cartilage,
impairing joint mobility and causing severe pain - making it one of the leading causes of
disability worldwide.12,110,111,113,119,120 Costs associated with OA have been described as
accounting for up to 2% of gross national product in the U.S., the United Kingdom,
Canada, France and Australia.12,120,121 Additionally, is estimated that the prevalence of
OA will double by 2020.122
Articular cartilage degradation is the result of multiple physical and biochemical
processes including, general wear and tear (the result of years of joint use), inappropriate
mechanical loading and inflammation.11,12,104,108,111,114,115,117,119,122 Both systemic (trauma,
obesity and genetic predisposition) and local inflammation (primarily synovial
inflammation) have been implicated in OA.11,108,110,123–126
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Though commonly associated with the degeneration of cartilage, OA is a disease
of the entire joint space.12,85,108,113,117,118,126–128 In OA, the subchondral bone, synovium,
ligaments

and

meniscus

interact

with

the

cartilage

via

non-homeostatic

mechanisms.12,85,108,113 Specifically, the subchondral bone can exhibit sclerosis, and
osteophyte formation is noted at the junction of the synovium with the periosteum.115,127
Synovial fluid - the fluid surrounding and lubricating the joint, becomes filled with proinflammatory mediators and cartilage degradation products.11,104 Currently, the exact
mechanisms of such processes are unknown, obscuring our understanding of OA
etiology.

Figure 15: Osteoarthritis (OA) is the result of numerous physical and biochemical processes. Though commonly
associated with cartilage injury, OA is also affiliated with osteophyte formation within the cartilage or at the
synovial/periosteal interface and chronic inflammation of the synovial membrane and the synovial fluid.

38

In OA, chondrocytes exist in an activated (“senescent” as opposed to quiescent)
state, resulting in rapid cell proliferation, cluster and matrix formation and increased
secretion of matrix degrading enzymes (ex. MMPs and A Disintegrin And
Metalloproteinase with Thrombospondin Motifs, ADAMTS).104,108,110,113,129

Figure 16: Activated Chondrocytes contribute to the microscopic changes observed in OA through increased
proliferation, clustering and the secretion of potent cartilage matrix degrading enzymes, MMPs and ADAMTs. These
enzymes contribute to the overall decrease in collagen and proteoglycan observed in OA cartilage.

Primary MMPs involved in OA pathogenesis include MMP-13, MMP-3 and to a
lesser extent MMP-2. MMP-13 is a collagenase (collagen degrading enzyme) with a
particular affinity for type II collagen.12,104 In OA, MMP-13 expression is increased
within both the synovium and cartilage.115 In addition to being an effective aggrecanase
(aggrecan degrading enzyme), MMP-3 is an upstream regulator and promoter of
downstream MMP synthesis.12,108 MMP-2 cleaves numerous types of collagen and also
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has a regulatory role, promoting the synthesis of other MMPs.115 The ADAMTS are a
family of potent aggrecanases. Those most often implicated in OA are ADAMTS 4 and
ADAMTS 5.12,108 In fact, ADAMTS 5 knockout mice have been shown to be protected
against OA progression.12,108,130 However MMP-13 knockout mice prevent collagen (but
not aggrecan) depletion.12,108
Activated chondrocytes also express unique surface receptors, promoting the
binding of inflammatory cytokines and chemokines (specifically those released from the
synovium), which activate downstream inflammatory cascades further promoting
cartilage destruction.104,108,131
1.10.2 Synovial Inflammation & OA
Under normal conditions, the synovial membrane (synovium) is composed of
fibrous extracellular matrix approximately 2-3 cell layers thick. The synovium acts as a
semi-permeable membrane, facilitating cartilage nutrient exchange through the regulation
of synovial fluid composition.113 The host cells of the synovium, synovial cells, are
responsible for secreting synovial fluid components. Two primary components include
lubricin and HA, which, as previously indicated, help protect and maintain the surface of
articular cartilage.108,109,113 Lubricin, specifically, is responsible for reducing the
deposition of pathologic proteins on the cartilage surface.113 These molecules are not
permeable, allowing high concentrations to be retained within the synovium. In OA, the
concentrations of lubricin and HA are lowered, limiting their intrinsic chondroprotective
roles. This depletion is attributed to a change in synovial membrane permeability.
Clinically, high serum HA concentrations and low synovial fluid HA concentrations have
been used to confirm synovitis.113
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Synovitis is a broad term used to describe (inflammatory) changes within the
synovium, which are characteristic of arthritic diseases. Classically, synovitis refers to
membrane compositional and organizational changes observed histologically.113 These
include thickening, increased populations of leukocytes and angiogenesis (indicated by
increased VEGF concentrations within the synovial fluid) within the synovial
membrane.132,133 However, the synovial biopsy required for such histological
examination is not always available. Thus, gross appearance during surgery or magnetic
resonance imaging (MRI) have also become acceptable observations.113,132 It has been
reported that as many as 50% of OA cases have significant synovitis that is visible
through MRI.132,134 In comparison to other inflammatory-based arthritis diseases (ex.
rheumatoid arthritis), OA synovitis is a low-grade chronic inflammation within the
membrane.113,119,133,135,136 Though synovial inflammation is more frequently observed in
end-stage OA135, the synovial lining is twice as thick (inflamed) in early stage OA
compared to late stage OA.119 Additionally, it has been shown that the degree of synovitis
positively correlates with patient pain.113,137 Synovitis is also directly related to cartilage
degradation.118,132,138,139
Numerous inflammatory pathways can promote the development and maintenance
of synovitis.104 Recently it has been suggested that the most likely pathway begins when
cellular stresses (as a result of injury or non-local inflammation) result in the release of
matrix degradation products. These matrix fragments activate toll-like receptors (TLRs)
along the cells of the synovial membrane through damage-associated molecular patterns
(DAMPS).108,113,135 The downstream consequence of TLR activation in the synovium is
nuclear-factor κB (NF-κB) activation, which is a transcription factor regulating pro-
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inflammatory chemokines (ex. IL-8) and cytokines (ex. IL-1, IL-6 and TNF-#).104,113,135
Synovial cell TLR activation is also responsible for the downstream up-regulation of
MMPs and aggrecanses.113,128,135,140 Similar NF-$B dependent pathways are also
responsible for the inhibition of transcription factors controlling chondrogenesis (ex. sox9).11

Figure 17: Toll-Like Receptor (TLR) Activation occurs through the binding of cartilage matrix fragments (i.e.
DAMPs) to both cells within the synovium or chondrocytes. This binding results in the up-regulation of proinflammatory transcription factor NF-$B. Downstream consequences of this up-regulation include increases in proinflammatory cytokines and cartilage matrix degrading enzymes.

Notably, in addition to synovial TLR activation, chondrocytes have exhibited
TLR activation in response to DAMPs.12,113 Though it has been suggested that this

42

activation pathway does not lead to the production of an activated form of IL-1,108 this
pathway still results in the up-regulation of MMPs and ADAMTS. Specifically, TLR-2
and TLR-4 are up-regulated in regions of cartilage erosion.104,113,135 Up-regulation of
these specific TLRs has been linked to downstream increases in master MMP regulator,
MMP-3.113,135 Additionally, TLR-4 activation has been shown to recruit and activate
macrophages to/within the synovium.113 Specific DAMPs have also been isolated from
OA synovial fluid; the concentration of DAMPs present was able to predict future
cartilage destruction.134
This multi-focal activation of TLRs is one reason OA is beginning to be described
as a feed-forward pathology, where the cartilage and the synovium act against one
another, each fueling the other’s disease progression. However, it is generally assumed
that cartilage injury initiates the propagation of OA.125,135 An alternate depiction of TLR
activation can be found in appendix A.
1.10.3 Synovial Macrophages & OA
Though commonly associated with host defense, macrophages are involved in
many other homeostatic and tissue remodeling activities.141–143 Tissue microenvironments
promote macrophage differentiation into functional phenotypes.143,144 The two most
prominent phenotypes are M1 (pro-inflammatory) and M2 (pro-regenerative/regulatory)
polarized macrophages.133,142,143 M1 macrophage differentiation is commonly induced by
interferon-γ (INFγ) or other pro-inflammatory cytokines (ex. TNF-α).141,142,144 M1
macrophages secrete potent pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6
and IL-12.144 Contrastingly, anti-inflammatory mediators (ex. IL-4, IL-10 and IL-13)
secreted during times of tissue remodeling and hypoxia induce M2 differentiation.142,144
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M2 macrophages do not express but rather down-regulate IL-1" expression.144 While M1
macrophages exhibit increased chemokine CCR7 expression, M2 macrophages display an
up-regulation of mannose receptors144, making both (CCR7 and mannose receptors)
functional biomarkers for M1 and M2 phenotypic analysis, respectively. Despite their
investigation in numerous pathologies, M1 and M2 macrophage phenotypes have not
been thoroughly studied in OA.133

Figure 18: Macrophage Polarization refers to the variable phenotypes of tissue macrophages, the most common
being M1 (pro-inflammatory) and M2 (pro-regenerative) macrophages. Pro-inflammatory mediators (ex. INF% or TNF#) promote M1 differentiation; while anti-inflammatory mediators (IL-4, IL-10 and IL-13) promote M2 differentiation.
M1 macrophages secrete potent pro-inflammatory mediators. The most significant downstream effect of M2
macrophage secretions is the down-regulation of IL-1.

Within the normal human joint space, the body maintains necessary populations
of M1 and M2 macrophages according to specific host needs. Therefore, normal
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synovium exhibits varying proportions of M1 and M2 synovial macrophages.145,146 As
previously described, in OA the synovial membrane becomes inflamed. This involves the
migration and accumulation of numerous macrophages within the synovial tissue.115,134
Macrophages and T-cells have been reported as the most prominent cells types within
OA synovial tissue.133 Though macrophage populations remain above physiologically
normal levels through all stages of OA, evidence suggests there are more CD68+ cells
(i.e. macrophages) present in synovium from early stage OA compared to late stage OA
tissue samples.12,119 However, in studies comparing late stage OA synovial fluid to that of
(healthy) controls, statistically higher levels of macrophage-related inflammatory
mediators are observed.147
Clinical studies have demonstrated infiltration of macrophages into the synovium
of patients with OA.110 The presence of synovial macrophages largely determines the
degree of synovitis and has been shown to positively correlate with OA cartilage
damage.127 The potent pro-inflammatory cytokines and chemokines expressed by
macrophages (specifically M1 macrophages) feed the previously described inflammatory
cascades, advancing the stage of the disease. Macrophages can produce an array of
MMPs and ADAMTS.110,115 However, they are also capable of secreting factors that
regulate and promote the synthesis of cartilage degrading enzymes.110,115,127,131,134 It is
also thought that growth factors secreted by macrophages (ex. TGFβ and BMP) can
directly promote osteophyte formation.127
Macrophages have been further implicated in OA pathology through experimental
models where synovial macrophages were systematically depleted. In such models, OA
progression was halted in macrophage depleted cultures.127,134 Additionally, culturing OA
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chondrocytes with macrophage-conditioned medium was shown to most accurately
reflect the in vivo human pathology (i.e. increased type X collagen production, increased
MMP activity, increased ADAMST 4 activity, decreased cartilage proteoglycan content)
compared to all other models tested.110

Figure 19: M1 Macrophage Infiltration in OA contributes to the state of chronic inflammation observed in OA
joints. Under normal conditions, the body maintains physiologically relevant levels of M1 and M2 macrophages within
the synovium. In OA, large populations of M1 macrophages infiltrate the synovium, disrupting homeostasis and
creating a pro-inflammatory milieu.

1.10.4 Notable Pro-Inflammatory Mediators in OA
IL-1" is a monocyte, macrophage and chondrocyte-secreted pro-inflammatory
cytokine suppressing aggrecan and collagen synthesis.110,113,118,135 Downstream
consequences of IL-1" production also include the up-regulation of ADAMTS-4, MMP1, MMP-3 and MMP-13 as well as IL-6, IL-8m MCP-1 and CCL5 (also known as
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RANTES).113,118,135 Clinically, blocking only IL-1 activity does not alleviate OA-induced
pain.113,122,147 There is also evidence suggesting a crucial role of this cytokine in normal
the regulation of cartilage homeostasis.118 Unlike other inflammatory based arthritis
diseases, IL-1β is not consistently elevated in OA patients.113,128,136,148 Additionally, it is
becoming more widely understood that IL-1β’s primary role is in early stage OA.147
When reported, IL-1β concentrations in late stage OA synovial fluid are typically <4.8
pg/mL,136,147,149 though there are isolated reports of concentrations as high as 250
pg/mL.148
Contrastingly, TNF-α is readily detectable in the synovial fluid of patients with
OA.113,118,136 However, there are varying reports on disease stage-dependent expression,
with late stage OA concentrations synovial fluid concentrations reported between 0-20
pg/mL.113,136,147 TNF-α, like IL-1β, is implicated in cartilage degradation via the
stimulation of collagenases and aggrecanases as well as the suppression of aggrecan and
type II collagen synthesis.110,118 Like IL-1β, downstream consequences of TNF-α
production also include the up-regulation of MMP-1, MMP-3 and MMP-13 as well as IL6, IL-8m MCP-1 and CCL5 (also known as RANTES). Similar to IL-1, trials blocking
only TNF-α do not uniformly result in the alleviation of patient pain.113,147
While the singular elimination of IL-1β or TNF-α has not shown clinical efficacy,
it has been demonstrated that simultaneous blocking of both cytokines results in OA
mitigation.150 This likely represents a redundancy in the OA pro-inflammatory cascade;
whereby suppression of both pro-inflammatory mediators is required to completely
modify (halt the progression) of the cascade. Studies utilizing bovine and porcine OA
explants suggest both IL-1β and TNF-α lead to increased expression of ADAMTS-4;
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however, neither cytokine affected the expression of ADAMTS-5, which is thought to be
the primary ADAMTS involved in OA.118
Other cytokines with more obscure connections to OA include IL-7 and IL-15.
IL-7, produced by chondrocytes, stimulates the production of MMPs and aggrecanases.113
IL-7 is routinely reported in OA synovial fluid.128 IL-15 is regulated by TLR-2 and TLR4 stimulation. It is elevated in early stage OA, and its expression has a positive
correlation with expression of MMP-1 and MMP-13.113,118,135
IL-6 has a less understood role in OA.118 Though commonly (but not always)
detected in patients with OA119,128,135,137, IL-6 has been shown to have a
chondroprotective effect in early stage OA while promoting disease progression (via
osteophyte formation) in late stage OA. It is routinely detected in the synovial fluid of
OA patients.118 High levels of circulating IL-6 have been associated with increased
likelihood of cartilage degradation.118 In an IL-1β-dependent manner, IL-6 up regulates
the expression of MMP-1 and MMP-13 and is thus associated with reduced cartilage
matrix component expression.118 Additionally, IL-6 concentrations have been positively
correlated with leukocyte counts.132
Chemokines mediate the recruitment and regulation of inflammatory cells.
Chemokines can also induce production of master MMP regulator, MMP-3.113
Chemokines also induce IL-6 production.118 Specific chemokines that have been linked to
worsening symptoms include CCL19, IL-8, MCP-1 and RANTES and CCR7.113,118 As
previously described, CCR7 is expressed by M1, pro-inflammatory, macrophages.
While cytokine and chemokines play crucial roles in the development and
maintenance of OA, it must be emphasized that individual biomarker results offer little
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research utility and clinical value. Many variables including circadian and diurnal
variation as well as differences between joint and circulating values influence biomarker
concentrations.118 Combined, many biomarkers and/or data regarding cartilage structure,
synovial inflammation and clinical data (symptom, pain levels, etc.) provide much more
meaningful insight into OA.
1.10.5 In Vitro Models of OA
Investigators have studied the pathogenesis of OA and the efficacy of potential
OA therapies via the use of in vitro co-culture models. These in vitro co-culture models
range in complexity and actual likeness to the disease state. Unfortunately many in vitro
studies are completed using non-human tissue samples.110 These results likely offer
limited mechanistic insight into OA due to the known differences in inflammatory-driven
matrix degradation, specifically the activation and regulation of ADAMTS 4 and
ADAMTS 5, between species.108,110,151,152
1.10.5.1 OA Chondrocyte/Cartilage Explant Culture
Monolayer culture of human OA chondrocytes remains the most common model
to study OA.110,114,129,131 However, monolayer culture has been shown to alter cell
phenotype limiting the translational applicability of such results.128,153,154 Specifically,
hypoxia and cell-matrix interactions can be altered/absent in monolayer cultures and are
better accomplished through 3-D culture.110 To overcome such barriers, human OA
chondrocytes have also been seeded onto tissue engineered scaffolds.110
OA cartilage and synovium explants have been successfully cultured (separate
from each other) in vitro for up to 21 days.128 Such cultures tend to show no differences
in proteoglycan loss and cell viability over time.128 It has also been suggested that the
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cytokine profiles obtained from individual explant co-culture media are less reflective of
the levels described in vivo.128
1.10.5.2 Chemical Doping of OA Explants
As our understandings of the inflammatory nature of OA have progressed, groups
have begun mimicking OA progression through the addition of pro-inflammatory
mediators, such as IL-1β and TNF-α, to OA cartilage explant cultures.128 There are also
reports of adding chemical/cytokines to chondrocyte-seeded scaffolds (or unseeded OA
chondrocytes) in order to model OA.110 While, IL-1β and TNF-α are central to OA
pathology, there are many other inflammatory mediators influencing OA disease
progression. Such chemical doping models fail to represent this complexity, and are
therefore not fully representative of OA pathology.110 Specific examples include the
failure to replicate a loss of type II collagen within the cartilage matrix and to
demonstrate hypertrophy within the chondrocytes.110 Additionally, chemical doping leads
to concentrations of pro-inflammatory mediators 10-1,000x greater than physiologically
reported concentrations, rapidly accelerating the time course of disease progression.128
1.10.5.3 OA Explant Co-culture
As previously discussed, OA is a multifactorial disease involving multiple tissues
in the joint. Therefore, greater mechanistic insight could likely be obtained from multitissue culture systems (i.e. co-culture). There are few reports of OA chondrocytes in coculture with OA synovial cells.128,155 These systems have the benefit of more accurately
modeling the human anatomy and involved tissues. However, they succumb to the same
previously mentioned limitations of cells in monolayer culture. Namely, monolayer
culture has been shown to alter cell phenotype limiting the translational applicability of
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such results.128,153,154
Co-culture

models

involving

joint

tissue

explants

have

also

been

described.128,140,156–158 The majority of such research has been completed using nonhuman tissues to study rheumatoid arthritis.156–158 However, Beekhuizen was among the
first to describe similar co-culture models for OA.128 In joint tissue explant co-culture,
OA cartilage explants are placed in the bottom of a tissue well plate. Synovial tissue is
added to the culture via a permeable well plate insert. Thus, the cartilage and synovium
share the same microenvironment without physically touching (similar to the anatomy of
a human joint). Beekhuizen was able to confirm the ability to culture OA cartilage and
synovial explants for up to 21 days without greatly compromising viability (viability
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Figure 20: Summary of In Vitro OA Models highlighting the advantageous and shortcoming of each approach.

assessments were made using a LDH cytotoxicity assay but were not included in the
manuscript; exact viability data is unavailable).128 They were also able to confirm the coculture system modeled certain aspects of OA disease, including the presence of CD68+
cells (i.e. macrophages) after 21 days in culture, a reduction in cartilage proteoglycan
production and similar cytokine profiles to those reported in vivo.128
Interestingly, there are reports of chemically doping joint tissue explant co-culture
models in an attempt to gauge the therapeutic efficacy of different HA products as
compared to progressing OA.159 However, as previously indicated, the un-natural
acceleration of disease progression observed in such studies does not lend itself to
translational applications.
1.10.6 In Vivo (Preclinical) Models of OA
The purpose of in vivo, preclinical, models are to reproduce the scale and
progression of OA in a controlled manner such that the disease itself can be studied and
new therapies can be developed.117,121,160,161 Ideal preclinical models are of low cost,
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reproducible and display likeness to the human pathology under investigation.117,160 In the
case of OA, one particularly important pathological consideration is the proper
progression of the disease (too rapid progression is not representative of the slowly
degenerative nature of OA and prevents the observation of subtle changes in disease
characteristics with time).117,121 One specific advantage of animal models is the ability to
establish intermediate and terminal end points of tissue collection, allowing assessment of
the disease in various stages of development.121 Genetically engineered, experimentally
induced and spontaneously occurring OA animal models are described in detail below.
Though not specific to OA, cartilage defect models have been employed to study
consequences of cartilage injury and efficacy of potential treatment options.162 Genetic
knock-out mice have been employed to study mechanisms of OA pathogenesis and
progression.163,164 However, genetic models are typically high cost and can produce lethal
genetic deletions.121 Additionally, OA can be induced through the intra-articular injection
of cartilage matrix degrading enzymes including collagenase, papain, and chondroitinase,
among others.117,161,165 These models have the advantage of being very rapidly
progressive, minimally invasive and easy to implement. However correlations between
this progression and human OA have yet to be established.121
Experimentally, OA can also be induced through surgical procedures aimed at
producing mechanical instability in the joint. These models have the advantages of
reflecting the inflammatory characteristics of OA and exhibiting quick disease
progression.117,161 However, due to the traumatic nature of OA induction these models are
not fit for studies researching degenerative OA pathogenesis.117,121 The most commonly
reported procedure to induce traumatic OA is anterior cruciate ligament transection.121
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Figure 21: Summary of Common In Vivo OA Models (arranged by size) highlighting the advantages and limitations
of each approach.

This approach has been successfully utilized in murine110,117,121,160,161,166,167 (however the
small nature of the joints limit research and applicability to humans160),
rabbit84,117,121,160,161,168,169 (however, it should be noted that rabbits primarily load the
lateral stifle and are therefore not reflective of human knee joint biomechanics121,160,161),
canine117,121,160,161 (anatomically and biomechanically, canine models are considered to
most closely mimic humans; however, public perception of canine use in research has
limited their abailability160), capra85,117,121,160 (while capra joints are similarly sized to
humans they are not prone to spontaneous OA, and the ability to reproducibly induce OA
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through surgical transection is under debate160) and cow121 models, with terminal points
varying from as little as six weeks to as long as two years. Other surgically-induced OA
models include medial meniscectomy, medial cruciate ligament transection, and
combinations thereof.117 Additionally, there are thirteen published studies assessing
randomized blinded placebo trials in traumatically-induced equine models of OA.116 The
specific advantages and disadvantages of these preclinical models have been succinctly
reviewed elsewhere.117
In some animals, OA occurs spontaneously during animal development.
Spontaneous OA has been noted in the knee joints of mice, though as previously
indicated the small nature of the joints limit the number of possible outcome measures.161
Non-human primates also exhibit spontaneous OA; however there are stringent
guidelines limiting their use in research.161 The most researched animal exhibiting
spontaneous OA is the guinea pig. Similar to the human condition, spontaneous models
have the advantage of being naturally occurring after 7 months of age, variable depending
on genetic and environmental factors such as weight and reflective of long-term
degenerative OA.117,121,160,170
Anatomically, the guinea pig knee is very similar to the human knee, though it is
much smaller.160 Additionally, guinea pigs exhibit the multi-factorial nature of bone
growth and growth plate fashion observed in humans.160 Notably, guinea pigs primarily
load the medial stifle, making the medial compartment most prone to OA development
(similar to humans).160 The histopathology of the guinea pig has been extensively
evaluated and deemed similar to human OA.160 Drawbacks of the guinea pig model
include an extensive time course (natural disease progression takes months-years to
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develop) incurring moderate-high costs.117,121,160 Though it has been suggested that more
advanced OA can be achieved through communal caging.117
The

male

Dunkin-Hartley

guinea pig model has been well
characterized and offers the following
similarities to the pathogenesis of nontraumatic, idiopathic human OA: 1) its
susceptibility to common OA risk
factors (i.e. advanced age and body
Figure 22: Guinea Pig Model of OA relies on the spontaneous
development of degenerative OA by guinea pigs, with age.
Other advantages include anatomical, biomechanical and
pathological similarities to the human condition. However, these
models require long study periods, heightening associated costs.

mass

index)171,172,

2)

spontaneous

development of progressive OA in the
medial compartment of the knee161, 3)

evidence of IL-1#, MMP-1, -3 and -13 involvement in OA173–175, 4) early-stage OA with
synovial inflammation, chondrocyte cell death, and proteoglycan loss160,176 5) its likeness
in histopathology.177 Both male and female DHGPs develop spontaneous OA. However,
the accelerated weight gain and maturation of males allows them to develop more
consistent changes consistent with OA.161 Additionally, the DHGP model illustrates
bilateral symmetry of the disease thus allowing for patient-matched degenerative
controls.161 Furthermore, recent studies indicate no adverse reaction of these animals
following implantation of human stem cells in this model.178
1.10.7 OA Treatment Options
Currently there is no cure for OA; meaning, there is no treatment option halting
the progression of the disease.11,116,118,128,129,140,160 Patients suffering from OA are offered
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palliative treatment options or surgery for symptomatic relief.11,117,120,122,128,129 These
options, as well as those currently under pre-clinical investigation, are described in detail
below.
1.10.7.1 Available Treatments
Common

treatments

for

OA

include

physical

therapy/strengthening

programs12,120,126,179, viscosupplementation12,122 and glucosamine/chondroitin sulfate
supplementation.12,120,122 All of the previously described treatment options have
demonstrated only minimal improvement compared to placebo treatment.12 The only
pharmacologic treatment recommended by the American Academy of Orthopedic
Surgeons is non-steroidal anti-inflammatory drugs (NSAIDs).11,12,118,120,126,179 Narcotics
such as Tramadol have also been utilized to alleviate pain in patients with severe OA
symptoms.12 Notably, the intra-articular injection of symptomatic slow acting drugs (ex.
HA) has met scrutiny as to whether the benefits meet the minimum clinically important
difference (MCID).126
Arthroscopic surgery (total joint replacement) has been employed to alleviate pain
and to help restore joint mobility to patients suffering from OA.11,12,120 However, a recent
comprehensive series reviewing of the success of such procedures (by the New England
Journal of Medicine) concluded that arthroscopic surgery is only minimally
effective.12,180–182 Another common surgical practice for the treatment of smaller chondral
defects is autologous chondrocyte implantation.11,12,87,112,120 Though there are reports of
increased Knee Injury and Osteoarthritis Scores, this method suffers from major draw
backs, including, the inabilities to rapidly expand chondrocytes, to maintain chondrocyte
phenotypes and to produce articular cartilage upon implantation.12,87,114 There is also data
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suggesting other experimental approaches, including one-step stem cell therapies, are
more effective than autologous chondrocyte transplantation at repairing osteochondral
lesions.183
Specifically for knee OA, the AAOS utilizes a guideline rating the level of
evidence and grade of recommendation for varying treatment modalities (patient
education & lifestyle changes, rehabilitation, mechanical intervention, pain relievers,
intra-articular injection, etc.).184 Those recommendations receiving “A” grades (i.e. most
positive endorsement) include: encouraging weight loss among overweight patients,
encouraging participation in low-grade aerobics, encouraging glucosamine or chondroitin
sulfate not be prescribed and recommending against arthroscopic debridement/lavage.
1.10.7.2 Clodronate (A Pre-clinically Investigated Treatment)
Di-chloromethylene bisphosphonate [Cl2MDP] (Clodronate) is a bisphosphonate
with known anti-bone resorption and anti-inflammatory properties.185 As a nonnitrogenous bisphosphonate, clodronate prevents the binding of specific transcription
factors to DNA, resulting in the production of a non-functional ATP competitor,
ultimately resulting in cell apoptosis.185–187 Though clodronate is primarily cited for
inducing apoptosis in macrophages, there is also evidence suggesting the induction of
apoptosis in osteoclasts and monocytes (pre-differentiated macrophages), both in vitro
and in vivo.185,188,189 Clodronate is water soluble, limiting its ability to freely cross the
phospholipid bi-layer of most cellular membranes. Thus, clodronate is commonly
delivered to the intracellular space through liposomes, taking advantage of the phagocytic
properties of the usual target cells: the osteoclast and the macrophage. In osteoclasts,
clodronate induces osteoclast cell apoptosis diminishing the overall number of
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osteoclasts, slowing the resorption of bone. This is a common therapeutic technique used
in osteoporosis.
In macrophages, clodronate induces macrophage apoptosis resulting in overall
macrophage depletion. Downstream consequences of this depletion include a reduction in
IL-1 and TNF- concentrations and overall cartilage destruction (i.e. reduced proteoglycan
and collagen loss) in experimental arthritis models.187,190,191 Macrophage depletion has
been used to model various inflammatory-based (ex. OA) as well as various growth and
development-based conditions. Historically, liposomes have been used to deliver a wide
array of genes, antigens, antimicrobials, etc. to macrophages.185,192 Liposomeencapsulation has been shown to increase clodronate efficacy by greater than 10x when
compared to free clodronate.187,193,194 This efficacy is typically analyzed through
immunohistochemical analysis of pan-macrophage marker CD68 and monocyte marker
CD14, as well as assessment of cartilage destruction at the time of surgery through Visual
Analogue Scales.185
Previously, clodronate has been shown to be somewhat effective as a therapeutic
agent in both rheumatoid arthritis and adjuvant arthritis preclinical models.185,195–197 With
mounting evidence suggesting a primary role of macrophages in OA pathogenesis,
clodronate (among other bisphosphonates) are beginning to be investigated for their
therapeutic efficacy of mitigating OA progression.122,198 Clodronate intra-articularly
injected into human knee joints resulted in improved VAS pain scores.199 Additionally,
some oral antiresorptive drugs resulted in decreased pain (assessed by WOMAC scores)
and less subchondral bone abnormalities.200
There is also evidence suggesting mesenchymal stem cells can be cultured with
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clodronate-encapsulated liposomes without adverse responses.201 Therefore, future
investigations could maximize therapeutic potential through a combined approach.
However, it should be noted that therapies targeting macrophage depletion suffer
from significant drawbacks. Firstly, for a sustained effect, clodronate therapy would need
to be administered (likely via intra-articular injection) routinely. Sustained macrophage
depletion is not possible in vivo due to recruitment of new monocytes/macrophages
through blood supply. In fact, it has been shown that the re-population of macrophages
occurs after 2 weeks.185 Secondly, there is conflicting evidence suggesting that mitigating
disease progression implies a clinical alleviation of symptoms.122 Thus, patients may
need a palliative drug regimen in addition to clodronate therapy. Thirdly, the regulatory
aspects surrounding bisphosphonate use in OA are strenuous and demanding. To date, no
such treatment has been approved through the appropriate regulatory channels.122
1.10.8 Stem Cells as an OA Therapeutic Agent
With the evolving view of OA as an inflammatory condition driven by
macrophages and their pro-inflammatory secretions, immunomodulatory therapies have
come to the forefront of investigation. Due to their trophic, anti-inflammatory and
immunomodulatory properties, stem cells may prove to be uniquely suited agents for OA
therapies.11,12,84,87,134,202
1.10.8.1 Pre-Clinical and Clinical OA Stem Cell Therapies
Numerous stem cell therapies have been described in animal models of OA. The
stem cells are typically delivered via intra-articular injection into the knee joint. In
comparison studies, stem cell therapies have been shown to yield better outcomes than
autologous chondrocyte transplantation.12 There is also evidence that the stem cells are
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still located within guinea pig joint tissues after 1 week120,170 and up to 8 weeks postimplantation in rats.120 There are also reports of the stem cells exhibiting signs of
proliferation and differentiation. 120,170
Twenty weeks post injection of 10x106 autologous BMSCs (within an HA carrier)
into goat knees, less osteophyte formation and cartilage degeneration were noted.85
Twelve weeks post injection of 9x105 BMSCs (within an HA carrier) into porcine knees,
increased type II collagen and better healing was observed.162 After 6 months, the
injection of 2x106 BMSCs (in an HA scaffold) into rabbit knees resulted in decreased
MMP activity and regenerated cartilage with increased type II collagen expression.168
The injection of 1-2x105 allogeneic ADSCs resulted in decreased MMP-1 and
TNF-α concentrations.169 ADSCs have also been shown to decrease synovitis and
proteoglycan loss in mice with collagen-induced arthritis.12 Scaffold-free infrapatellar fat
pad-derived stem cells injected into rabbit knees showed less cartilage degeneration and
osteophyte formation after 12 weeks.203
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Table 3: Summary of Stem Cell Therapies for Osteoarthritis
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Table 3: Summary of Stem Cell Therapies for Osteoarthritis noting the animal model employed, the type and
dosage of stem cells as well as significant study results. Orange text indicates the stem cells were administered via an
HA carrier.

Equine studies compared the efficacy of BMSC and ADSC intra-articular
injections through arthroscopically inducing OA in the middle carpal joint.116 There were
no significant differences reported between groups, though it was noted that the BMSCs
appeared to have a more beneficial impact.

116

Additionally, one study injecting 7x106

commercially available human stem cells into guinea pig knees reported no immune
response after 5 weeks.178 Stem cell therapies have also been experimentally utilized in
humans. Autologous BMSCs (8x106-4x107) have been intra-articularly injected with
patient follow-up for up to 2 years.

120,204–206

Such methods have resulted in decreased

patient pain as reported by WOMAC and VAS pain scales.120,204–206 Autologous ADSCs
(1x107-10x107) were injecting in a dosing study, which reported that high doses resulted
in improved joint function and decreased pain.13 Infrapatellar fat pad-derived stem cells
seeded onto PRP scaffolds have resulted in improved VAS, Lysholm and OA index
scores after 2 years.207 Injection of allogeneic BMSCs (5x107) 10 days after
meniscectomy resulted in decreased pain.208 Similar reports in France utilize autologous
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ADSCs.84
1.10.8.2 Potential Mechanisms behind OA Mitigation
Hyaluronan facilitates granulation tissue formation, the initial phase of tissue
regeneration, during natural wound healing.85,209 Stem cells also enable wound healing
through facilitating and accelerating granulation tissue formation. Additionally, many
stem cell therapies are injected in the presence of a hyaluronan (or HA) carriers.85,168,206
Such approaches likely amplify and accelerate natural tissue repair mechanisms.
As previously indicated, stem cells, especially stem cells combined with
biomaterial scaffolds, have the potential to differentiate into target cells, establishing new
populations of healthy cells in diseased areas.11,84,85 For the purposes of OA, stem cells
exhibiting enhanced chondrogenic differentiation potential would prove advantageous, as
these cells would more readily differentiate into chondrocytes upon implantation into OA
joint spaces. Though it has been demonstrated that stem cell implantation into rabbit
femoral condyles with cartilage defects resulted in the production of new cartilage, this
cartilage was not continuous with the host tissue.210,211 As previously indicated, integrity
of the surface layer of cartilage is paramount to its health and function. Thus, the
intended use of stem cells as chondrocyte progenitor cells remains questionable in
translational regenerative medicine approaches.
A more intriguing therapeutic mechanism of action is stem cell paracrine effects.
Stem cells secrete mediators which attract and home host stem cells to target areas.11,84
Focal inflammatory cells express monocyte chemoattractant protein-1 (MCP-1). Stem
cells express the MCP-1 receptor, CCR2, resulting in their recruitment to the area.84
Interestingly, stem cell therapies rarely lead to new chondrocyte formation (i.e.
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differentiation of stem cells); rather the majority of stem cells home to the synovium.140
Stem cells release a variety of growth factors and anti-inflammatory mediators
which could help modulate diseases characterized by immune-dysregulation.11,84,119,129,207
Such immunomodulatory regulators can inhibit the activation and recruitment of
inflammatory cells. Those most researched include: indoleamine 2,3-dioxygenase (IDO),
interleukin receptor antagonist (IL-1ra), prostaglandin E2 (PGE2) and IL-10.11,84,134
These anti-inflammatory mediators have been proposed as a primary mechanism through
which stem cells establish immune-suppressive local environments, aiding in their
immune-privileged status.11 Notably, stem cells also have the documented ability to
induce anti-inflammatory (M2) phenotypes in macrophages.134,212,213
It has been demonstrated that stem cells must be “primed” in order to exhibit antiinflammatory and immunomodulatory characteristics.134,214 Typically this involves the
stimulation of stem cells through potent pro-inflammatory cytokines such as INFγ.84,214
Though the exact timeline has not been established, the need for priming does represent
an inherent delay in the efficacy of OA stem cell therapies. This could be one explanation
for delays in patient progress post initiation of stem cell therapy.
1.10.9 Amniotic Membrane Derived Stem Cells & OA
Though adult stem cells have been widely investigated as a potential OA
therapeutic, there are drawbacks associated ADSCs and BMSCs that are less attributable
to alternative stem cell sources (such as perinatal stem cells). Examples include the
inability of BMSCs isolated from OA patients to proliferate and differentiate as
effectively as BMSCs from healthy donors.10–12,85 Adult trabecular bone mesenchymal
stem cells have exhibited similar deficiencies.12 OA BMSCs exhibit an increased
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potential for osteogenic and a decreased potential for chondrogenic differentiation.10,11,112
Though it has been suggested that additional exogenous growth factor supplementation
can curb these abnormal effects.12,215,216 Human periosteal mesenchymal stem cells
exhibit spontaneous chondrogenic differentiation in younger donors (< age 30).12
However, the majority of OA cases occur in patients above age 65. Additionally,
implantation of pre differentiated BMSC (into a chondrogenic phenotype) in a capra OA
model resulted in non-maintenance of the chondrocyte phenotype (cell demonstrated an
increased likelihood of hypertrophy an decalcification).87,217
Additional drawbacks of using adult stem cells include low stem cell yields and
painful harvest procedures.87 More recently perinatal stem cells have illustrated promise
as an alternative stem cell source for regenerative medicine.68,218 Previously it has been
shown that cord blood MSCs differentiate more readily into chondrocytes compared to
ADSCs and BMSCs.87,219 Moreover, cord blood MSCs have the capacity to differentiate
into chondrogenic phenotypes in pro-inflammatory environments comparable to OA;
whereas BMSCs do not.87 Furthermore, cord blood MSCs exhibit increased expression of
anti-inflammatory mediators (compared to BMSCs) in OA co-culture models.87
An equally intriguing, though less researched, perinatal stem cell source are those
stem cells derived from the amniotic membrane (a tissue routinely discarded as medical
waste following the birth of full-term babies). Advantages of amniotic membrane derived
stem cells (hAMSCs) include 1) their capacity for chondrogenic differentiation and
generation of cartilage91,97,220, 2) their availability of large cell yields at harvest49,54,71, 3)
their ontogenically youthful status limiting their exposure to detrimental age-related
changes221, 4) their proven immunomodulatory and immunosuppressive nature.55,68,220,222–
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224

Furthermore, recent evidence suggests that perinatal stem cells exhibit superior

chondro-protective effects in an inflammatory environment, exhibiting the ability to
induce a pro-regenerative (M2) phenotype within synovial macrophages.73,87 There is
also evidence suggesting hAMSCs do not require inflammatory priming prior to initiating
therapeutic benefit.225 Notably, such characteristics do not appear to be affected by
freeing or heating cycles, a necessary property owing to the likely need for tissue banking
of such a stem cell source.225
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CHAPTER TWO
PROJECT APPROACH
2.1 Significance
Stem cells are being investigated as alternative therapeutics for numerous
orthopedic regenerative medicine approaches, largely due to their musculoskeletal
differentiation, anti-inflammatory and immunomodulatory capacities.4,6,7,11 In order for
stem cell therapies to be effective, high numbers of stem cells must be utilized.
Therefore, stem cells exhibiting musculoskeletal differentiation, anti-inflammatory and
immunomodulatory capacities as well as high yields would be an ideal stem cell source
for orthopedic regenerative medicine approaches.
The largest subset of musculoskeletal tissue pathologies involves bone and/or
cartilage. Currently, no side-by-side comparative analyses have been conducted in order
to determine which stem cell source(s) most robustly differentiates into osteogenic and
chondrogenic lineages. Such information would allow clinicians to utilize the best-suited
stem cells source in future therapeutic approaches.
While stem cells have shown promise in prevalent musculoskeletal tissue
pathologies, including osteoarthritis, few stem cell sources have been evaluated in such
therapeutic approaches.85,116,162,168,178,203 Amnion membrane derived stem cells have yet
to be investigated as an OA therapeutic. Additionally, no side-by-side comparisons have
been conducted in order to determine the relative efficacy of amnion-based approaches
with those currently under pre-clinical investigation (adipose derived stem cells and bone
marrow derived stem cells). These authors also know of no (ex vivo or in vivo) studies
comparing the differential therapeutic effects of stem cell administration location.
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Stem cells from the amniotic membrane (a tissue routinely discarded after the
birth of term pregnancies) exhibit numerous characteristics of an ideal stem cell source,
including, heightened differentiation potential, availability in high yields, heightened
immunomodulatory properties, the ability to induce pro-regenerative (M2) phenotypes
within macrophages.49,54,55,68,71,73,87,91,97,220,222–224 Additionally, perinatal stem cells may
offer accelerated treatment time lines as they do not require pro-inflammatory priming
prior to initiating therapeutic benefit.225 Thus, amnion membrane derived stem cells are
likely an under investigated stem cell source for orthopedic tissue engineering and
regenerative medicine strategies.

2.2. Specific Aims
Our goal is to investigate the utility of amnion derived stem cells for orthopedic
regenerative medicine. Through standardized ex vivo comparative analyses, we aim to
compare the relative efficacy of amnion derived stem cell differentiation and therapeutic
relevance with a commonly utilized stem cell source, adipose derived stem cells.
2.2.1 Aim I: To directly compare the abilities of amnion and adipose derived stem
cells to differentiate towards osteogenic and chondrogenic lineages
Our goal is to compare the efficacy of amnion and adipose stem cell
differentiation towards osteogenic and chondrogenic lineages, offering initial insight into
the utility of amnion derived stem cells in orthopedics. In order to accomplish this, an
amnion stem cell harvest procedure and optimized differentiation protocols must be
developed. Utilizing such methods a controlled ex vivo comparison of differentiation
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should be conducted evaluating both genes and proteins characteristic of the respective
lineages being examined.
2.2.2 Aim II: To validate a human explant joint tissue co-culture model of OA
Our goal is to validate an ex vivo platform for testing potential future OA
therapeutics, including amnion derived stem cells. Such a platform (i.e. a validated model
of osteoarthritis) should demonstrate likeness to the human condition by demonstrating
disease progression, pathophysiological levels of pro-inflammatory cytokines and
synovial macrophage involvement. Macro and micro-architecture, inflammatory as well
as biochemical assessments should be employed in order to verify such characteristics.
Aim III: To evaluate the ability of MSCs to mitigate OA progression in this
validated ex vivo model
Our goal is to investigate the utility of amnion derived stem cells as an OA
therapeutic, ex vivo, and to compare their efficacy against a field standard stem cell,
adipose derived stem cells. This controlled comparison (where all experimental variables
excluding one (i.e. stem cell type or administration location) are held constant) should
investigate differential therapeutic effects between routes of administration and allow for
meaningful insights regarding the efficacy and mechanism of action of MSCs in OA. As
before, macro and micro-architecture, inflammatory as well as biochemical assessments
should be employed in order to examine these claims.
Aim IV: To compare the therapeutic effects of hAMSCs and hADSCs to attenuate
OA progression in vivo
Our goal is to investigate the differential therapeutic effects of amnion and
adipose derived stem cells in an established animal model of OA. This pilot study will
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provide foundation in vivo evidence into the utility of amnion membrane derived stem
cells as an efficacious therapeutic for OA. This approach involves demonstrating OA
disease progression in non-treated control animals as well as showing mitigation of
disease progression in treated animals. As before, macro and micro-architecture,
inflammatory as well as biochemical assessments should be employed in order to
examine these claims.
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CHAPTER THREE
AIM I: TO DIRECTLY COMPARE THE ABILITIES OF AMNION AND ADIPOSE
STEM CELLS TO DIFFERENTIATE TOWARDS & CHONDROGENIC LINEAGES
3.1 Introduction
Cartilage defects represent debilitating lesions, which cause patients significant
pain and oftentimes lead to patient immobility.226,227 A majority of these are classified as
full thickness cartilage defects, which involve not only the articular cartilage but also the
sub-chondral bone.227–229 Cartilage in particular lacks the intrinsic ability to repair and
regenerate itself.226,229 This is in part due to the senescent phenotype of the host cells,
chondrocytes, preventing the generation of healthy extracellular matrix (ECM) required
to fill defect areas. Surgically, such defects are currently addressed by micro fracture or
autologous chondrocyte transplantation.227–229 Both of these techniques function by
introducing populations of healthy, reparative cells to the defect area in the hopes that the
cartilage ECM will be regenerated and joint function will be improved.227–229
Mesenchymal stem cells represent a recently investigated alternative approach to
cartilage defect repair largely due to their ability to differentiate into both cartilage and
bone phenotypes.226,227,229,230
Adult mesenchymal stem cells are considered alternative cell sources for use in
orthopaedic regenerative medicine. Typically derived from bone marrow (hBMSCs) or
adipose tissue (hADSCs), these cells have the ability to self renew, exhibit
immunomodulatory properties and differentiate towards numerous tissue lineages.63 Both
cell types have been extensively investigated in preclinical osteochondral defect models
as well as in human clinical trials, demonstrating significant clinical improvement (i.e.
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reduced pain, decreased symptom intensity and/or radiographic evidence of cartilage
damage) as well as various degrees of cartilage regeneration.226,227,229,230 Additionally,
early results indicate greater therapeutic efficacy using such approaches as compared to
autologous chondrocyte transplantation.22,229
Recently, researchers have begun investigating the potential efficacy of perinatal
stem cell populations (isolated from the amnion harvested after the birth of term
pregnancies) for orthopaedic applications.68 Based on the minimal criteria established by
the International Society for Cellular Therapy; 1) the ability to differentiate into
osteogenic, chondrogenic and adipogenic lineages, 2) >95% positive expression of CD73,
CD90 and CD105, and 3) <2% positive staining for CD45, CD34, CD14 or CD11b, and
CD79 or CD19)25, there exists two primary cell types within the amnion exhibiting stem
cell characteristics: amniotic epithelial cells (hAECs) and amniotic mesenchymal stem
cells (hAMSCs). Developmentally, these cells arise from the pluripotent epiblast.218,221
This may imply that these cells retain embryonic stem cell-like characteristics, potentially
offering more robust therapeutic advantages.
While some have attempted to validate the use of perinatal cells in orthopaedic
applications, none have conducted side-by-side comparisons of human amnion derived
cells with adult mesenchymal stem cells in regards to their capacity to differentiate
towards musculoskeletal tissue cell types. Significantly, the osteogenic and chondrogenic
differentiation capacities of hADSCs and hBMSCs have been well established to occur at
approximately 21-28 days.231–234 However, there is evidence suggesting the
differentiation of perinatal stem cells may occur earlier than this, indicating perinatal
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stem cells may be an alternative therapeutic with an accelerated timeline to clinical
benefit.
It has been widely established that numerous experimental conditions impact stem
cell properties, including their differentiation capacity.54,89,92 Experimental variables
including stem cell passage number, media type and growth factor supplementation, cell
seeding method or densities and gas exchange (i.e. hypoxic conditions), are often held
consistent within studies. However various researchers employ different experimental
methods making it difficult to directly compare results across studies found throughout
published literature. Herein, studies were undertaken to compare the osteogenic and
chondrogenic differentiation potential of human amnion and adipose derived stem cells
under identical, standardized culture conditions with the goal of providing meaningful
insight into the potential clinical efficacy of these cell types for the management of
osteochondral defect repair/regeneration.
3.2 Materials & Methods
hADSCs were purchased from Invitrogen (R7788-110). Trypsin was purchased
from Fisher scientific (MT-25-053CI). Collagenase was purchased from Worthington
Biochemicals (LS004196). Ambion Trizol Reagent (15-596-026) and Turbo DNA Free
Kit (AM10907) were purchased from Fisher Scientific. Ambion RETROscript Reverse
Transcription Kit was purchased from Life Technologies (AM1710). Qiagen QuantiTect
Primer Assays employed in this work included: runx-2 (QT00020517), osteocalcin
(QT00232771),

sox-9

(QT00001498),

aggrecan

(QT00001365),

collagen-2

(QT00049518) and GAPDH (QT00079247). QuantiTect SYBR Green PCR Kit was also
purchased from Qiagen (204143). Alizarin Red (A5533-25G) and Alcian Blue (A3157-
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10G) stains were purchased from Sigma. Normal Horse Serum (S2000), VECTASTAIN
Elite ABC Kit, Rabbit IgG (PK-6101) and DAB Substrate Kit (SK4100) were purchased
from Vector Laboratories, Inc. Triton X-100 and other basic chemicals were purchased
from Fisher Scientific. Antibodies employed in this work included: mouse anti CD105
(BD Biosciences, 555690), mouse anti CD73 (BD Biosciences, 550256), mouse anti
CD45 (BD Biosciences, 555480), mouse anti CD90 (BD Biosciences, 555593), mouse
anti EpCAM (BD Biosciences, 347198), rabbit anti collagen-2 (Abcam, Ab85266), and
goat anti-mouse FITC secondary antibody (abD Serotec STAR117F).
3.2.1 Amniotic Membrane Harvest
Human placentas were obtained from consenting patients immediately following
delivery via elective cesarean sections of full-term babies (Pro00031185-Greenville
Health System). Amniotic membrane derived cells were isolated within 4 hours of
delivery.
3.2.2 Isolation and Enrichment of hAEC and hAMSC Populations
Placentas (n=3) were placed with the umbilical cord facing upward such that the
fetal (amniotic) surface was accessible (Figure 23A). The amniotic and chorionic
membranes were identified and mechanically peeled from each other (Figure 23B).
Enriched hAEC and hAMSC cell isolation methods were adapted from Barbati et al.55
Briefly, amnions were digested twice in 0.25% trypsin for 30 minutes at 37°C with
agitation to completely liberate hAECs followed by complete digestion in two digestions
of collagenase [2mg/mL collagenase (249 U/mg)] for 30 minutes at 37°C with agitation
each to subsequently liberate hAMSCs.
3.2.2.1 Histological Confirmation of Amnion Cell Isolation
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Amnion sections were secured within a tissue processing cassette, fixed in 10%
phosphate buffered formalin overnight at room temperature prior to undergoing standard
tissue processing, paraffin embedding and sectioning to 5 µm thickness. Sections were
stained with Hematoxylin and Eosin (H&E) for visualization of ECM and cell nuclei.
3.2.2.2 Flow Cytometric Analysis for Stem Cell Markers
Cells were incubated in primary antibody (either CD105, CD73, CD45, CD90, all
at 5µg/mL dilution or EpCAM at 0.3µg/mL dilution) for 30 minutes at room temperature.
After 30 minute room temperature incubation in goat anti-mouse FITC secondary
antibody (at 5µg/mL dilution), samples were read on a Guava easyCyte™ Single Sample
Flow Cytometer.
3.2.3 Confirmation of a Mixed Amnion Cell Population
Briefly, the amnion (n=1) was digested twice in 0.125% trypsin for 30 minutes at
37°C with agitation to incompletely liberate hAECs followed by complete digestion in
collagenase (two 2mg/mL collagenase (249 U/mg) digestions for 30 minutes at 37°C
with agitation) to liberate the remaining hAECs and hAMSCs, termed the “Mixed” cell
population. Cells were analyzed histologically and via flow cytometry as previously
described.
3.2.4 hADSC and Amnion Derived Cell Osteogenic Differentiation Potential
3.2.4.1 Culture Conditions for Stem Cell Differentiation
In preparation for in vitro differentiation studies, all cell types were expanded in
standard culture medium under standard culture conditions (37°C with 5% CO2) with
media changes every 3 days. The standard culture expansion medium for hAECs
consisted of DMEM supplemented with 10ng/mL epidermal growth factor, 10% fetal
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bovine serum and 1% antibiotic/antimitotic. The standard medium for hAMSCs and
Mixed cells consisted of DMEM supplemented with 10% fetal bovine serum and 1%
antibiotic/antimitotic. The standard (manufacture recommended) culture medium,
MesenPro, was used for expanding hADSCs following the manufacturer’s instructions.
All cells were used at passage 2. To induce osteogenic differentiation, cells were seeded
at a density of 2.1x104/cm2 into tissue treated 12-well plates and cultured in monolayer
for up to 28 days in osteogenic differentiation media (DMEM, 10% FBS, 1%AB/AM,
0.1uM dexamethasone, 50µM ascorbate-2-phosphate, 10mM β-glycerophosphate).
Negative

controls

were

maintained

in

standard

culture

media

(DMEM+10%FBS+1%ABAM). Differentiation capacity was assessed via histological
staining (n=2/condition, described below) and gene transcript expression (n=4/condition,
described below).
3.2.4.2 Gene Transcript Analysis
Total RNA from all differentiated and control conditions were isolated using
Trizol reagent according to the manufacture’s instructions. RNA integrity and
quantification was assessed using a BioTek Epoch reader according to the manufacture’s
instructions. A total of 600µg-1mg of RNA was reverse transcribed using the Ambion
RETROscript kit. Resulting cDNA was amplified using a Rotogene 3000 thermocycler.
Reaction products were detected using human QuantiTect primers in conjunction with a
QuantiTect SYBRgreen polymerase chain reaction (PCR) kit. Gene expression ratios
were calculated using the 2-Δct method with GAPDH serving as a housekeeping gene.
Gene expression is reported as fold increase. For native (baseline) gene expression, fold
increase was calculated by the following equation: 2-Δctamnion cell group / 2-ΔcthADSCs. For
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induced gene expression, fold increase was calculated according to the following
equation: 2-Δctinduced /2-Δctcontrol, where control gene expression values were derived from
controls of the same cell type cultured to the same time-point in the absence of induction
medium.
3.2.4.3. Alizarin Red Histological Staining for ECM Calcification
Well plates were fixed in 4% formaldehyde for 30 minutes at room temperature
prior to 3-minute Alizarin Red staining (2% aqueous Alizarin Red, pH 4.2) for
visualization of calcium deposition. The percentage of the total well-plate area stained
positive was quantified via color threshold analysis using NIH Image-J software by two
blinded observers.
3.2.5 hADSC and Amnion Derived Cell Chondrogenic Differentiation Potential
3.2.5.1 Culture Conditions for Stem Cell Differentiation
To induce chondrogenic differentiation, cells were seeded in pellet culture (1x105
cells per pellet) and cultured in chondrogenic differentiation media (DMEM, 1% FBS,
1% ABAM, 6.25µg/mL Insulin Transferrin Selenium, 50nM Ascorbate-2-phosphate,
10ng/mL human TGF-β). Controls were plated at a density of 2.1x104/cm2 into tissue
treated 12-well plates (i.e. 1x105 cells per well) and cultured in monolayer with standard
culture media (DMEM+10%FBS+1%ABAM). Differentiation capacity was assessed via
histological staining (n=2/condition, described below) and gene transcript expression
(n=4/condition, previously described).
3.2.5.2 Alcian Blue Histological Staining for ECM Glycosaminoglycan Content
Chondrogenic cell pellets (n=3 pellets/condition) were fixed in 10% phosphate
buffered formalin for 30 minutes at room temperature before undergoing manual tissue
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processing (utilizing the standard protocol of serial ethanol washes followed by Xylene
and paraffin washes), paraffin embedding and sectioning. Sections were mordant in 3%
aqueous Acetic Acid solution for 3 minutes prior to 30-minute staining in Alcian Blue
(1% Alcian Blue in 3% aqueous Acetic acid, pH 2.5) for visualization of GAG
deposition. Sections were counterstained with 0.1% aqueous Nuclear Fast Red for 5
minutes for visualization of cell nuclei. The percentage of the total cell pellet area stained
positive was quantified via color threshold analysis using NIH Image-J software by two
blinded observers.
3.2.5.3 Immunohistochemistry for Collagen Type 2
Immunohistochemistry (IHC) on rehydrated paraffin sections was performed for
detection of collagen type 2 in chondrogenic cell pellets (n=3 pellets/condition). Briefly,
antigen retrieval was accomplished via 10mM Citric Acid incubation at 90°C for 20
minutes. Sections were permeabilized with 0.025% Triton X-100 for 10 min and then
incubated in normal blocking serum for 45 min at room temperature. Primary antibody
(rabbit anti-collagen-2, 5µg/mL dilution) was applied for 1 h at room temperature.
Negative staining controls did not receive primary antibody. Blocking of endogenous
peroxidases was accomplished via incubation in 0.3% hydrogen peroxide in 0.3% horse
normal serum for 30 min at room temperature. Visualization of antibody was
accomplished via staining with the Vector ABC peroxidase substrate kit. Sections were
counterstained with Hematoxylin prior to microscopic imaging.
3.2.6 Microscopic Imaging
Images were captured on a Zeiss Axiovert.A1 microscope with Axiovision
software (Release 4.9.1 SP08-2013).
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3.2.7 Statistical Analysis
Results are represented as a mean ± standard error of the mean (SEM). All
statistical analyses were performed by two-tailed Student’s t-test of unequal variance or
analysis of variance (ANOVA) with a Tukey’s post-hoc analysis. Significance was
defined in all cases as p<0.05.
3.3 Results
3.3.1 Amniotic Membrane Harvest

Figure 23: Amniotic Stem Cell Harvest, Isolation and Characterization. A) Representative image of a human
placenta with umbilical cord (black arrowhead) and epithelial layer of the amniotic membrane (white arrowhead)
facing upwards. B) Image depicting the separation of the amniotic membrane (white arrowhead) from the chorion
(black arrowhead). Representative H&E histological sections of C) fresh amniotic membrane exhibiting a continuous
layer of hAECs (arrow heads) and intact stroma containing hAMSCs (box), D) amniotic membrane following
incomplete removal of hAECs (arrowheads) with 0.125% trypsin and E) amniotic membrane after complete removal of
hAECs with 0.25% trypsin. Polarized light microscopy of monolayer culture expanded amnion derived cells; F)
hAECs (cuboidal morphology - black arrowheads), G) a mixed population of hAECs (black arrowheads) and hAMSCs
(white arrowheads) following incomplete dissociation of hAECs (0.125% trypsin) and H) hAMSCs (spindle
morphology - white arrowheads). I) Average viable cell yields from term human amniotic membrane. J) Flow
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cytometric analysis of cell surface mesenchymal stem cell, hematopoietic and epithelial markers expressed on passage
2 hAECs, hAMSCs and a mixed population of both cell types (data represented as % positive staining ± SEM).

Human placentas were successfully harvested (Figure 23A) and amniotic
membranes were isolated (Figure 23B) within 3 hours of delivery of full-term babies.
Histological analysis prior to membrane manipulation revealed a confluent layer of
epithelial cells (Figure 23C – arrowheads) and an intact stromal layer (Figure 23C – box)
containing mesenchymal cells.
3.3.2 Confirmation of Enriched hAEC and hAMSC Populations from Amniotic
Membrane
Histological analysis of amniotic membranes following two serial digestions in
0.25% Trypsin showed that the confluent epithelial layer was completely removed
(Figure 23E). Subsequent collagenase digestion released the remaining cells from the
stromal layer. Phase contrast microscopy of these plated cells revealed two distinct
morphologies: cobblestone- and spindle-shaped (Figures 23F & H, respectively)
indicative of epithelial and mesenchymal cells, respectively. Flow cytometric analysis of
these cells at passage 2 illustrated that both cell types were positive for mesenchymal
stem cell markers (CD73, CD90 and CD105) and negative for the lymphocyte common
antigen, CD45 (Figure 3.1J). Cells isolated from the epithelial layer via trypsin digest
(hAECs) were positive for epithelial marker, EpCAM, whereas cells isolated from the
stroma via collagenase digestion (hAMSCs) were negative. Viable hAEC and hAMSC
yields at harvest were determined to be 2.3x106 ± 3.7x105 and 1.6x106 ± 4.7x105 per
milliliter of amnion, respectively. Considering the average amniotic membrane size at
harvest, approximately 4.2x107 ± 8.2x106 hAECs and 2.8x107 ± 7.2x106 hAMSC were
obtained from each membrane.
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3.3.3 Confirmation of a Mixed Amnion Cell Population
Histological analysis of amniotic membrane following two serial digestions in
0.125% Trypsin revealed a partially intact epithelial layer (Figure 23D). Subsequent
collagenase digestion released the remaining cells from the epithelial and stromal layers.
Phase contrast microscopy of these plated cells revealed a mixed morphology of
cobblestone and spindle-shaped cells (Figure 23G). Flow cytometry further confirmed
this mixed population of cells, as the surface profiles of these cells appeared to be a
hybrid of the enriched hAEC and hAMSC populations with roughly 40% of the cell
exhibiting positive staining for EpCAM (Figure 23J).
3.3.4 hADSC and Amnion Derived Cell Osteogenic Differentiation Potential
Gene transcript analysis of cells under normal culture conditions (in the absence
of osteogenic differentiation media) indicated that hAECs demonstrated a significant
increase in runx-2 expression at day 14 compared to their respective day 3 values (Figure
24A). Conversely, runx-2 expression was significantly decreased in hAMSCs compared
to their day 3 values. Furthermore, the amnion cell cultures trended towards having
increased runx-2 expression compared to hADSCs (dotted line) at all time-points
analyzed. With respect to osteocalcin, hAEC expression tended to be higher than
hADSCs at all time-points investigated (Figure 24B).
After osteogenic induction, runx-2 expression peaked at earlier time points in the
hAECs and mixed cell groups compared to hADSCs (Figure 24C). Additionally, the fold
increases in runx-2 expression was significantly greater in the mixed and hAMSC groups
compared to hADSCs at day 3 and 7, respectively. Interestingly, hAECs demonstrated a
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significantly (p<0.05) lower fold change in runx-2 expression as compared to hADSCs at
all time-points. The fold increases in osteocalcin observed in all amnion derived cell
groups were significantly greater (p<0.05) than the changes observed in hADSCs at day
14 (Figure 24D).

Figure 24: Osteogenic Gene Transcript Expression of Human Amnion Derived Cells and hADSCs. Native
(baseline) transcript expression levels of A) runx-2 and B) osteocalcin in hAECs, mixed (hAEC+hAMSC) and hAMSC
groups relative to hADSCs (dotted line). C) runx-2 and D) osteocalcin expression of all osteogenically induced cell
types as compared to control expression levels (i.e. cells of the same type cultured in non-induction media cultured to
the same time-point; dotted line). * indicates statistical difference from hADSC group at same time point (p<0.05). #
indicates statistical difference from day 3 time point (p<0.05).

Semi-quantitative Alizarin Red staining indicated that the hAEC and mixed cell
groups deposited significantly (p<0.05) more calcium at day 3 compared to hADSC
(Figure 25A). Additionally, all amnion groups demonstrated significantly (p<0.05)
increased presence of calcified matrix as compared to hADSCs at day 14 (Figure 25B).
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Interestingly, hAECs cultured under normal conditions (in the absence of osteogenic
media) demonstrated calcium deposition after 28 days (Figure 25C), whereas mixed
amnion cell groups (Figure 25D) and hADSCs (data not shown) did not.

Figure 25: Osteogenic Calcified Matrix Expression of Human Amnion Derived Cells and hADSCs. A) Alizarin
red staining of monolayer cultures of osteogenically induced hAECs, mixed (hAEC+hAMSC), hAMSCs, and hADSCs
(red=positive staining for calcium deposition) at day 7 and 14. B) Quantitative analysis of percent area of the well
stained positive for calcium deposition. Alizarin Red staining of C) hAECs and D) mixed cells cultured in the absence
of osteogenic induction medium. * indicates statistical difference (p<0.05) from hADSC group at same time point. #
indicates statistical difference from day 3 time point (p<0.05).

3.3.5

Comparison

of

hADSC

and

Amnion

Derived

Cell

Chondrogenic

Differentiation Potential
Gene transcript analysis of cells under normal culture conditions (in the absence
of chondrogenic differentiation media) showed that hADSCs (dotted line) had higher
expression of the master chondro-regulatory transcription factor sox-9 as compared to the
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hAMSC and mixed amnion cell groups at day 14 (Figure 26D). Conversely, hAECs
tended to express greater levels of sox-9 compared to hADSCs (dotted line) at all timepoints. Conversely, hAEC and hAMSC cell groups innately expressed higher levels of
aggrecan gene transcript compared to hADSCs by day 14 (Figure 26E). The mixed
amnion cell group demonstrated a significant increase in innate collagen type 2 gene
expression as the culture period increased and both mixed and hAMSC groups tended to
have increased collagen type II gene expression as compared to hADSCs (Figure 26B).
Of note, collagen type 2 expression was highly variable in the hAEC study group (data
not shown).

Figure 26: Chondrogenic Gene Transcript Expression of Human Amnion Derived Cells and hADSCs. Native
(baseline) transcript expression levels of D) sox-9 and E) aggrecan in hAECs, mixed (hAEC+hAMSC) and hAMSC
groups relative to hADSCs (dotted line). A) sox-9, B) aggrecan and C) runx-2 expression of all chondrogenically
induced cell types as compared to control expression levels (i.e. cells of the same type cultured in non-induction media
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cultured to the same time-point; dotted line). * indicates statistical difference from hADSC group at same time point
(p<0.05). # indicates statistical difference from day 3 time point (p<0.05).

After chondrogenic induction, all amnion derived cells exhibited significantly
(p<0.05) increased sox-9 gene transcript expression as early as day 3 (in Mixed and
hAMSCs cell groups) and day 7 (in hAECs) as compared to hADSCs at the same time
points (Figure 26A). As expected, peaks in sox-9 expression tended to precede peaks in
aggrecan expression; however these peak values tended to appear earlier in hAMSC and
Mixed cell groups as compared to hAEC and hADSCs. The fold change in aggrecan gene
transcript expression peaked at day 7 in all amnion derived cell groups; these values were
significantly greater than those of hADSCs at day 7 (Figure 26B). Notably, Mixed and
hAMSC cell groups exhibited the largest fold change in aggrecan gene transcript
expression of all differentiated cell types. The fold change in collagen type 2 gene
transcript expression peaked in all differentiated cell types at day 7 (Figure 27C).
Additionally, hAMSC and mixed amnion cell groups expressed greater levels of collagen
type 2 compared to hADSCs at this time point (Figure 27C). Interestingly, runx-2 gene
transcript expression in chondrogenically induced cells tended to be greater in hADSCs
as compared to all amnion derived cell groups, though this difference was only
significant at day 3 (Figure 26C).
Immunohistochemical staining of cell pellets for collagen type 2 illustrated that
Mixed and hAMSC cell groups produced collagen type 2 enriched matrix as early as 7
days (Figure 27A). This continued through 14 days, at which time hADSC groups
exhibited minimal collagen type 2 matrix production.
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Figure 27: Chondrogenic gene transcript and cartilage matrix expression of collagen-2 in human amnion
derived cells and hADSCs. A) Immunohistochemical staining (brown=positive staining for collagen-2 matrix) of
chondrogenically induced hAMSC, Mixed (hAEC+hAMSC) and hADSC cell pellets. B) Native (baseline) transcript
expression levels of collagen-2 in hAECs, mixed (hAEC+hAMSC) and hAMSC groups relative to hADSCs (dotted
line). C) Collagen-2 expression of all chondrogenically induced cell types relative to native (baseline) expression levels
(dotted line). * indicates statistical difference from hADSC group at same time point . # indicates statistical difference
from day 3 time point (p<0.05).

Histological analysis of chondrogenic cell pellets indicated a progressive increase
in pellet diameter with time in culture (Figures 28A & C). At 7 days, the Mixed and
hADSC cell groups exhibited the largest pellet diameter, whereas hAMSC pellets were
the smallest. However, semi-quantitative Alcian Blue staining indicated that pellets
formed by Mixed and hAMSC cell groups had significantly increased areal staining of
GAG-enriched matrix at all time-points investigated as compared to the hADSC cell
group (Figure 28B).
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Figure 28 Chondrogenic matrix component expression of human amnion derived cells and hADSCs. A) Alcian
Blue staining for glycosaminoglycan of chondrogenically induced hAEC, Mixed (hAEC+hAMSC), hAMSC and
hADSC cell pellets (blue=positive staining for GAG) at day 7 and day 14. B) Quantitative analysis of percent area of
the cell pellet stained positive for GAG C) Comparison of chondrogenically induced hAEC, Mixed (hAEC+hAMSC),
hAMSC and hADSC cell pellet diameter at day 7 and 14. * indicates statistical difference from hADSC group at same
time point (p<0.05). # indicates statistical difference from day 3 time point (p<0.05).

3.4. Discussion
Herein, we demonstrate the ability of amnion derived stem cells to differentiate
earlier and more robustly into osteogenic and chondrogenic lineages compared to a
commonly used stem cell source; hADSCs. Specifically, our results highlight the utility
of hAECs and hAMSCs as well as hAMSCs and mixed (hAEC+hAMSC) cell
populations for osteogenic and chondrogenic differentiation, respectively. Furthermore,
we confirm the availability of amnion cells to be obtained in large quantitates. The
prevalence of osteochondral defects coupled with the progression of such lesions to
debilitating musculoskeletal tissue pathologies (i.e. osteoarthritis), highlight the need for
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alternative therapeutic strategies, addressing both the bone and cartilage. Therefore, a
stem cell source exhibiting enhanced osteogenic and chondrogenic differentiation could
prove beneficial.
Histological analysis prior to enzyme digest indicated that the mechanical
separation of the amniotic membrane from the chorion during tissue harvest and
subsequent transport did not detrimentally alter the native architecture of the amnion as
evidenced histologically by an intact amniotic epithelium and underlying stroma.
Histological and flow cytometric results demonstrated the ability to isolate both hAECs
and hAMSCs via sequential enzymatic digestion with trypsin and collagenase,
respectively and that they maintain stemness markers through passage two. These results
are in alignment with previous reports which demonstrate that both cell populations
exhibit stem cell characteristics.54,58,92,224,235 In addition to the minimal criteria established
by the International Society for Cellular Therapy, hAECs have been shown to express
pluripotent stem cell markers such as NANOG and SOX-2, only minimally express
HLA-A/B/C, and do not express HLA-DP/DQ/DR surface antigens.58,236 However, there
are mixed reports of hAEC surface expression (particularly CD105), especially with
serial passaging.49,237,238 hAECs have been shown to express similar major
histocompatibility complex surface profiles as hAMSCs.54,57,224,235 Flow cytometric
analysis performed within the current study allowed for the confirmation of the isolation
of these two distinct cell populations from one another, or in the case of the Mixed cell
group, the hybrid isolation of these cell types. The Mixed group was included in this
study for two primary purposes. First, it potentially represents a more clinically relevant
amnion-based therapeutic approach, where the entire amnion (with its two comprising
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stem cell like cell populations) would be utilized. Examples of such previously
investigated approaches have been succinctly reviewed elsewhere.68 However our results
appear to indicate lower levels of CD90 and CD73 from cells in this Mixed population
state. Second, some isolation methods described throughout literature indicate that in
many instances collagenase digestion is performed on the amniotic membrane without
prior trypsinization thus yielding a mixed population of amniotic cells. Thus it would be
beneficial to determine if the presence of both stem cell types simultaneously have an
effect on differentiation potential and so that comparisons to these studies could be
drawn.
Isolated amniotic membranes varied in size (16.8mL±3.8mL), with cell yield
directly relating to amnion weight [mg] and volume [mL]. Similar to previous reports,
our results demonstrated higher numbers of hAECs than hAMSCs isolated from the
amniotic membrane.10,49,54,55,71 We report an average of 2.3x106 hAEC and 1.6x106
hAMSC per mL amniotic tissue, which is significantly greater than the reported 5.4x105
hADSCs isolated per mL from adipose tissue.61
hADSCs were chosen as a representative mesenchymal stem cell for comparative
analysis due to their proven osteogenic and chondrogenic differentiation potential, the
numerous studies confirming their stem cell criteria, and their clinical relevance (relative
abundance with minimally invasive harvest procedures).63 The osteogenic and
chondrogenic differentiation capacities of hADSCs and hBMSCs have been well
established to occur after 21 days in their respective induction media.231–234 Considering
this, the current study was designed to analyze initial time points at less than 21 days in
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order to establish if amnion derived cells were capable of differentiation prior to this
time.
Innate gene transcript expression results for the current experiments were
consistent with reports that amnion derived cells exist in a multi-differentiated state,
meaning in their natural, undifferentiated state they can express genes of each germ layer
(i.e. endodermal and mesodermal for hAECs and hAMSCs, respectively).89 Consistent
with previous reports, our analysis also revealed all three cell types investigated could be
successfully differentiated into osteogenic and chondrogenic lineages.42,63,89,93
With respect to osteogenic gene transcript expression, hAECs demonstrated a
trend towards increased innate expression of runx-2 and osteocalcin compared to
hADSCs. Following induction, hAMSCs demonstrated the highest runx-2 expression at
day 7. Additionally, all amnion derived cell groups demonstrated significantly higher
osteocalcin expression at day 14 compared to hADSCs with hAECs demonstrating the
highest fold change in expression.
Furthermore, differentiation of amnion derived cells appeared to precede hADSCs
and resulted in more robust matrix production. More specifically at nearly every timepoint investigated, significantly more calcified matrix was found in the presence of
amnion derived cells as compared to hADSCs, especially in cultures with hAMSCs and
hAECs suggesting enhanced osteogenesis.

Of note, in the absence of osteogenic

induction media, hAECs were able to produce calcified ECM by 28 days; a phenomenon
that was not observed in hAMSC, mixed or the hADSC group. This is not the first report
on the innate capacity of hAECs to differentiate into an osteogenic lineage.as other have
also observed this innate capacity for osteogenic differentiation.239 Interestingly, mixed
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cells did not display this innate capacity for osteogenic differentiation in the absence of
induction media despite flow cytometric results which indicated that the mixed amnion
cell group contained as much as 40% hAECs, yet the ability of the hAECs to
spontaneously differentiate appears to be reduced in the presence of hAMSCs.
Furthermore, these results indicate that osteogenic differentiation of hAECs can be
obtained without the addition of exogenous chemicals, potentially minimizing lab costs
and concerns of chemical manipulation and toxicity for clinical application. Thus both
hAMSCs and hAECs may be more optimal for bone repair/regeneration applications as
compared to hADSCs.
With respect to induced chondrogenic differentiation, hAMSCs and amnion
derived mixed cells consistently produced ECM containing more collagen type 2 and
glycosaminoglycan as compared to hADSCs at the time-points investigated. Gene
expression data demonstrating increased sox-9, aggrecan, and collagen type 2 expression
corroborated these findings. Although the chondrogenic cell pellets containing hAMSCs
only tended to be smaller and more compact as compared to all other groups by day 7, the
percent areal staining for glycosaminoglycan-rich ECM was highest possibly indicating
an enhanced recapitulation of condensation observed during chondrogenesis during
embryological development. hAMSCs and mixed amnion cell groups also trended
towards having innately higher collagen type 2 and aggrecan gene transcript expression
in the absence of chondrogenic induction media suggesting that these cells may be more
optimal for cartilage repair/regeneration applications as compared to hADSCs. These
results also add to previous findings that indicate hAMSCs may be more efficient in
chondrogenic differentiation than hAECs.239
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The pre-mature ossification of mesenchymal stem cells is thought to be one of the
greatest drawbacks to their clinical use.228 Considering this, it has been demonstrated
herein that amniotic cell types undergoing chondrogenic differentiation express
significantly less osteogenic markers than hADSCs, potentially indicative of a decreased
potential for endochondral ossification. Thus, hAMSCs may prove more useful for
regenerative therapies requiring continual chondrogenesis as opposed to the typical
progression of chondrogenesis through endochondral ossification, however further
studies illustrating this point are warranted.
Although care was taken to standardize the experimental conditions during these
in vitro investigations, so study limitations were noted. Unavoidably, amniotic
membranes and hADSCs were obtained from different donors. It has been shown that
donor health and age impact stem cell properties.5,10,11,98 The most accurate comparative
analysis would have been to obtain stem cells from the same donor; however this was not
possible in this case for patient safety. Additionally, some reports have concluded that
bone marrow stem cells (hBMSCs) are potentially more robust at musculoskeletal tissue
differentiation.233,240 Therefore, future studies will aim to perform similar analyses
comparing amnion derived cells to hBMSCs as well. It may also be advantageous to
complete chondrogenic differentiation comparative analyses under hypoxic conditions, as
numerous reports indicate increased clinical relevance and enhanced differentiation
utilizing such approaches.32,241
Taken together, this data suggests amniotic cells are an ideal alternative cell
source for orthopaedic regenerative medicine approaches. Amniotic stem cell yields are
higher per tissue volume compared to hADSCs and they appear to more readily
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differentiate into osteogenic and chondrogenic lineages. Moreover, these differentiation
capacities make amnion stem cells a candidate stem cell for osteoarthritis therapies.
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CHAPTER FOUR
AIM II: TO VALIDATE A HUMAN EXPLANT JOINT TISSUE CO-CULTRE
MODEL OF OA
4.1 Introduction
Osteoarthritis (OA) is the most common form of arthritis, affecting over 30% of
the U.S. population over the age of 65.11,12,110,111,113–117 OA is the result of cartilage
degradation, impaired joint mobility and severe pain - making it one of the leading causes
of disability worldwide.12,110,111,113,119,120 Though commonly associated with the
destruction of cartilage, OA is a disease of the entire joint space.12,85,108,113,117,126–128
While OA is stereotypically described as a physical wear and tear disease242,243,
mounting evidence suggests that synovial inflammation significantly contributes to its
pathogenesis.243 In OA, macrophages infiltrate the synovium and secrete supraphysiological levels of pro-inflammatory cytokines (including TNF- α and IL1-β), which
create a caustic joint environment promoting articular cartilage degradation.127,243
Degraded matrix fragments activate toll-like receptors (TLRs) within cells of the synovial
membrane, activating nuclear-factor κB (NF-κB), a potent pro-inflammatory
transcription factor.108,113,135 TLR activation is also responsible for the downstream upregulation of MMPs and aggrecanses.113,128,135,140 In addition to synovial TLR activation,
chondrocytes have exhibited TLR activation in response to degraded matrix
fragements.12,113 Ultimately, this TLR cascade results in the recruitment of increased
numbers of macrophages and pro-inflammatory cytokine secretion, creating a state of
chronic, low-grade inflammation.113,135,244 Thus, OA is most accurately described as a
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feed-forward pathology where the cartilage and synovium exhibit reciprocal pathologic
effects on one another.
Investigators have studied this pathogenesis and efficacy of potential future OA
therapies via the use of in vitro culture models of human cartilage explants exposed to
supra-physiological levels of exogenous inflammatory cytokines (i.e. IL-1 and TNF-α)
commonly observed in OA in order to accelerate cartilage destruction.140,245 More
recently, researchers have begun co-culturing human joint tissue explants (cartilage
together with synovium) in an attempt to more accurately reflect the complexity of the
joint space environment as well as the many known mediators of OA resulting from the
natural progression of the disease.128,140 Although such co-culture models have
demonstrated likeness to the natural disease state246, to our knowledge these systems have
not been extensively validated in order to determine the degree to which they model:
cartilage destruction in the presence of both synovial macrophages and pathophysiologic
levels of pro-inflammatory cytokines, gradual progression with time and, significantly, a
feed-forward progression.
In an attempt to confirm that such co-culture models reflect human OA pathology
and progression, herein an investigation into human joint tissue explant co-culture has
been undertaken. This was accomplished by comparing human joint explant co-cultures
of cartilage and synovium together with cultures of isolated human cartilage (in order to
determine the effects of the synovium on the cartilage) and isolated human synovium (in
order to determine the effect of the cartilage on the synovium), ultimately to demonstrate
the ability of OA explant co-culture to effectively model the feed-forward nature of OA
as well as gradual disease progression with time.
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Furthermore, the impact/role of

synovial macrophage’s contribution to the OA model was investigated by selective
depletion via clodronate. Taken together, validation of such a model may highlight its
utility in OA research, as it may prove to be an effective system for investigating OA
pathology and evaluating potential future therapies.
4.2 Materials & Methods
Insulin Transferrin Selenium was purchased from Life Technologies (41400045).
Ascorbate-2-phosphate (59-990-141) and trans-well culture plates (07-200-157) were
purchased from Fisher Scientific. Clophosome A was purchased from FormuMax
Scientific Inc (F70101C-A-2). Live/Dead Animal Cell Kit was purchased from VWR
(89260-208). 1,9 Dimethyl-Methylene Blue (341088-1G), Chondroitin Sulfate (C43845G), Hydroxyproline Assay Kit (MAK008-1KT), Safranin-O Stain (S2255-25G) and Fast
Green Stain (F7258-25G) were purchased from Sigma. Normal Horse Serum (S2000),
VECTASTAIN Elite ABC Kit, Rabbit IgG (PK-6101) and DAB Substrate Kit (SK4100)
were purchased from Vector Laboratories, Inc. Triton X-100 and other basic chemicals
were purchased from Fisher Scientific. Antibodies employed in this work included: antimannose receptor (ab32527) and anto-CCR7 (ab64693). All ELISAs employed in this
work were purchased from RayBiotech: Human TNF-alpha (LH-TNFa-1), Human MMP13 (ELH-MMP13-1) and Human IL-1 beta (ELH-IL1b-1).
4.2.1 Joint Tissue Harvest and Culture Initiation
Human cartilage and synovium were obtained from consenting patients immediately
following total knee arthroplasty for OA (IRB# PRO00031185 Greenville Health System). All
patients were classified as having Kellgran-Lawrence grade 4 OA. Using aseptic technique,
cartilage and synovium tissues were biopsied into 6mm diameter samples in preparation for in
vitro culture. Tissue biopsies were placed in 12-well plates (1 cartilage and 1 synovium biopsy /
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well) and maintained in 2mL DMEM supplemented with 1% Insulin Transferrin Selenium (ITS),
1% antibiotic/antimitotic (ABAM) and 50nM Ascorbate-2-phosphate for 3 days in standard
culture conditions (5% CO2; 20% O2; 37° C). Henceforth, this media formulation will be referred
to as “explant medium.” Care was taken to ensure the cartilage and synovium were not in direct
contact. After 3 days, the media was removed and labeled “day 0” media.

n=15

n=14

n=15

n=7

Figure 29: Methods Schematic demonstrating the described comparative analysis between control OA explant coculture (“OA”), OA tissue cultured in isolation (“cartilage only” and “synovium only”) and macrophage depleted OA
cultures, after 15 days.

4.2.1.1 In Vitro Co-Culture
Cartilage biopsies (n=15) were placed in the bottom of a 12-well trans-well plate (1
cartilage biopsy/well) and submerged in 1.5mL explant medium. The well insert was returned to
the well and patient- matched synovial biopsies were placed within inserts (1 synovium
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biopsy/well) with 500µL explant medium. Media was changed every 3 days until the termination
of culture at 15 days. This is depicted in figure 29.

4.2.1.2 In Vitro Cartilage Only Culture
Cartilage biopsies (n=14) were placed in the bottom of a 12-well trans-well plate (1
cartilage biopsy/well) and submerged in 1.5mL explant medium. Media was changed every 3
days until the termination of culture at 15 days. This is depicted in figure 29.

4.2.1.3 In Vitro Synovium Only Culture
Synovial biopsies (n=15) were placed within well inserts (1 synovium biopsy/well) and
treated as previously described until the termination of culture at 15 days. This is depicted in
figure 29.

4.2.1.4 In Vitro Macrophage Depleted Co-culture Culture
Synovial biopsies (n=7) were placed in the wells of a 12 well plate and submerged
in 1.5mL explant medium. To deplete synovial macrophage populations, 24 hours prior
to the initiation of co-culture each synovial biopsy was treated with 0.2mL
Clophosome®-A (liposome encapsulated clodronate). After 24 hours, each synovial
biopsy was washed 3x in explant medium prior to co-culture initiation with patientmatched OA cartilage as previously described. This is depicted in figure 29.
4.2.2 Synovial Macrophage Phenotype
Immunohistochemistry (IHC) on rehydrated paraffin synovium sections was performed
for detection of synovial macrophages. Briefly, antigen retrieval was accomplished via 10mM
Citric Acid incubation at 90°C for 20 minutes. Slides were rinsed twice in TBS for 5 minutes,
permeabilized in 0.025% Triton X-100, non-specific binding and endogenous peroxidases were
blocked with normal serum and a solution of 0.3% hydrogen peroxide in 0.3% normal serum,
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respectively. A rabbit polyclonal antibody towards human CCR7 (0.5µg/mL dilution) or human
mannose receptor (1µg/mL dilution) was incubated for 1 hour at room temperature prior to
thorough rinsing and incubation at room temperature for 30 minutes with a secondary
biotinylated antibody and avidin biotin complex according to manufacturer’s instructions
(Vectastain®ABC Elite Kit Rabbit IgG - Vector Labs). A DAB substrate kit (Vector Labs:
SK4100) was used to visualize positive staining prior to counterstaining with a dilute
hematoxylin solution for 30 seconds. Negative controls did not receive primary antibody.

4.2.3 Live/Dead Staining
Live/Dead staining was completed on cartilage and synovium according to
manufacture instructions. Briefly, cartilage and synovium were incubated in a Live/Dead
working solution (2µM calcein AM and 4µM Ethd-1) and at room temperature for 45
minutes. Tissues were placed on a microscope slide prior to fluorescent imaging.
4.2.4 Histopathological Assessment of Explant Tissue
Cartilage sections were secured within a tissue processing cassette, fixed in 10%
phosphate buffered formalin overnight at room temperature prior to undergoing standard
tissue processing, decalcification, paraffin embedding and sectioning at 5 µm thickness.
Sections were stained with Safranin-O counterstained with Fast Green for visualization of
proteoglycan rich cartilage matrix. Briefly, rehydrated sections were differentiated in 1%
acid alcohol for 2 seconds prior to room temperature incubation in 0.02% Fast Green for
2.5 minutes. After 30 second incubation in 1% Acetic acid, sections were stained with
1% Safranin-O for 15 minutes. Three images were taken spanning the surface length of
the sample. An observer blinded to the condition of the cartilage completed the OARSI
histopathological assessment on each image according to the direction of Pritzker et al.247
These results were averaged to obtain the final sample OARSI score.
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4.2.5 Assessment of Cartilage Degradation
4.2.5.1 Cartilage Glycosaminoglycan (GAG) Content
Lyophilized cartilage tissues were digested in 125µg/mL Papain in PBE Buffer,
pH 7.5 overnight at 65°C. Tissue digests were assessed for GAG content via
Dimethylmethylene Blue Assay (DMMB). Briefly, 200µL DMMB reagent (46µg
DMMB, 40mM Glycine, 40mM NaCl, pH 3) was added to 50µL samples. Standards
were created using a 1mg/mL stock solution of Chondroitin-6-Sulfate. Sample
absorbance was read at 525nm.
4.2.5.2 Collagen Leaching to Culture Media
Culture media was assessed for hydroxyproline collagen content via
Hydroxyproline Assay Kit according to manufacture instructions. Briefly, samples were
hydrolyzed with hydrochloric acid at 120°C for 3 hours prior to well plate transfer. Wells
were evaporated to dryness at 60°C. Equal amounts of Chloramine T/Oxidation Buffer
Mixture and Diluted DMAB Reagent followed by 5-minute room temperature and 90minute 60°C incubations, respectively. Standards were created using a 1mg/mL stock
solution of Hydroxyproline Standard Solution. Sample absorbance was read at 560nm.
4.2.6 Co-culture Media Pro-Inflammatory Profile
ELISA was performed according to manufacture instructions. Briefly, 96-well plates
were incubated overnight at 4°C with standards and explant co-culture media samples
(n=3 per condition). After several washes, wells were incubated with biotinylated
antibodies (either TNF-α, IL-1β or MMP-13) for 1&h, followed by incubation in HRP-
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conjugated streptavidin for 45&min. Enzymatic reactions were allowed to develop, and the
absorbance of each plate was read at 450&nm.
4.2.7 Microscopic Imaging
Images were captured on a Zeiss Axiovert.A1 microscope with Axiovision
software (Release 4.9.1 SP08-2013). For all semi-quantitative histological data, three
images were taken of each sample. An observer blinded to the condition of the sample
manually counted each of these three images in order to determine the relative number of
positive cells (i.e. brown cells (IHC), live cells or dead cells (Live/Dead), etc.) per
sample. These three results were averaged in order to obtain the final percentage of
positive cells for each sample.
4.2.8 Statistical Analysis
Results% are% represented% as% a% mean% ±% standard% error% of% the% mean% (SEM).% % All%
statistical% analyses% were% performed% by% twoPtailed% Student’s% tPtest% of% unequal% variance% or%
onePway%analysis%of%variance%(ANOVA).%Significance%was%defined%in%all%cases%as%p<0.05.%

4.3 Results
4.3.1 Joint Tissue Harvest and Culture Initiation
Human joint tissues were successfully harvested and 6mm biopsies of patientmatched cartilage and synovium were obtained. Tissues were maintained in in vitro
culture for 15 days without any macroscopic signs of tissue deterioration or bacterial
infection.
4.3.2 Synovial Macrophage Phenotype
IHC staining of CCR7 (figure 30) showed a relatively constant percentage (84.5%
to 76.8%) of M1 polarized macrophages over 15 days in OA co-culture. Over 15 days,
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the synovium only culture group exhibited a statistical decrease in the percentage of cells
staining positive for macrophage markers (84.6% to 58.6%). IHC staining confirmed the
targeted depletion of macrophages in the macrophage depleted group (17.2% positive
staining at day 0). This depletion effect remained throughout the culture period (14.8% at
day 15). After 15 days in culture, synovium from OA co-culture contained a statistically
higher percentage of macrophages compared to the other conditions tested.

Figure 30: Confirmation of Macrophage Depletion. Semi-quantitative analysis of immunohistochemical stain for
synovial M1 macrophages in all study groups over 15 days. At right, corresponding representative images of M1
macrophage staining (brown = positive) across study groups. Image inserts are negative controls. # indicates statistical
difference (P<0.05) from day 0 to day 15. * indicates statistical difference (p<0.05) between study groups within time
point.
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4.3.3 Live/Dead Staining
Live/Dead staining of cartilage biopsies (figure 31A) revealed a statistical
decrease (85.3% to 56.8%) in chondrocyte viability over 15 days in OA co-culture.
Conversely, cartilage from the cartilage only culture exhibited relatively constant (85.3%
to 74.9%) chondrocyte viability. Over 15 days, the macrophage depleted culture group
demonstrated a statistical increase in chondrocyte viability (to 97.7%). By day 15,
chondrocyte viability was significantly different (p<0.05) between all groups, with
macrophage depleted cultures demonstrating the highest viability followed by cartilage
only and OA co-culture.
Live/Dead staining of synovium biopsies (figure 31B) revealed a statistical
decrease in synovial cell viability over 15 days in both the OA co-culture (72.1% to
44.6%) and the synovium only culture (72.1% to 54.1%). Conversely, the synovium from
the macrophage depleted co-culture exhibited a statistical increase in synovial cell
viability (to 98.7%). Therefore after 15 days in culture, synovium from the macrophage
depleted co-culture contained a statistically greater percentage of viable cells compared
to synovium cultured alone or with OA cartilage.

103

Figure 31: Cell Viability Assessment. A) Semi-quantitative analysis of Live/Dead chondrocyte staining from each
group over 15 days with corresponding representative day 15 Live/Dead images of the cartilage. B) Semi-quantitative
analysis of Live/Dead synovial cell staining (Red = dead cell; Green = viable cell) from each study group over 15 days
with corresponding representative day 15 Live/Dead images of the synovium. White scale bar is equal to 100µm. #
indicates statistical difference (P<0.05) from day 0 to day 15. * indicates statistical difference (P<0.05) between study
groups within time point.
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4.3.4 Histopathological Assessment of Explant Tissue

Figure 32: OARSI Histopathological Evaluation of Cartilage Microarchitecture. Graph of average OARSI scores
(stage OA x grade OA) for each study group, with greater scores indicating greater cartilage deterioration. Graph insert
is a Safranin-O stained cartilage section (Red= Proteoglycan-rich Cartilage; Green= Background) depicting cartilage
surface microarchitecture after 15 days in macrophage depleted culture. At right, a patient matched set of Safranin-O
stained cartilage sections, showing relative progression of OA in OA co-culture and cartilage only culture groups over
15 days. # indicates statistical difference (P<0.05) from day 0 to day 15. * indicates statistical difference (P<0.05)
between study groups within time point.

Safranin-O stained cartilage evaluated via the OARSI histopathological
assessment is represented in figure 3. The cartilage exhibited increased surface
fibrillation across greater portions of the cartilage surface, manifesting in a statistically
increased (worse) OARSI score when OA joint explants were co-cultured together
(p<0.05). Conversely, cartilage from the cartilage only culture and macrophage depleted
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co-culture trended towards decreased (better) scores. After 15 days, the OA co-culture
OARSI score was statistically higher (worse) than the cartilage only culture.
4.3.5 Assessment of Cartilage Degradation
As seen in figure 33, cartilage GAG content evaluated via DMMB assay revealed
that OA co-culture resulted in a significant and progressive loss of GAG content (from
141.9µg/mg to 65.7µg/mg). Conversely, over 15 days the cartilage only culture and
macrophage depleted co-culture showed no statistical progression. Therefore after 15
days in culture, cartilage from the OA co-culture contained a statistically lower
percentage of GAG compared to other tested groups.
Culture media evaluated via hydroxyproline assay revealed that OA co-cultures
trended toward an increase in the amount of collagen leached from OA cartilage into the
culture media. Conversely, cartilage only culture and macrophage depleted co-culture
appeared to remain constant throughout the culture period. After 15 days, OA co-culture
resulted in significantly more collagen leached into the media as compared to cartilage
only culture.
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Figure 33: Biochemical Evaluation of Cartilage. A) DMMB glycosaminoglycan (GAG) assay depicting average
cartilage GAG content from each study group after 15 days. The range of D0 values is depicted as a shaded box from
140-210ug GAG/mg Tissue. B) Hydroxyproline assay depicting average amount of collagen leached from the cartilage
into the culture media from each study group after 15 days. The range of D0 values is depicted as a shaded box from
0.007-0.009µg/uL. # indicates statistical difference (P<0.05) from day 0 to day 15. * indicates statistical difference
(P<0.05) between study groups within time point.
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4.3.6 Co-culture Media Pro-Inflammatory Profile

Figure 34: Cytokine Analysis over 15 Days in Culture. A) Average IL1-#concentration in cell culture media from
each study group. B) Average TNF-%concentration in cell culture media from each study group. C) Average MMP13
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concentration in cell culture media from each study group. “Not detected” indicates no sample from the study group
contained sufficient cytokine concentrations for detection (Minimum detection limit of IL1-β, TNF-α and MMP13
ELISA kits: 0.3 pg/mL, 30 pg/mL and 6 pg/mL, respectively). * indicates statistical difference (P<0.05) between study
groups within time point.

Figure 34A illustrates day 0 IL-1β media content tended to be lower in
macrophage depleted groups; however this was not found to be statistically significant.
By day 15, IL-1β was only detected in media from the OA co-culture group.
TNF-α ELISA performed on cell culture media revealed that macrophage
depletion did not significantly influence day 0 TNF-α concentrations. However, figure
34B demonstrates by day 15 TNF-α was no longer detected in macrophage depleted cocultures. While TNF-α concentrations remained constant in OA co-cultures, cartilage
only culture and synovium only culture trended towards reduced concentrations.
MMP-13 ELISA performed on cell culture media revealed that over 15 days in
culture, OA co-cultures significantly increased in MMP-13 content (p<0.05). MMP-13
was only minimally detected at day 0 and not detected at day 15 in macrophage depleted
co-cultures.
A thorough cytokine profile via RayBiotech QAH-CYT-SW-1 cytokine array can
be found in appendix a.
4.4 Discussion
We successfully demonstrate human joint tissue explant co-culture mimics OA
pathogenesis by modeling: 1) cartilage destruction in the presence of synovial
macrophages and pathophysiologic levels of inflammatory cytokines, 2) gradual
progression with time and 3) a feed-forward progression, where the cartilage and
synovium each contribute to the other’s disease progression.
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OA is a multifactorial disease affecting the major components of the human joint
space: the cartilage, the synovium and the synovial fluid.242,243,248,249 In OA, the cartilage
matrix degrades.113,135 The synovial fluid provides not only nutrients to joint tissues but
also a potent cocktail of pro-inflammatory cytokines (ex. IL-1β and TNF-α), as
well.113,135 The synovial fluid becomes filled with degradation products, primarily
cleaved collagen, from the cartilage.11 The synovium becomes inflamed, a condition
known as synovitis in which this traditionally 2-3 cell layer membrane undergoes
hypertrophy as macrophages infiltrate the fibrous matrix.113,135,242
An ideal in vitro model would mimic the aforementioned characteristics of OA
through evidence of cartilage matrix degradation (i.e. loss of proteoglycan and collagen
content), maintenance of the pro-inflammatory milieu within the culture (media)
environment and maintenance of inflammatory cell populations within the synovium. A
model exhibiting progression of the disease would display worsening matrix degradation
with time and increasing concentrations of pro-inflammatory cytokines and downstream
matrix degrading enzymes.
The OA co-culture system described herein effectively models gradual OA
progression with evidence of statistically increased cartilage fibrillation and decreased
cartilage GAG content, as well as trends towards increased pro-inflammatory cytokines
and collagen concentrations within the culture media. Given the short-term nature of the
study, it was unlikely to observe statistical differences in collagen leaching into the
culture media due to previous reports that collagenolytic activity in OA tissues peaks at 4
weeks.250
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Significantly, the control groups in this study allowed us to confirm OA explant
co-culture’s ability to model the feed-forward pathogenesis of the disease, where the
cartilage and synovium appear to feed off each other, working in tandem to further
disease progression. Decreases in cartilage GAG and leached collagen contents as well as
microscopic surface fibrillation were observed to a lesser extent when OA cartilage was
cultured alone, without synovial contributions. The relatively constant percentage of
macrophages observed in the OA co-culture group seems to indicate that the
macrophages receive continued stimulation within the explant co-culture model; whereas
synovium only cultures exhibited a statistical decrease in the percentage of macrophages
potentially due to the removal of such stimulatory cues (likely from the cartilage, as OA
chondrocyte TLR activation has been extensively described by others12,113). This
activation pathway results in the up-regulation of MMPs and ADAMTS. Specifically,
TLR-2 and TLR-4 are up-regulated in regions of cartilage erosion.113,135 Up-regulation of
these specific TLRs has been linked to downstream increases in master MMP regulator,
MMP-3.113,135 This could be one pathway accounting for the increases in MMP-13
observed in our OA co-culture and cartilage only groups.
Interestingly, though there is a constant presence of macrophages observed during
OA co-culture, the percentage of viable cells within OA co-cultured synovium
statistically decreases with time. This may indicate that the viability of host synovial
(fibroblastic) cells, not macrophages, was compromised. This could be a further
indication of the worsening health of the synovial tissue as OA progresses. Though
general tissue manipulation and in vitro culture can account for some loss in viability, our
viability results generally support a feed-forward inducing effect of cell death when
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cartilage and synovium are cultured together. In order to ensure these effects were not the
result of culture system overload (i.e. depriving the cells of appropriate levels of
nutrients), we seeded an additional 1.5x105 human stem cells onto the surface of the
cartilage and monitored viability effects. This data (not shown) demonstrated that cell
viability was maintained, and in some cases increased OA chondrocyte viability.
Corroborating viability results in joint explant co-culture models used by others were not
found in current literature. However, these results could indicate a currently overlooked
mechanism whereby OA progression is driven by a loss in specialized tissue cell types in
favor of inflammatory cell populations.
In order to specifically assess the impact of synovial macrophages on OA
progression in the model, select synovium samples were pre-treated with Clodronate
(“macrophage depleted co-culture”), a bisphosphonate known to induce apoptosis in
phagocytic cells without affecting non-phagocytic cell viability, prior to the initiation of
co-culture.185,186,188,193,251 Previously it has been shown that such depletion results in
downstream reductions in IL-1β and TNF-α concentrations as well as reduced cartilage
destruction in experimental models of arthritis.189,191,193 Results from the current study
confirmed similar outcomes in this joint tissue explant co-culture model.
Though macrophages were successfully depleted in our in vitro model, it is worth
noting that such sustained macrophage depletion may not likely be an advantageous
therapeutic avenue in vivo due to macrophage recruitment/replenishment though the
native synovial blood supply.185 However, macrophage depletion more likely represents a
mechanistic tool for researchers as opposed to a potential future therapeutic.
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Interestingly, clodronate is currently being investigated as an OA therapeutic both in
animals and in human clinical trials, albeit with mixed results.122,198–200
OA explant co-culture also more effectively models pro-inflammatory cytokine
involvement in the human pathology. IL-1β is a macrophage secretion product
suppressing aggrecan and collagen synthesis, which is heavily implicated in OA disease
pathology and progression.104,110,113,135 Physiological levels of IL-1β in osteoarthritic
synovial fluid have been reported at <4.8pg/mL.136,147,149 At all culture time-points in this
study, values for this cytokine fell within reported in vivo ranges, which is significantly
lower than the reported 5mg/mL of IL-1β used in studies which chemically induce OA
through the addition of supraphysiological levels of cytokines to cartilage explant only
culture models.245,252 This seems to indicate that cartilage-synovial co-culture provides a
more natural model of the cytokine profile of OA, though further comparative analyses
would need to be completed to corroborate this claim. Others have noted extremely low
concentrations of IL-1β in ex vivo cultures.252–254 This has been attributed to the extreme
lability associated with this cytokine, and researchers have cautioned conclusions based
solely on IL-1β biochemical analysis.173,255 Both IL-1β and TNF-α induce signaling
pathways resulting in pro-inflammatory stimulation and decreased collagen expression.104
As TNF-α is a macrophage-secreted product, the dramatic concentration reduction
observed in the macrophage depleted groups was expected. In a similar manner, the
removal of the synovium (“cartilage only”) represents the removal of synovial
macrophages and would thus also be expected to lower TNF-α concentrations. It is
interesting that the removal of the cartilage (“synovium only”) yields a similar effect,
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again potentially supporting the concept that OA progresses via a feed-forward, cell
mediated destructive mechanism.
In conclusion, we were able to successfully demonstrate human joint tissue
explant co-culture mimics OA pathogenesis by modeling: 1) cartilage destruction in the
presence of inflammatory cytokines and synovial macrophages, 2) gradual progression
with time and 3) a feed-forward progression, where the cartilage and synovium exhibit
reciprocal pathologic effects on one another. Additionally, our mechanistic evaluations
utilizing macrophage depletion studies indicate synovial macrophages and/or their
secretions are likely primary effectors driving disease progression in the model. This
work highlights the utility of joint tissue explant co-culture in OA research, as it is an
effective system for investigating OA pathology and evaluating potential future therapies.
Though this ex vivo model mimics key aspects of human OA, any in vitro model
is subjected to limitations. Specifically, this experimental design requires tissue biopsies
that demonstrate relatively equal disease status at the time of culture initiation. While
care was taken to ensure only the use of cartilage immediately surrounding areas of OAinduced cartilage erosion, there is inherent variability associated with each biopsy. In
future studies, we suggest minimizing this variability through halving each sample, using
one half as a biopsy-matched day 0 control. An additional limitation is inherent interpatient variability. We attempted to overcome such variability through increased sample
sizes (n=15). Normalization of data to each patient’s matched day 0 values is also
suggested thus eliminating result biases from inter-patient variability. Lastly, there is
extremely limited data describing the use of human joint tissue explant co-culture making
it difficult to validate results across different investigators via comparisons with peer-
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reviewed literature sources. As more studies are published using such models,
comparative data should become available to allow for cross comparisons. However, as
of now we caution cross comparisons of this work with those employing smaller sample
sizes and tissue samples from different species. As previously indicated, a sample size of
at least 14 was required in order to obtain the statistical differences and trends described
herein. Additionally, the known differences in inflammatory-driven cartilage matrix
degradation between species limit the utility of cross-species comparisons.108,110,151,152
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CHAPTER FIVE
AIM III: TO EVALUATE THE ABILITY OF MSCs TO MITIGATE OA
PROGRESSION IN THIS VALIDATED EX VIVO MODEL
5.1 Introduction
While osteoarthritis (OA) is traditionally viewed as a physical wear and tear
disease, mounting evidence suggests that M1 macrophage-driven synovial inflammation
significantly contributes to its pathogenesis.243 Pro-inflammatory, M1, macrophage
secretions create a degenerative joint environment, ultimately resulting in the upregulation of effectors promoting cartilage degradation and causing patients immense
pain. Current OA treatments are palliative, failing to halt the progression of the disease.
Stem cells offer a potential therapeutic alternative due to their anti-inflammatory and
immunomodulatory properties.54,218 Current stem cell-based therapies focus on the intraarticular injection of adult stem cells including those derived from adipose tissue
(hADSCs).120,207 However, perinatal stem cells, specifically those derived from the
amniotic membrane (a tissue routinely discarded as medical waste following the birth of
full-term babies), have illustrated promise as an alternative stem cell source for
regenerative medicine.68,218 Though perinatal stem cells have yet to be tested as a
therapeutic strategy combatting OA, recent evidence suggests perinatal stem cells exhibit
superior chondro-protective effects, exhibiting the ability to induce a pro-regenerative
(M2) phenotype within synovial macrophages.73,87
Herein, we describe efforts undertaken to establish the ability of stem cells to
mitigate OA progression in an established ex vivo co-culture model of naturally
progressing OA. We employed standardized comparative analyses utilizing two stem cell
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sources, hADSCs and human amniotic mesenchymal stem cells (hAMSCs), in order to
determine the relative efficacies of a newly investigated (perinatal) and a clinically
established (hADSC) stem cell source as potential OA therapeutics. Furthermore,
following the current paradigm of intra-articular administration, it is likely that injected
stem cells would be found in a mixed contact scenario with OA cartilage where only
some stem cells remain in direct contact with the cartilage (see appendix A). In an effort
to better understand the potential efficacy of intra-articular administration of perinatal
stem cells as a future OA treatment paradigm, we evaluated and compared the potential
differential effects of administering hAMSCs in two different co-culture models (i.e.
direct and indirect contact co-culture with OA cartilage in the presence of synovium).
Taken together, such results would highlight the utility of a currently under investigated
stem cell source (hAMSCs) for OA regenerative medicine approaches and provide
significant mechanistic into their clinical use.

5.2 Materials & Methods
Insulin Transferrin Selenium was purchased from Life Technologies (41400045).
Ascorbate-2-phosphate (59-990-141) and trans-well culture plates (07-200-157) were
purchased from Fisher Scientific. Clophosome A was purchased from FormuMax
Scientific Inc (F70101C-A-2). Live/Dead Animal Cell Kit was purchased from VWR
(89260-208). 1,9 Dimethyl-Methylene Blue (341088-1G), Chondroitin Sulfate (C43845G), Hydroxyproline Assay Kit (MAK008-1KT), Safranin-O Stain (S2255-25G) and Fast
Green Stain (F7258-25G) were purchased from Sigma. Normal Horse Serum (S2000),
VECTASTAIN Elite ABC Kit, Rabbit IgG (PK-6101) and DAB Substrate Kit (SK4100)
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were purchased from Vector Laboratories, Inc. Triton X-100 and other basic chemicals
were purchased from Fisher Scientific. Antibodies employed in this work included: antimannose receptor (ab32527) and anto-CCR7 (ab64693). All ELISAs employed in this
work were purchased from RayBiotech: Human TNF-alpha (LH-TNFa-1), Human MMP13 (ELH-MMP13-1) and Human IL-1 beta (ELH-IL1b-1).
5.2.1 Joint Tissue Harvest and Culture Initiation
Human cartilage and synovium were obtained from consenting patients immediately
following total knee arthroplasty for OA (IRB# PRO00031185 Greenville Health System). All
patients were classified as having Kellgran-Lawrence grade 4 OA. Using aseptic technique,
cartilage and synovium tissues were biopsied into 6mm diameter samples in preparation for in
vitro culture. Tissue biopsies were placed in 12-well plates (1 cartilage and 1 synovium biopsy /
well) and maintained in 2mL DMEM supplemented with 1% Insulin Transferrin Selenium (ITS),
1% antibiotic/antimitotic (ABAM) and 50nM Ascorbate-2-phosphate for 3 days in standard
culture conditions (5% CO2; 20% O2; 37° C). Henceforth, this media formulation will be referred
to as “explant medium.” Care was taken to ensure the cartilage and synovium were not in direct
contact. After 3 days, the media was removed and labeled “day 0” media.

5.2.1.1 hAMSC Culture

Figure 35: Methods Schematic Demonstrating the Described Comparative Analysis between Control OA
Explant Co-culture (“OA”) and OA Co-cultures Treated with Stem Cells Applied Directly or Indirectly to the
Cartilage Surface after 15 days. This comparative analysis will determine the relative efficacies of two potential
clinically relevant routes of administration.
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Joint co-culture was initiated as previously described. hAMSCs were isolated
from term amniotic membrane as previously described (Aim I). Each stem cell treated coculture was simultaneously cultured with a patient matched “OA” control.
5.2.1.1.1 OA+hAMSC (Direct Culture)
At day 0, 1x105 hAMSCs were seeded directly on top of cartilage biopsies.
5.2.1.1.1 OA+hAMSC (Indirect Culture)
At day 0, 1x105 hAMSCs were seeded indirectly onto the bottom on a porous
trans-well insert.
5.2.1.2 OA+hADSC Culture
Joint co-culture (n=5) was initiated as previously described. hADSCs were
purchased from a commercial vendor for comparative analysis. At day 0, 1x105 hADSCs
were seeded directly on top of cartilage biopsies. Each stem cell treated co-culture was
simultaneously cultured with a patient matched “OA” control.

Figure 36: Methods Schematic Demonstrating the Described Comparative Analysis between Control OA
Explant Co-culture (“OA”) and OA Co-cultures Treated with either hAMSCs or hADSCs after 15 days. This
comparison will determine the relative efficacies of a commonly utilized (hADSC) with a newly investigated (hAMSC)
stem cell therapy for OA mitigation.

5.2.2 Synovial Macrophage Phenotype
Immunohistochemistry (IHC) on rehydrated paraffin synovium sections was performed
for detection of synovial macrophages. Briefly, antigen retrieval was accomplished via 10mM
Citric Acid incubation at 90°C for 20 minutes. Slides were rinsed twice in TBS for 5 minutes,
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permeabilized in 0.025% Triton X-100, non-specific binding and endogenous peroxidases were
blocked with normal serum and a solution of 0.3% hydrogen peroxide in 0.3% normal serum,
respectively. A rabbit polyclonal antibody towards human CCR7 (0.5µg/mL dilution) or human
mannose receptor (1µg/mL dilution) was incubated for 1 hour at room temperature prior to
thorough rinsing and incubation at room temperature for 30 minutes with a secondary
biotinylated antibody and avidin biotin complex according to manufacturer’s instructions
(Vectastain®ABC Elite Kit Rabbit IgG - Vector Labs). A DAB substrate kit (Vector Labs:
SK4100) was used to visualize positive staining prior to counterstaining with a dilute
hematoxylin solution for 30 seconds. Negative controls did not receive primary antibody.

5.2.3 Live/Dead Staining
Live/Dead staining was completed on cartilage and synovium according to
manufacture instructions. Briefly, cartilage and synovium were incubated in a Live/Dead
working solution (2µM calcein AM and 4µM Ethd-1) and at room temperature for 45
minutes. Tissues were placed on a microscope slide prior to fluorescent imaging.
5.2.4 Histopathological Assessment of Explant Tissue
Cartilage sections were secured within a tissue processing cassette, fixed in 10%
phosphate buffered formalin overnight at room temperature prior to undergoing standard
tissue processing, decalcification, paraffin embedding and sectioning at 5 µm thickness.
Sections were stained with Safranin-O counterstained with Fast Green for visualization of
proteoglycan rich cartilage matrix. Briefly, rehydrated sections were differentiated in 1%
acid alcohol for 2 seconds prior to room temperature incubation in 0.02% Fast Green for
2.5 minutes. After 30 second incubation in 1% Acetic acid, sections were stained with
1% Safranin-O for 15 minutes. Three images were taken spanning the surface length of
the sample. An observer blinded to the condition of the cartilage completed the OARSI
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histopathological assessment on each image according to the direction of Pritzker et al.247
These results were averaged to obtain the final sample OARSI score.
5.2.5 Assessment of Cartilage Degradation
5.2.5.1 Cartilage Glycosaminoglycan (GAG) Content
Lyophilized cartilage tissues were digested in 125µg/mL Papain in PBE Buffer, pH
7.5 overnight at 65°C. Tissue digests were assessed for GAG content via
Dimethylmethylene Blue Assay (DMMB). Briefly, 200µL DMMB reagent (46µg
DMMB, 40mM Glycine, 40mM NaCl, pH 3) was added to 50µL samples. Standards
were created using a 1mg/mL stock solution of Chondroitin-6-Sulfate. Sample
absorbance was read at 525nm.
5.2.5.2 Collagen Leaching to Culture Media
Culture media was assessed for hydroxyproline collagen content via Hydroxyproline
Assay Kit according to manufacture instructions. Briefly, samples were hydrolyzed with
hydrochloric acid at 120°C for 3 hours prior to well plate transfer. Wells were evaporated
to dryness at 60°C. Equal amounts of Chloramine T/Oxidation Buffer Mixture and
Diluted DMAB Reagent followed by 5-minute room temperature and 90-minute 60°C
incubations, respectively. Standards were created using a 1mg/mL stock solution of
Hydroxyproline Standard Solution. Sample absorbance was read at 560nm.
5.2.6 Co-culture Media Pro-Inflammatory Profile
ELISA was performed according to manufacture instructions. Briefly, 96-well plates
were incubated overnight at 4°C with standards and explant co-culture media samples
(n=3 per condition). After several washes, wells were incubated with biotinylated
antibodies (either TNF-α, IL-1β or MMP-13) for 1&h, followed by incubation in HRP-
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conjugated streptavidin for 45&min. Enzymatic reactions were allowed to develop, and the
absorbance of each plate was read at 450&nm.
5.2.7 Microscopic Imaging

Images were captured on a Zeiss Axiovert.A1 microscope with Axiovision
software (Release 4.9.1 SP08-2013). For all semi-quantitative histological data, three
images were taken of each sample. An observer blinded to the condition of the sample
manually counted each of these three images in order to determine the relative number of
positive cells (i.e. brown cells (IHC), live cells or dead cells (Live/Dead), etc.) per
sample. These three results were averaged in order to obtain the final percentage of
positive cells for each sample.
5.2.8 Statistical Analysis

Results are represented as a mean ± standard error of the mean (SEM). All
statistical analyses were performed by two-tailed Student’s t-test of unequal variance or
one-way analysis of variance (ANOVA). Significance was defined in all cases as p<0.05.
5.3 Results
5.3.1 Joint Tissue Harvest and Culture Initiation
Human joint tissues were successfully harvested, 6mm biopsies of patientmatched cartilage and synovium were obtained, and the tissues were maintained in ex
vivo culture for 15 days without any macroscopic signs of bacterial infection.
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5.3.2 Synovial Macrophage Phenotype

Figure 37: Semi-Quantitative Analysis of M1 Polarized Macrophages in hAMSC and hADSC-Treated Cultures
demonstrating stem cell treatment results in a statistical reduction in M1 macrophages within the synovium.
Corresponding representative images of macrophage staining (brown = positive) are located to the right of each graph.
Photo inserts represent negative controls. # indicates statistical difference (P<0.05) from day 0 to day 15 * indicates
statistical difference (P<0.05) between study groups within time point.

IHC staining of CCR7 (Figure 37) showed a relatively constant percentage
(84.1% to 79.9%) of M1 polarized macrophages over 15 days in OA co-culture. Over 15
days, both the OA+hAMSC and the OA+hADSC groups exhibited a statistical decrease
in the percentage of cells staining positive for macrophage markers (88.7% to 48.6% and
79.5% to 57.2%, respectively).

123

Figure 38: Semi-Quantitative Analysis of M1 Polarized Macrophages in Direct and Indirect-Treated Cultures
demonstrating stem cell treatment results in a statistical reduction in M1 macrophages within the synovium regardless
of the route of administration. Corresponding representative images of macrophage staining (brown = positive) are
located to the right of each graph. Photo inserts represent negative controls. # indicates statistical difference (P<0.05)
from day 0 to day 15 * indicates statistical difference (P<0.05) between study groups within time point.

Similarly, figure 38 shows both the direct and the indirect hAMSC groups exhibited a
statistical decrease in the percentage of cells staining positive for macrophage markers
over 15 days (88.7% to 48.6% and 79.9% to 36.5%, respectively).
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Figure 39: Semi-Quantitative Analysis of M2 Polarized Macrophages in hAMSC and hADSC-Treated Cultures
demonstrating hAMSC treatment results in a statistical increase in M2 macrophages. Corresponding representative
images of macrophage staining (brown = positive) are located to the right of each graph. Photo inserts represent
negative controls. # indicates statistical difference (P<0.05) from day 0 to day 15 * indicates statistical difference
(P<0.05) between study groups within time point.

As illustrated in figure 39, in OA+hAMSC cultures, this decrease in M1 polarized
macrophages was concomitant with a statistical increase in M2 polarized macrophages.
However, OA and OA+hADSC cultures exhibited almost no change in the percentage of
M2 polarized macrophages within the synovium over 15 days. In figure 40, both direct
and indirect hAMSC culture produced this statistical increase in M2 macrophages
(Interestingly, direct and indirect culture accomplished this equally effectively).
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Figure 40: Semi-Quantitative Analysis of M2 Polarized Macrophages in Direct and Indirect-Treated Cultures
demonstrating both routes of administration result in a statistical increase in M2 macrophages. Corresponding
representative images of macrophage staining (brown = positive) are located to the right of each graph. Photo inserts
represent negative controls. # indicates statistical difference (P<0.05) from day 0 to day 15 * indicates statistical
difference (P<0.05) between study groups within time point.

5.3.3 Live/Dead Staining
Live/Dead staining of cartilage biopsies (figure 41) revealed a statistical decrease
(87.8% to 59.1%) in chondrocyte viability over 15 days in OA co-culture as well as
OA+hADSC culture (87.1% to 49.9%). Conversely, cartilage treated with hAMSCs
exhibited relatively constant (88.5% to 89.8%) chondrocyte viability.
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Figure 41: Semi-Quantitative Analysis of Chondrocyte Viability in hAMSC and hADSC-Treated Cultures with
representative day 15 Live/Dead images, demonstrating OA+hAMSC ability to most effectively maintain chondrocyte
viability. White scale bar is equal to 100µm. # indicates statistical difference (p<0.05) from day 0 to day 15. * indicates
statistical difference (p<0.05) between study groups within time point.

However, figure 42 illustrates that this observed increase in chondrocyte viability is
dependent on the route of administration of the hAMSCs.
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Figure 42: Semi-Quantitative Analysis of Chondrocyte Viability in Direct and Indirect-Treated Cultures with
representative day 15 Live/Dead images, demonstrating OA+hAMSC ability to most effectively maintain chondrocyte
viability. White scale bar is equal to 100µm. # indicates statistical difference (p<0.05) from day 0 to day 15. * indicates
statistical difference (p<0.05) between study groups within time point.

5.3.4 Histopathological Assessment of Explant Tissue
Safranin-O stained cartilage evaluated via the OARSI histopathological
assessment is represented in figures 43 and 44. The cartilage exhibited increased surface
fibrillation across greater portions of the cartilage surface, manifesting in a statistically
increased (worse) OARSI score when OA joint explants were co-cultured together
(p<0.05). Conversely, figure 43 demonstrates OA+hAMSC cartilage exhibited less
surface fibrillation, manifesting in a statistically decreased OARSI score. While
OA+hADSC cultures trended towards a similar decrease.

128

Figure 43: Average OARSI Scores in hAMSC and hADSC-Treated Cultures with corresponding safranin-o stained
cartilage sections depicting worsening microarchitecture in un-treated groups as well as the ability of stem cells to deter
surface fibrillation.

Interestingly, figure 44 depicts that this chondroprotective effect of the hAMSCs appears
to be dependent on the route of administration, as Indirect cultures still exhibited a trend
towards worse cartilage surface fibrillation (worsening OARSI score), though this trend
was not as dramatic as OA control cultures. Interestingly indirect cultures exhibited
statistically decreased number of chondrocyte clusters, another metric employed by
researchers to gauge OA progression, compared to OA+hADSC cultures (see appendix
A).
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Figure 44: Average OARSI Scores in Direct and Indirect-Treated Cultures with corresponding safranin-o stained
cartilage sections depicting worsening microarchitecture in un-treated groups as well as the ability of stem cells in
direct contact with cartilage to deter surface fibrillation.

5.3.5 Assessment of Cartilage Degradation
As seen in figure 45, cartilage GAG content evaluated via DMMB assay revealed
that OA co-culture resulted in a progressive loss of GAG content (from 181.9µg/mg to
141.7µg/mg). Conversely, over 15 days the OA+hADSC culture showed no progression,
and the OA+hAMSC groups exhibited a trend towards increased cartilage GAG content
(156.4µg/mg to 247.0µg/mg).
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Figure 45: Average Cartilage GAG Content in hAMSC and hADSC-Treated Cultures demonstrating the ability of
hAMSCs to mitigate cartilage GAG deterioration. The range of D0 values is depicted as a shaded box from 148-200µg
GAG/mg dry weight tissue.

Similar to previous assessment measures, indirect culture of hAMSCs resulted in a trend
toward less change in cartilage GAG content (-12.2 ± 21.0% Indirect vs. -40.2 ± 8.9%
OA). However, figure 46 illustrates direct contact culture of hAMSCs resulted in a
significant positive change in GAG content (30.7% ± 17.1%).
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Figure 46: Average Cartilage GAG Content in Direct and Indirect-Treated Cultures demonstrating the ability of
hAMSC seeded directly onto the cartilage surface to mitigate cartilage GAG deterioration.

Culture media evaluated via hydroxyproline assay revealed that OA co-cultures
trended toward an increase in the amount of collagen leached from OA cartilage into the
culture media (Figure 47). OA+hADSC cultures exhibited similar trends. Conversely,
OA+hAMSC cultures maintained the amount of collagen leached into culture media.
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Figure 47: Average Change in Media Hydroxyproline Content in hAMSC and hADSC-Treated Cultures
depicting the relative increase in collagen leached from OA cartilage into the culture media in OA control and
OA+hADSC groups, while hAMSC treated groups remained constant.

Culture media evaluated via hydroxyproline assay revealed that the ability of hAMSCs to
halt the progression of collagen leaching from cartilage appears to be dependent on the
route of administration (Figure 48). While indirect cultures exhibited no change in the
amount of collagen released into culture media, direct cultures demonstrated a trend
towards decreased collagen released into culture media.
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Figure 48: Average Change in Media Hydroxyproline Content in Direct and Indirect-Treated Cultures depicting
the relative increase in collagen leached from OA cartilage into the culture media in OA control and OA+hADSC
groups, while hAMSC treated groups remained constant.

5.3.6. Pro-Inflammatory Profile Assessment

Figure 49: IL-1β Analysis in hAMSC and hADSC-Treated Cultures depicting the average IL-1β concentrations in
cell culture media from each study group. (Minimum detection limit: 0.3 pg/mL).
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Figure 49 illustrates a trending decrease in IL-1β concentrations in OA+hAMSC
treated cultures, while all other cultures remained constant. Figure 50 depicts the
relationship between IL-1β concentration and route of administration. The ability of
hAMSCs to quell IL-1β secretion appeared to be dependent on the route of
administration.

Figure 50: IL-1β Analysis in Direct and Indirect-Treated Cultures depicting the average IL-1β concentrations in
cell culture media from each study group. (Minimum detection limit: 0.3 pg/mL).

While TNF-α concentrations remained constant in OA co-cultures, OA+hAMSC
and OA+hADSC cultures trended towards reduced concentrations (figure 51).

135

Figure 51: TNF-α Analysis in hAMSC and hADSC-Treated Cultures depicting the average TNF-α concentrations
in cell culture media from each study group. (Minimum detection limit: 6pg/mL).

Direct and indirect administration of hAMSCs accomplished this equally effectively.

Figure 52: TNF-α Analysis in Direct and Indirect-Treated Cultures depicting the average TNF-α concentrations in
cell culture media from each study group. (Minimum detection limit: 6pg/mL).
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MMP-13 ELISA performed on cell culture media revealed that over 15 days in
culture, there were no significant changes in MMP-13 media concentration. However, the
stem cell treated groups exhibited trends towards decreased MMP-13 concentrations
(Figure 53).

Figure 53: MMP-13 Analysis in hAMSC and hADSC-Treated Cultures depicting the average MMP-13
concentrations in cell culture media from each study group. (Minimum detection limit: 30pg/mL).

Analysis of direct and indirect hAMSC cultures showed no significant changes in MMP13 concentrations. However, the direct group did exhibit a trend towards decreased
MMP-13 while the indirect group exhibited no change compared to OA controls (Figure
54).
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Figure 54: MMP-13 Analysis in hAMSC and hADSC-Treated Cultures depicting the average MMP-13
concentrations in cell culture media from each study group. (Minimum detection limit: 30pg/mL).

In addition to these ELISA data, a comprehensive cytokine array was completed (see
appendix B for complete results). Most notably, this showed statistical increases in antiinflammatory marker IL-13 in OA+hADSCs cultures and anti-inflammatory marker IL-4
in OA+hAMSC cultures.
5.4 Discussion
With the evolving view of OA as an inflammatory condition driven by
macrophages and their pro-inflammatory secretions, immunomodulatory therapies have
come to the forefront of investigation. Due to their trophic, anti-inflammatory and
immunomodulatory properties, stem cells may prove to be uniquely suited agents for OA
therapies.11,12,84,134 In fact pre-clinical animal studies and human trial results support OA
mitigation through the intra-articular injection of stem cells.12,120
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Though two specific stem cell sources have been widely investigated as a
potential OA therapeutic, there are drawbacks associated ADSCs and bone marrow
derived stem cells (BMSCs) that are less attributable to alternative stem cell sources
(such as perinatal stem cells), including 1) the inability of BMSCs isolated from OA
patients to proliferate and differentiate as effectively as BMSCs from healthy donors, 2)
low cell yields and 3) painful harvest procedures.11,12,84
Conversely, perinatal stem cells exhibit significant advantageous qualities
including, 1) high cell yields, 2) ontogenetically youthful status limiting their exposure to
detrimental age-related changes and 3) superior chondro-protective effects in an
inflammatory environment, exhibiting the ability to induce a pro-regenerative (M2)
phenotype within synovial macrophages.68,73,87,221 Significantly, our data further supports
this ability of hAMSCs (but not hADSCs).
It has been demonstrated that stem cells must be “primed” in order to exhibit antiinflammatory and immunomodulatory characteristics.134,214 Typically this involves the
stimulation of stem cells through potent pro-inflammatory cytokines such as INF-γ.84,214
Though the exact timeline has not been established, the need for priming does represent
an inherent delay in the efficacy of OA stem cell therapies. This could be one explanation
for delays in patient progress post initiation of stem cell therapy. Interestingly, it has been
demonstrated that perinatal stem cells do not require priming prior to initiating
therapeutic benefit; this could explain why hAMSCs appear to more effectively mitigate
OA progression in our investigation. Additionally, it has been demonstrated that
reductions in both IL-1β and TNF-α are necessary to mitigate OA disease progression.225
Only hAMSCs are able to elicit reduction in both cytokines. IL-13, IL-10 and IL-4 induce
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an M2 phenotype within macrophages.256,257 IL-13 and IL-4 have demonstrated the
ability to mitigate cartilage degradation in vitro.258 While IL-4 and IL-10 have direct
effects on chondroprotection through the down regulation of ADAMTSs and MMPs,
respectively, IL-13 produces an indirect anti-inflammatory effect through the regulation
of PGE2.259 There is limited data providing insight into the relative efficacy of IL-4 and
IL-13 therapeutic strategies. However, this mechanistic insight seems to offer a potential
explanation for the heightened and more rapid mitigation of OA observed in hAMSCtreated cultures. Please see appendix B for more detailed mechanistic insight into stem
cell mode of action (accomplished via a comprehensive cytokine analysis).
The intra-articular administration of stem cell therapies delivers stem cells into
the joint space, likely resulting in a mixed contact scenario where only some stem cells
remain in direct contact with the cartilage. Interestingly there is evidence suggesting stem
cells do not tend to stay in direct contact with the cartilage; they home to the
synovium140, furthering the need for researchers to understand the potential mechanistic
differences and differential therapeutic effects of both treatment modalities. While stem
cells likely generate therapeutic benefit via the secretion of immunomodulatory mediators
(thus not requiring direct contact with cartilage)11,120, potential advantages of direct
contact with the damaged cartilage have yet to be established. Interestingly, indirect
contact co-culture of hAMSCs (which as figure 54 illustrates may actually be in direct
contact with synovium via porosity in the trans-well insert) seem to exhibit similar
mitigation of synovial pro-inflammatory M1 macrophages, though this does not translate
into an increased chondro-protective effect in the timeframe studied. OA has increasingly
become understood as a multi-focal disease, where both the cartilage and the synovium
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Figure 54: Indirect Contact hAMSCs May be in Direct Contact with Synovium due to the porosity of the insert
being large enough to allow passage of extension but not entire cells.

exhibit key surface receptors (toll-like receptors) fueling the pro-inflammatory activation
pathways characteristic of OA progression.12,125,135,260 While the exact etiology of OA is
still largely unknown, it is generally assumed that cartilage injury (as opposed to synovial
inflammation) initiates the propagation of OA.125,135 If true, it could be argued that
therapies targeting the source of OA pathogenesis, the cartilage, would be most
efficacious. Our results seem to indicate that such a targeted approach would be
therapeutically beneficial.
In conclusion, we were able to successfully demonstrate that perinatal stem cells
are capable of mitigating disease progression in an explant co-culture model of OA.
Moreover, perinatal stem cells appear to more effectively mitigate OA disease
progression compared to a commonly employed stem cell, hADSCs. The observed
reduction in M1 macrophage populations could be a primary mechanism explaining the
halt of OA progression observed in stem cell treated groups. Likewise, the increase in M2
macrophage populations observed in hAMSC treated groups could be a primary
mechanism explaining the enhanced ability of hAMSCs to mitigate OA progression.
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Significantly, both direct and indirect contact co-culture of hAMSCs with human OA
cartilage seem to result in the mitigation of OA progression. However, direct contact coculture with human OA cartilage seems to result in enhanced chondro-protective effects,
exhibited by enhanced chondrocyte viability, maintenance of cartilage GAG content and
trending reductions in the concentrations of cartilage matrix degrading enzymes and
collagen leaching. Taken together, these results (and those highlighted in Appendix B)
highlight the utility of hAMSCs for OA regenerative medicine approaches and provide
significant mechanistic into their clinical use.
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CHAPTER SIX
TO COMPARE THE THERAPEUTIC EFFECTS OF hAMSCs AND hADSCs TO
ATTENUATE OA PROGRESSION IN VIVO
6.1 Introduction
With the evolving view of OA as an inflammatory condition driven by macrophages and
their pro-inflammatory secretions, immunomodulatory therapies have come to the
forefront

of

investigation.

Due

to

their

trophic,

anti-inflammatory

and

immunomodulatory properties, stem cells may prove to be uniquely suited agents for OA
therapies.11,12,84,87,134,202
Numerous stem cell therapies have been described in animal models of OA. The
stem cells are typically delivered via intra-articular injection into the knee joint. In
comparison studies, stem cell therapies have been shown to yield better outcomes than
autologous chondrocyte transplantation.12 There is also evidence that the stem cells are
still located within guinea pig joint tissues after 1 week120,170 and up to 8 weeks postimplantation in rats.120 There are also reports of the stem cells exhibiting signs of
proliferation and differentiation. 120,170
Preliminary results from our group support the enhanced mitigation of OA by
amnion compared to adipose stem cell treated groups, ex vivo (chapter V). However, to
date amniotic stem cells have yet to be tested in vivo as an OA therapeutic. Additionally,
no direct comparative analyses have been conducted investigating the relative therapeutic
potential of amniotic stem cells with current clinically investigated stem cell sources (i.e.
bone marrow and adipose tissue).
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Herein, we describe efforts undertaken in order to determine: 1) if amniotic
mesenchymal stem cells are capable of mitigating OA progression in vivo and 2) if this
therapeutic approach is at least as beneficial as those utilizing adipose derived stem cells.
6.2 Materials & Methods
hADSCs were purchased from Invitrogen (R7788-110). Trypsin was purchased
from Fisher scientific (MT-25-053CI). Collagenase was purchased from Worthington
Biochemicals (LS004196). Guinea pigs were purchased from Charles River RMS.
Pharmaceutical grade HA was purchased from Lifecore Biomedical (HA700K-1). Indian
Ink was purchased from Dr. Martin’s Bombay.
6.2.1 Stem Cell Preparation
Human placentas were obtained from consenting patients immediately following
delivery via elective cesarean sections of full-term babies (Pro00031185-Greenville
Health System). Amniotic membrane derived cells were isolated within 4 hours of
delivery. hAMSCs were isolated as previously described (chapter III). Briefly, placentas
were placed with the umbilical cord facing upward such that the fetal (amniotic) surface
was accessible. The amniotic and chorionic membranes were identified and mechanically
peeled from each other. Amnions were digested twice in 0.25% trypsin for 30 minutes at
37°C with agitation to completely liberate the epithelial layer followed by complete
digestion in two digestions of collagenase [2mg/mL collagenase (249 U/mg)] for 30
minutes at 37°C with agitation each to subsequently liberate hAMSCs. hAMSCs were
expanded until p2 in standard culture medium (DMEM+10%FBS+1%AB/AM), with the
media changed every 3 days.
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hADSCs were purchased from a commercial vendor and expanded until p2
according to manufacturer’s instructions, with the media changed every 3 days.
At p2, all cell types were suspended in sterile HA in order to obtain 1x106 viable
stem cells/100µL HA aliquot. HA suspensions were loaded into 21g syringes in
preparation for injection.
6.2.2 Stem Cell Intra-Articular Injections
As illustrated in figure 55, n=24 guinea pigs were allowed 14 days upon arrival to
our facilities for acclimation. According to approved animal used protocols, at day 0 n=6
guinea pigs were used to practice injections. Briefly, a HA+hAMSCs suspension was
injected into the left stifle and a saline injection was administered into the right stifle of
these guinea pigs. Ultrasound guidance was utilized similar to methods described by
Vazquez et al.1 Briefly, stifles were placed in flexion, the ultrasound probe was covered
with gel and applied to the leg surface near the patella. A 21-gague syringe (loaded
HA+hAMSCs) was inserted posterior to the medial edge of the patellar ligament. After
initial insertion, the leg was placed in extension to facilitate visualization of the intraarticular space. The needle was inserted until it was in direct contact with the femur, and
the contents of the syringe were injected.
Additionally, at day 0 our experimental group underwent their first round of
injections. The left stifle received an injection of either an HA+hAMSC suspension, an
HA+hADSC suspension or HA alone (the HA group was included to ensure the HA itself
did not offer significant therapeutic benefit, confounding our results). Notably, the
passage (2), number of stem cells (1x106/injection) and injection volume (100µL)

145

remained constant between groups. The right stifle received a saline injection; these
limbs served as terminal time point OA controls.
After 7 days, the set of 6 practice guinea pigs were euthanized and their saline
injected limbs served as day 0 degenerative controls. After 1.5 months, the remaining
guinea pigs (n=18) were administered a second injection according to the methods
previously described. Finally after 3 months, the guinea pigs were euthanized. Outcome
measures for this study included macro and micro surface architecture and biochemical
assessments of the cartilage; as well as synovial inflammation.
6.2.3 Cartilage Surface Macro Architecture
Formalin fixation (48 hours) was followed by 7 days in decalcification solution.
After 3x washing in PBS, joints were dissected until the femoral condyles and tibial
plateaus were easily accessible. Approximately 100µL of 20% vol/vol solution of Indian
Ink in PBS was applied to the exposed cartilage surfaces, excess liquid was blotted away
and macroscopic images were taken.
6.2.4 Cartilage Surface Micro Architecture
Guinea pig stifles were secured within a tissue processing cassette, fixed in 10%
phosphate buffered formalin overnight at room temperature prior to undergoing standard
tissue processing, decalcification, paraffin embedding and sectioning at 8 µm thickness.
Sections were stained with Safranin-O counterstained with Fast Green for visualization of
proteoglycan rich cartilage matrix. Briefly, rehydrated sections were differentiated in 1%
acid alcohol for 2 seconds prior to room temperature incubation in 0.02% Fast Green for
2.5 minutes. After 30 second incubation in 1% Acetic acid, sections were stained with
1% Safranin-O for 15 minutes.

146

6.2.5 Assessment of Cartilage Degradation
As depicted in figure 56, stifles for biochemical analysis were removed from the
guinea pig. The femur and tibial surfaces were identified, and these surfaces were divided
into their medial and lateral components. The cartilage was then removed using a curette.
As guinea pigs primarily load the medial compartment of their joint; this area is most
susceptible to OA. To ensure results were not skewed by the tibial portions, assessments
were completed in quartered sections. The results from the medial tibial surface, which is
the surface most prone to OA in this model, are described herein.

Figure 56: Methods Schematic of Cartilage Harvest for biochemical evaluation. Stifles were dissected to expose the
femoral and tibial surfaces. These surfaces were further divided into medial and lateral components. Only results from
the medial tibial surfaces are reported, as this is the area most prone to OA development in this animal model.

6.2.5.1 Cartilage Glycosaminoglycan (GAG) Content
Lyophilized cartilage tissues were digested in 125µg/mL Papain in PBE Buffer,
pH 7.5 overnight at 65°C. Tissue digests were assessed for GAG content via
Dimethylmethylene Blue Assay (DMMB). Briefly, 200µL DMMB reagent (46µg
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DMMB, 40mM Glycine, 40mM NaCl, pH 3) was added to 50µL samples. Standards
were created using a 1mg/mL stock solution of Chondroitin-6-Sulfate. Sample
absorbance was read at 525nm.
6.2.5.2 Collagen Leaching to Culture Media
Cartilage was assessed for hydroxyproline collagen content via Hydroxyproline
Assay Kit according to manufacture instructions. Briefly, samples were hydrolyzed with
hydrochloric acid at 120°C for 3 hours prior to well plate transfer. Wells were evaporated
to dryness at 60°C. Equal amounts of Chloramine T/Oxidation Buffer Mixture and
Diluted DMAB Reagent followed by 5-minute room temperature and 90-minute 60°C
incubations, respectively. Standards were created using a 1mg/mL stock solution of
Hydroxyproline Standard Solution. Sample absorbance was read at 560nm.
6.2.6 Histological Confirmation of Synovitis
Synovial sections were secured within a tissue processing cassette, fixed in 10%
phosphate buffered formalin overnight at room temperature prior to undergoing standard
tissue processing, paraffin embedding and sectioning to 8 µm thickness. Sections were
stained with Hematoxylin and Eosin (H&E) for visualization of cellularity and membrane
hypertrophy.
6.2.7 Microscopic Imaging
Images were captured on a Zeiss Axiovert.A1 microscope with Axiovision
software (Release 4.9.1 SP08-2013).
3.2.8 Statistical Analysis
Results are represented as a mean ± standard error of the mean (SEM). All
statistical analyses were performed by two-tailed Student’s t-test of unequal variance or
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analysis of variance (ANOVA) with a Tukey’s post-hoc analysis. Significance was
defined in all cases as p<0.05.
6.3 Results
6.3.1 Stem Cell Preparation
Stem cell populations were successfully expanded and prepared for intra-articular
injection.
6.3.2 Stem Cell Intra-Articular Injections
Stem cell suspensions were successfully injected into the intra-articular space of
guinea pig stifles. See appendix A for more detailed information on these confirmation
assessments.
6.3.3 Cartilage Surface Macro Architecture

Figure 57: Cartilage Surface Macro-Architecture demonstrating medial tibial surface erosion in 3-month saline and
HA injected groups. Varying amounts of surface fibrillation/erosion is noted within stem cell treated groups.
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Figure 57 illustrates cartilage surface macro architecture assessments. A
macroscopic image of a stifle with the femoral condyles exposed on the top and the tibial
surface exposed on the bottom is presented in the top left of figure 57. The creamy and
shiny quality of the cartilage is easily noticeable; it is present everywhere except over the
medial tibial surface, which is highlighted by the black circle.
Indian ink stains bone as well as fibrillation of the cartilage surface. After 3
months, the medial tibial surface of saline injected stifles, which macroscopically looked
quite eroded, stains deep blue (figure 57). The HA group exhibited similar intense blue
staining on the medial tibial surface (figure 57). However, the stem cell treated groups
showed varying evidence of surface fibrillation and/or erosion (figure 57).
6.3.4 Cartilage Surface Micro Architecture

Figure 58: Cartilage Surface Micro Architecture of Controls, indicating high cartilage proteoglycan content at day
0. However by 3 months, the proteoglycan content has been largely degraded.

At day 0, there was a large volume of proteoglycan rich matrix (figure 58).
However, after 3 months this rich proteoglycan matrix appeared to have degraded away
(figure 58). Comparatively the HA group showed similar if not lower proteoglycan
content (compared to 3-month saline injected controls). While stem cell treated groups
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showed at least comparable if not more proteoglycan rich matrix (figure 59).

Figure 59: Cartilage Surface Micro Architecture of Experimental Groups, indicating low proteoglycan content in
HA-treated groups. However, stem cell treated groups show at least equivalent levels of proteoglycans compare to
controls.

6.3.5 Assessment of Cartilage Degradation
hAMSC treatment resulted in significantly greater (p<0.05) cartilage GAG
content compared to our untreated and HA controls (figure 60).

Figure 60: Cartilage GAG Content in all guinea pig groups. hAMSC-treated groups exhibit the highest cartilage
GAG content after 3 months.
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Additionally, hAMSC treatment resulted in significantly greater (p<0.05)
cartilage collagen content compared to HA controls (figure 61).

Figure 61: Cartilage Collagen Content in all guinea pig groups. hAMSC-treated groups exhibit the highest cartilage
collagen content after 3 months.

6.3.6 Histological Confirmation of Synovitis
Figure 62 shows H&E staining of synovium sections for assessment of synovitis.
Beginning with day 0 controls, there is intense cellularity near the lining; therefore the
lining does exhibit hyperplasia, with an addition 4+ layers of cells than what would
typically be expected in the synovial lining (this is highlighted by the black boxes). After
3 months, the non-treated group (this was the group which received saline injections)
showed similar cellularity and membrane hypertrophy; indicating at least equivalent
levels of synovitis over this 3-month period. After 3 months, the HA group also showed
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high cellularity and extensive membrane hypertrophy, likely indicating the HA treatment
had no therapeutic, immunomodulatory effect. Conversely, after 3 months the hAMSC
treated group showed moderate cellularity with less hypertrophy. Like the hAMSC
group, the hADSC group appeared to contain less cells along the synovial lining.

Figure 62: Histological Assessment of Synovitis demonstrating trends between control (untreated) stifles and treated
stifles with time. Black boxes highlight the synovial lining.

3-month saline injected right stifles (pictured along the top in figure 63) were then
compared with their subject matched 3-month treatment injected left stifles (pictured
along the bottom of figure 63). Synovitis appeared to progress in the HA-treated group.
The hAMSC treated group appeared to show improvement in both cellularity and
membrane hyperlasia. Lastly, the synovitis in hADSC treated guinea pigs appeared to be
the same.
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Figure 63: Subject-Matched Histological Assessment of Synovitis demonstrating trends between subject-matched
left (treatment) and right (control) stifles.

6.4 Discussion
We were able to confirm and employ our approach of intrtopa-articular injection
of stem cells in a pilot guinea pig study (see appendix A). We also demonstrated
preliminary trends supporting the therapeutic efficacy of hAMSC and hADSC therapies
mitigating OA progression in vivo. While we are continuing to analyze this data, the
biochemical data specifically seems to indicate hAMSCs, in particular, are having a
beneficial effect.
The Dunkin Hartley guinea pig animal model was employed in this study,
because anatomically, the guinea pig knee is very similar to the human knee, though it is
much smaller.160 Additionally, guinea pigs exhibit the multi-factorial nature of bone
growth and growth plate fashion observed in humans.160 Notably, guinea pigs primarily
load the medial stifle, making the medial compartment most prone to OA development
(similar to humans).160 The histopathology of the guinea pig has been extensively
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evaluated and deemed similar to human OA.160
All guinea pigs showed no signs of immunologic rejection throughout the study.
There were no abnormal behavioral changes (aggressiveness or lethargy) typically
associated with bio-incompatability. However, IHC detection of lymphocytes should be
employed in order to confirm this.
Both macro- and microscopically, it appeared the guinea pigs did reliably develop
OA of the medial tibial plateau at 6-months of age (animals were 6-months old upon
study termination at 3-months). Though the Dunkin Hartley guinea pig model does
reliably develop OA in the entire medial compartment by 1-year of age.2,3 Our results
indicate OA was limited to the medial tibial compartment. An extended treatment
timeline as well as the use of older animals would likely yield more advanced disease
progression.
Synovial inflammation also confirmed OA progression in the guinea pigs with
time. The grouping, size and shape of the cells observed in synovial inflammatory
assessments appear to be some sort of inflammatory cell, potentially a macrophage, but
macrophage-specific staining via IHC would be necessary to confirm this. These
assessments proved particularly useful as they also led to the determination that due to
small sample sizes, increased control (n=6) vs. experimental (n=2) subject numbers and
moreover, large inter-subject variability, the most appropriate reporting of the in vivo
data involved comparing the subject-matched treatment and saline injected limbs. Such
comparisons

appeared

to

offer

more

progression/mitigation.
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accurate

depictions

of

disease

We noted the hAMSC-treated group appears to more successfully mitigate
synovial inflammation. Not surprisingly, this group also preliminarily exhibited superior
chondro-protection compared to hADSC and HA treated groups. As previously
discussed, OA is an inflammatory condition driven by a feed-forward, macrophage-based
mechanism. Based on previous results and the preliminary results of this study, hAMSCs
me in fact be lowering the number of M1 macrophages or facilitating some sort of
macrophage polarization shift. Whether this results or is a result of chondro-protective
effects remains to be seen.
There are many more analyses that can be conducted on these samples, including
tracking of the stem cells and macrophage/lymphocyte detection. Tracking of stem cells
could be accomplished utilizing IHC detection of human mitochondria. In future
iterations of such studies, the stem cells could be fluorescently tagged prior to injection as
another metric of stem cell tracking. Similar to those results reported in chapter V, it
would be interesting to track macrophage phenotype over time. Ex vivo we have
demonstrated hAMSC treatment seems to shift macrophage polarization to an M2
phenotype. However, it remains to be seen if similar phenomena occur in vivo.
Unfortunately, this will require anti-body development, as the necessary antibodies are
not currently available in the guinea pig. IHC detection of lymphocytes will help further
claims of biocompatibility of the injected stem cell therapeutics. Though such methods
utilizing human cells in this guinea pig model have been previously described with no
immune rejection,4 this should be confirmed in our investigation. In future guinea pig
studies, it would be ideal to obtain synovial fluid samples. Cytokine profiling would be a
potential alternative method of gaining insight into macrophage polarization.
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Additionally, it would be interesting to confirm the IL-4 and IL-13-dependent therapeutic
mechanisms proposed in aim III, in vivo.
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CHAPTER SEVEN
CONCLUSIONS
In conclusion, we were able to successfully demonstrate stem cells from the
amniotic membrane exhibit heightened differentiation potential, availability in high
yields, heightened immunomodulatory properties, and the ability to induce proregenerative (M2) phenotypes within macrophages, in musculoskeletal tissue-related
experiments. Additionally, perinatal stem cells appeared to offer accelerated treatment
time lines compared to a field standard stem cell, adipose derived stem cells.
In aim I, we were able to successfully isolate amniotic stem cells in high yields
and differentiate them into osteogenic and chondrogenic lineages more readily than
hADSCs. These differentiation capacities verified that amnion stem cells a candidate
stem cell for osteoarthritis therapies. We therefore, continued to examine the utility of
amnion stem cells through investigations into their OA therapeutic efficacy.
In aim II, we were able to successfully demonstrate human joint tissue explant coculture mimics OA pathogenesis by modeling: 1) cartilage destruction in the presence of
inflammatory cytokines and synovial macrophages, 2) gradual progression with time and
3) a feed-forward progression, where the cartilage and synovium exhibit reciprocal
pathologic effects on one another. Additionally, our mechanistic evaluations utilizing
macrophage depletion studies indicate synovial macrophages and/or their secretions are
likely primary effectors driving disease progression in the model. This work highlights
the utility of joint tissue explant co-culture in OA research, as it is an effective system for
investigating OA pathology and evaluating potential future therapies.
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In aim III, we were able to successfully demonstrate that perinatal stem cells are
capable of mitigating disease progression in an explant co-culture model of OA.
Moreover, perinatal stem cells appear to more effectively mitigate OA disease
progression compared to a commonly employed stem cell, hADSCs. Significantly, both
direct and indirect contact co-culture of hAMSCs with human OA cartilage seem to result
in the mitigation of OA progression. However, direct contact co-culture with human OA
cartilage seems to result in enhanced chondro-protective effects. Lastly, we were able to
propose a mechanism for the observed mitigation via M2 macrophage anti-inflammatory
secreted products.
In aim IV, we were able to successfully complete pilot animal study comparing the
relative therapeutic efficacy of hAMSC and hADSC therapies for the mitigation of OA.
Evidence, specifically biochemical analyses, appears to suggest hAMSCs offer superior
therapeutic benefit.
For these reasons, we believe amnion membrane derived stem cells are an
efficacious stem cell source for orthopedic tissue engineering and regenerative medicine
strategies.
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CHAPTER EIGHT
RECOMMENDATIONS
8.1 What Worked Well
Many of the methodologies employed in this research proved extremely efficacious
and/or added validity to the work. I suggest the following methods continue to be
implemented in future iterations of this work:
1. Conducting%standardized%experiments%comparing%the%investigated%amnion%stem%
cells% against% commonly% employed% stem% cells% allowed% for% conclusions% regarding%
the% validation% of% amnion% as% a% stem% cell% source% for% orthopedic% regenerative%
medicine%(validation%requires%comparison%to%established%standards;%in%this%case%
hADSCs).%I%encourage%similar%comparative%analysis%to%be%conducted%with%another%
commonly% employed% stem% cell,% hBMSCs,% as% well% as% some% more% widely%
researched%perinatal%stem%cells,%CMSCs%and%chord%blood%stem%cells.%Comparisons%
between% human% joint% tissue% explant% coPculture% and% chemical% doping% models%
would%also%prove%beneficial.%%%%
2. All%histological%assessments%were%conducted%by%at%least%one%blinded%researcher.%
This/these% researcher(s)% remained% blinded% to% the% condition/treatment% of% the%
sample%being%analyzed.%This%added%significant%validity%to%the%obtained%results,%as%
it%limits%peerPreview%rejection%of%the%results%due%to%researcher%bias.%
3. Large%sample%sizes%were%required%in%order%to%overcome%interPpatient%variability%
of% OA% disease% characteristics.% Based% on% this% work,% utilizing% sample% sizes% below%
10% is% highly% discouraged,% as% it% does% not% seem% to% accurately% reflect% the% trends%
and/or%statistical%differences%observed%with%n=15+%samples.%
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8.2 Future Suggestions for Aim I
Chondrocytes above the non-calcified zone in cartilage live under hypoxic
conditions. While researchers are unsure of the exact mechanism(s), it appears that
obtaining the appropriate ratios of aggrecan and collagen-II described in articular
cartilage requires hypoxic conditions. Our experiments were conducted under normoxic
conditions. Thus, chondrogenic differentiation characteristics could have been altered or
more likely, will be enhanced and/or accelerated if completed under hypoxic conditions.
Mechanical stimulation is necessary in order to maintain cartilage homeostasis.
This stimulation provides many functions, including facilitating synovial fluid movement
and preventing the secretion of pro-inflammatory cytokines. The development of a
bioreactor system that could apply appropriate mechanical loading to the cell system may
enhance and/or accelerate chondrogenic differentiation of amnion stem cells.
Many musculoskeletal tissue pathologies, including OA, involve the creation and
maintenance of a pro-inflammatory milieu within the pathologic tissue. Differentiation of
most stem cells, including hADSCs, has been shown to be less effective under such
inflammatory conditions. However, there is evidence that perinatal stem cells are able to
differentiate under inflammatory conditions. Therefore, the results of our differentiation
study (which favor amnion stem cells) could become even more skewed if the experiment
were conducted with media supplemented with pro-inflammatory cytokines (ex. INF-γ,
TNF-α, IL-1β).
Lastly, there are minor adjustments to the method that could be employed to
increase the clinical relevance of the study. Firstly, the amino stem cells could be isolated
using the explant culture technique (i.e. without enzymatic digestion). Secondly, the
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amnion cells should undergo at least one freeze-thaw cycle prior to use in the
differentiation study, as this will more closely mimic the tissue-banking processes that
would be necessary with the clinical use of amnion. Finally, during stem cell expansion
and differentiation, animal-serum media should be employed.

8.3 Future Suggestions for Aim II
As previously indicated, cartilage homeostasis requires hypoxia and mechanical
stimulation. The development of a bioreactor system that could apply appropriate
mechanical loading to the co-culture systems would more closely mimic the native
anatomy and physiology being modeled.
For similar reasons, the meniscus, a highly inflammatory tissue of the OA joint
space, could be added to the co-culture system. As OA progression seems to be
inflammatory based, this may further enhance the OA progression observed. Extending
the length of the study to at least 28 days would also likely show greater disease
progression. However, our low synovium viability results seem to indicate that culture
past this time period may not be possible.
While literature-based comparisons are possible based on these results,
standardized comparative analyses employing this OA co-culture model and those
employing chemical doping of the co-culture media are strongly encouraged. Such results
would bolster claims of this model more accurately reflecting the natural and progressive
nature of human OA.
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8.4 Future Suggestions for Aim III
Significant variability was observed both within and between samples in the OA
co-culture studies. In order to be sure such variability does not significantly alter the
observed data trends, the 6mm biopsy tissue samples could be cut in half prior to
initiating culture. One half of the sample could receive hADSC treatment while the other
half of the sample could receive hAMSC treatment. Additionally, a dosing study to
determine a the stem cells required to effectively mitigate disease progression would
offer significant, clinically relevant, insight.
The model could also be employed in further mechanistic studies in order to
further confirm and/or advance studies of OA. For example, M2 macrophage specific
clodronate could be introduced into the culture system in order to systematically deplete
M2 macrophages. Disease progression similar (if not worsened compared) to OA coculture controls would be anticipated. Additional biochemical screening could include
PGE2 (to further investigate hADSC mitigation via auxiliary pathways), IL-1Ra (a known
competitor of IL-1 binding which could be up-regulated by stem cells) and ADAMTS-5
(the primary ADAMTS involved in OA which could be differentially down-regulated).
Additionally, this experimental design could be modified in order to test the regenerative
(vs. mitigation) capacity of the stem cells. Creating a reproducible defect within the
cartilage biopsies and monitoring the condition of the defect with time/treatment could
accomplish this.
In an attempt to make these studies more clinically relevant, minced amnion could
be employed as an alternative (therapeutic) study group. There is precedence for the use
of amniotic membrane, as numerous amniotic membrane-based products are

163

commercially available. If minced amnion is an efficacious therapeutic alternative, it may
prove easier to obtain FDA backing than stem cell therapies.

8.5 Future Suggestions for Aim IV
Dunkin-Hartley guinea pigs reliably exhibit severe OA by one year of age.
Therefore increasing the study duration and/or utilizing older animals would be
encouraged in order to ensure each animal exhibited OA prior to stem cell injection.
A stem cell tracking study would provide information regarding the length of time
the stem cells remain in the joint space as well as the location of the stem cells. This
could provide mechanistic insight into the primary mode of action of the stem cells
(differentiation into chondrocytes vs. immunomodulatory). Such a study may also help
ease concerns regarding the short lifespan of HA within the joint, as stem cell migration
from the HA carrier into the joint space could be monitored. While IHC or
immunofluorescence for human mitochondria is one method for tracking stem cells,
immunofluorescent tagging of the stem cells is another commonly employed alternative.
Though such an approach would require the use of female guinea pigs, the use of male
cells in a female animal model would allow the tracking of stem cells via Y-chromosome
in situ hybridization.
The inabilities to test for M1/M2 macrophages and to obtain synovial lavages
were severe limitations of our pilot guinea pig study described in aim IV. It is strongly
recommended to obtain synovial fluid samples in order to obtain further mechanistic
insight into the action of the stem cells. Particularly, it would be interesting to see if the
up-regulation of IL-13 and IL-4 in hADSC and in hAMSCs, respectively, observed ex
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vivo is also observed in vivo.
Lastly, steps could be taken to increase clinical relevance. The addition of more
clinically relevant outcome measures would also enhance the validity of further guinea
pig investigations. Functional testing through the use of cage platforms (monitoring
animal activity levels) or guinea pig pedometers could be employed. Radiographic-based
assessments of the joint space would also more accurately reflect clinical grading and
assessment of the joint. Additionally, synthetic HA could be investigated as a stem cell
carrier due to its more prevalent use compared to natural HA. Furthermore, there is
precedence (from a regulatory standpoint) for the use of amniotic membrane as a wound
covering. Therefore investigating the use of amniotic membrane as a “band aid” covering
the synovial membrane (vs. a stem cell therapy) may be worthwhile. Results from our
hAMSCs seeded in indirect contact with the cartilage surface (aim III) seem to support
such an approach.
%
%
%
%
%
%
%
%
%
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APPENDIX A
ADDITIONAL DATA/FIGURES

Figure A.1: Detailed Methods Schematic describing the experimental design of the differentiation study described in
aim I.
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Figure A.2: Alternate depiction of TLR-activation highlighting the ability of chondrocytes (in additional to synovial
cells) to contribute to TLR-activation.
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Figure A.3: Pictorial Representation of the Multi-Focal Therapeutic Potential of Stem Cells highlighting two of
the proposed mechanisms of action: differentiation and immune modulation.
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Figure A.4: Detailed Methods Schematic Describing Joint Tissue Explant Tissue Harvest and the initiation of coculture.
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Figure A.5: The Fate of Intra-Articularly Injected Stem Cells is Unknown. Stem cells are typically administered
via intra-articular injection, and it is currently not known what tissue(s) the stem cells actually remain in contact with. It
is possible the stem cells are directed to that surface via signaling cues and settle (due to gravity) on the surface of the
cartilage. It is also possible that the movement of the joint would actually prevent the stem cells from settling and they
could remain in indirect contact with the cartilage surface. Therefore we wanted to investigate the effects of varying
stem cell administration location on therapeutic potential.
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Alternative Method of Achieving Chondrogenic Differentiation: Micro Mass Culture

Methods: hAESCs, hADSCs, and Mixed cell groups (n=4 per cell type per treatment) for
use in chondrogenic differentiation were seeded in micro-culture at 8x104/10µL media.
After 2 hours, the remaining media was added to the micro-culture. At select time points,
cultures were stained with Alcian Blue and underwent semi-quantitative analysis as
described previously in chapter IV.

Results: All negative control cell groups exhibited GAG deposition by day 14, and figure
A.6 confirms this deposition continued through day 28. Staining of the negative controls
appeared to be less extensive than in the test groups (Figure A.7), and semi-quantitative
analysis confirmed this in most cases. Additionally it was noted that, in comparison to the
hAESCs and hADSCs, the hybrid cell population proliferated much more extensively,
and yielded greater staining, by each time point (Figure A.7).

Day&28&
&&
Day&14&
&&
Day&7&
&&
Day&3&
&&

Table&A.1:&Average&%&Area&Stained&by&Alcian&Blue&&
hAEC&
hAEC&Neg.&
Mixed&
Mixed&Neg.& hADSC&
+
+
+#
43.02* &
31.28* &
86.70* &
97.13*+#&
26.20*#&
hAESC&
hAESC&J&
hAMSC&
hAMSC&J&
hADSC&
+#
+
+#
+#
28.41* &
26.15* &
30.15* &
26.39* &
20.30*#&
hAESC&
hAESC&J&
hAMSC&
hAMSC&J&
hADSC&
0.01&
0.00&
0.00&
0.00&
0.00&
hAESC&
hAESC&J&
hAMSC&
hAMSC&J&
hADSC&
0.00&
0.00&
0.00&
0.00&
0.00&

hADSC&Neg.&
24.22*+&
hADSCJ&
25.88*+&
hADSC&J&
0.00&
hADSC&J&
0.00&

Table A.1: Semi-Quantitative Alcian Blue results demonstrating the increased chondrogenic differentiation of
amnion groups compared to hADSCs. *Denotes statistical difference (P<0.05) between test group and respective
control within time point +Denotes statistical difference (P<0.05) between cell group and hADSC test group within
time point # Denotes statistical difference (P<0.05) between cell group and hADSC negative group within time point

172

Figure A.6: Micro Mass Chondrogenic Differentiation of Negative Controls with Alcian Blue staining. GAG
deposition was apparent across all groups by 14 days. No significant morphological changes were noted.

Figure A.7: Micro Mass Chondrogenic Differentiation of Experimental Group with Alcian Blue staining. GAG
deposition was visible across all groups by day 14. Morphological changes were apparent in both amniotic membranederived cell groups as early as day 3, whereas hADSCs maintained their spindle shape a through 28 days.
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Chondrocyte Clustering in OA Co-culture

As previously indicated, normal
chondrocytes are held in place due
to their senescent state. However,
in

OA

chondrocytes

activate:

proliferating and secreting matrix.
This results in the chondrocytes
moving and forming cell clusters.
An

example

of

chondrocyte

clustering observed in OA cartilage
explants can be seen in figure A.8.
Counting the number of cell
clusters is a method employed by
Figure A.8: Chondrocyte Clustering observed in a safranin-O
stained cartilage explant. Prominent clusters are circled.

researchers to convey the extent of
OA progression. Clusters were

only counted if they consisted of at least 3 chondrocytes. Figure A.9 demonstrates the
limited differences between study groups. There appeared to be no difference in the
number of chondrocyte clusters observed in OA, cartilage only or hADSC-treated groups
after 15 days. However, hAMSCs in direct contact with cartilage demonstrated a trend
towards reduced chondrocyte clustering and hAMSCs in indirect contact with cartilage
demonstrated statistically reduced chondrocyte clustering compared to hADSC-treated
groups.
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Figure A.9: Chondrocyte Clustering observed in OA explant co-culture over 15 days.

Figure A.10 shows a patient-matched set of safranin-o stained cartilage explants,
demonstrating the trending decrease in clusters observed in hAMSC-treated groups.

Figure A.10: Chondrocyte Clustering in Patient-Matched Cartilage Explants observed after 15 days

The depth of chondrocyte clustering is also considered to be reflective of the stage of
OA; where clustering within the superficial-middle zones represents early stage OA and
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clustering within the middle-deep zones represents late stage OA. Figure A.11 illustrates
the relative depth of chondrocyte clusters observed within study groups.

Figure A.11: Relative Depth of Chondrocyte Clustering observed after 15 days in explant co-culture.
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Initial Feasibility Assessment for Guinea Pig Injection Study: Stem Cell Viability
In an attempt to ensure stem cell viability post submersion in HA and injection through a
syringe, the viability of hAMSCs and hADSCs was tracked through this process in an
initial feasibility study (n=3 per stem cell type). In order to gain meaningful insight into
the affect of HA suspension and syringe injection, all stem cell culturing conditions and
materials employed in this study were identical to those previously described in chapter
VI (i.e. this feasibility study employed identical methods to those utilized in the actual
guinea pig injections).

Methods: Passage 1 hAMSCs and hADSCs were plated under standard expansion culture
conditions. At confluence, cells were passaged and initial viability of these passage 2
cells was established via Trypan Blue counting in a BioRad TC-20 cell counter. 1x106
cells were submerged in individual aliquots of 100µL HA, loaded into a 21-gauge syringe
and the total volume of HA+SC suspension was ejected. The HA+SC suspension was
then counted to determine the effect of the HA carrier and injection process on cell
viability.

Results: As illustrated in figure A.12, cell viability was not affected by submersion in HA
followed by injection through the syringe. The average HA suspension and injection
process lowered cell viability by <1.5%. No statistical differences were observed between
initial and final viability counts or between stem cell types.
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Figure A.12: Stem Cell Viability Assessment post submersion in the HA carrier, loading and injection through a
syringe.
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Initial Feasibility Assessment for Guinea Pig Injection Study: Stem Cell Injection
In an attempt to ensure the joint space could be successfully located, and the injections
could be delivered into the intra-articular joint space, n=3 rats and n=6 guinea pigs were
used in ultra-sound guided practice injections.

Methods: Ultrasound guidance was utilized similar to methods described by Vazquez et
al.261 Briefly, rat stifles were placed in flexion, the ultrasound probe was covered with gel
and applied to the leg surface near the patella. A 21-gague syringe was loaded with PBS,
and the needle was inserted posterior to the medial edge of the patellar ligament. After
initial insertion, the leg was placed in extension to facilitate visualization of the intraarticular space. The needle was inserted until it was in direct contact with the femur, and
the PBS was injected.

Results: As illustrated in figure A.13A, the intra-articular space was correctly identified.
The needle was inserted into the intra-articular space and identified via ultra-sound
(figure A.13B). The PBS was not injected until the needle was successfully guided to the
femur surface (figure A.13C).
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Figure A.13: Ultrasound Confirmation of Practice Injection showed
that the intra-articular space could be identified (A), the needle could be
inserted (B) and the PBS injection could be ejected when the needle was at
the surface of the femur.
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APPENDIX B
COMPREHENSIVE INFLAMATORY ASSESSMENT OF
OA EXPLANT CULTURES

Initial probes into the inflammatory profile of the described OA explant culture
system included enzyme-linked immunosorbent assay (ELISA) for primary OA
mediators: IL-1β, TNF-α and MMP-13, were described in chapters IV and V. In order for
more thorough model validation efforts as well as further mechanistic confirmation of the
therapeutic efficacy of the described stem cell therapies, a comprehensive inflammatory
cytokine array was completed on media samples from OA explant co-cultures (OA day 0
(n=13), OA day 15 (n=13), Macrophage depleted day 15 (n=5), OA+hADSC day 15
(n=4), OA+hAMSC in direct contact with cartilage day 15 (n=5), OA+hAMSC in
indirect contact with cartilage day 15 (n=3)). This array provided quantitative
measurements of 20 human chemokines and cytokines. 13 of these provide proinflammatory stimulation (IL-1α, IL-1β, TNF-α, RANTES, MCP-1, IL-8, IL-6, IL-2, IL5, IL-12, MIP-1a, MIP-1b and GM-CSF), while 3 are known anti-inflammatory
mediators (IL-4, IL-10, IL-13). An additional marker, VEGF, has been used as a marker
of synovitis (as synovitis is characterized by enhanced angiogenesis within the
synovium). In this appendix we describe the results of this array and highlight the
implications of these results. For clarification, please see the below list of formal and
alternative names for each mediator investigated.
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Table B.1 Clarification of Terminology & Cytokine Source
OA Tissue Source
Name on Cytokine
Abbreviation Alternative Name(s)
of Cytokine
Array
104,118,132,260,262,263
Hematopoietin 1
Interleukin 1 alpha

Interleukin 1 beta

Tumor Necrosis
Factor alpha
Interleukin 8
Monocyte
Chemoattractant
Protein-1
Regulated on
Activation, Normal T
cell Expressed and
Secreted

IL-1α

IL-1β

TNF-α
IL-8
MCP-1

RANTES

Leukocytic pyrogen,
Eukocytic
endogenous
mediator, Ononuclear
cell factor,
Lymphocyte
activating factor
Cachexin, or
Cachectin
CXCL8
Chemokine (C-C
motif) ligand 2
(CCL2)
Chemokine (C-C
motif) ligand 5
(CCL5)
Interferon Beta 2

Interleukin 6
Macrophage
Inflammatory
Protein-1a
Macrophage
Inflammatory
Protein-1b
GranulocyteMacrophage ColonyStimulating Factor

IL-6
MIP-1a
MIP-1b
GM-CSF

Interleukin 10

IL-10

Interleukin 13
Interleukin 4

IL-13
IL-4

Chemokine (C-C
motif) ligand 3
(CCL3)
Chemokine (C-C
motif) ligand 4
(CCL4)
Colony stimulating
factor 2 (CSF2)
human Cytokine
Synthesis Inhibitory
Factor (CSIF)
NA
NA
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Cartilage,
Subchondral bone,
Synovium
Cartilage,
Subchondral bone,
Synovium
Cartilage,
Subchondral bone,
Synovium
Synovium
Synovium
Subchondral bone,
Synovium
Cartilage,
Subchondral bone,
Synovium
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Figure B.1: Summary of Mediators Investigated.

Figure B.2: Summary of IL-1# concentrations from each OA explant group examined.

IL-1# is typically secreted in early stage OA. IL-1a has been used as a prognostic
indicator of early OA, as its serum detection successfully differentiated early stage OA
patients from controls.262 Like IL-1", IL-1# is a potent pro-inflammatory mediator,
which stimulates the secretion of numerous downstream pro-inflammatory mediators.252
It would be expected that due to the removal of macrophages and increased antiinflammatory activity, IL-# would decrease in macrophage depleted and stem cell treated
groups, respectively. However, no statistical differences are noted.
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Figure B.3: Summary of IL-1" concentrations from each OA explant group examined.

IL-1" is typically secreted in late stage OA. IL-1" stimulates the production of
cartilage degrading enzymes MMP-1, MMP-3 and MMP-13, cytokine IL-6 and
chemokines IL-8, MCP-1 and RANTES.118 As this cytokine has been previously
discussed in detail, this discussion will focus specifically on the reported results.
Consistent with the ELISA data described in chapters IV and V, IL-1" decreased in
macrophage depleted and stem cell treated cultures. Additionally, trends towards
decreased Il-1" expression in amnion groups were observed (p<0.055 compared to OA
day 0; p<0.061 compared to hADSC treated cultures). At all points in culture, our results
fell within physiological ranges, further demonstrating this OA co-culture system
provides a more natural model of Il-1" involvement in OA pathogenesis.136,147,149 Others
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have noted extremely low concentrations of IL-1β in ex vivo cultures.252–254 This has
been attributed to the extreme lability associated with this cytokine, and researchers have
cautioned conclusions based solely on IL-1β biochemical analysis.173,255 However, our
other cytokine results coupled with our previous analyses described in chapters IV and V
reinforce the validity of such conclusions.
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Figure B.4: Summary of TNF-# concentrations from each OA explant group examined.

TNF-# stimulates the production of cartilage degrading enzymes MMP-1, MMP3 and MMP-13, cytokine IL-6 and chemokines IL-8, MCP-1 and RANTES.118 As this
cytokine has been previously discussed in detail, this discussion will focus specifically on
the reported results. No statistical differences are noted. Notably, the ELISA data
described in chapter V showed a more distinctive trend of TNF-# reduction in amnion
treated groups. This reduction concomitant with the observed reduction in IL-1" by was
hypothesized to be a mechanism behind the enhanced mitigation observed in hAMSC
treated groups, as it has been demonstrated that reductions in both are necessary for OA
mitigation.150 This discrepancy in TNF-# results can likely be attributed to differences in
sample sizes as well as in the detection method employed.
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Figure B.5: Summary of IL-8 concentrations from each OA explant group examined.

IL-8 is a chemokine responsible for monocyte/macrophage recruitment. IL-8
induces proteoglycan loss through the up regulation of MMPs as well as IL-6
production.118 It would be hypothesized that macrophage depleted and stem cell treated
cultures would express less IL-8 compared to other culture groups. However, no
statistical differences are noted.
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Figure B.6: Summary of MCP-1 concentrations from each OA explant group examined.

MCP-1 plays a primary role in the recruitment and infiltration of
monocytes/macrophages into target tissues.264 MCP-1 is specifically associated with
chemotaxis of monocyte, memory T lymphocyte and natural killer cells.264 MCP-1 is
secreted by a variety of cells, but it is largely associated as a macrophage secretion, and is
thus used as a marker of pro-inflammatory activity. MCP-1 induces proteoglycan loss
through the up regulation of MMPs as well as IL-6 production.118 It would be
hypothesized that macrophage depleted and stem cell treated cultures would express less
MCP-1 compared to other culture groups. However, no statistical differences are noted.
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Figure B.7: Summary of RANTES concentrations from each OA explant group examined.

RANTES is largely (but not exclusively) a macrophage secreted product that
induces proteoglycan loss through the up regulation of MMPs as well as IL-6
production.118 RANTES is up-regulated by other potent pro-inflammatory mediators,
including IL-1" and TNF-#.265 RANTES is readily detected in normal adult joint tissues;
however, it has been readily detected in OA patient joint tissues.265 MCP-1, RANTES
and MIP-1b are all chemotactic for monocytes, but they bind with specific (different)
receptors.264 This could be one explanation why the observed trends between these three
cytokines are different. Notably, hAMSC-treated cultures in direct contact with cartilage
exhibit statistically reduced RANTES expression compared to hADSC-treated cultures.
Therefore, it could be hypothesized that hAMSC-treated cultures would also demonstrate
the down-regulation of primary OA pro-inflammatory mediator IL-6.
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Figure B.8: Summary of IL-6 concentrations from each OA explant group examined.

IL-6 is a prominent cytokine in the pathogenesis of osteoarthritis.118 IL-6 is
known to be elevated within the synovial fluid of OA patients.118 IL-6 secretion results in
the reduction in type II collagen from cartilage via the up regulation of MMP-1 and
MMP-13.118 IL-6 secretion is dependent on IL-1, TNF-#, IL-8, MCP-1 and RANTES
production (i.e. IL-6 is a downstream mediator). Since the previously described data
demonstrates trending and/or statistical reductions in IL-1", TNF-# and RANETS
expression in hAMSC-treated groups (compared to hADSC-treated groups), it was
hypothesized that a reduction in IL-6 would also be observed. Our results confirm this
hypothesis for hAMSCs in direct contact with the cartilage.
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Figure B.8: Summary of MIP-1a concentrations from each OA explant group examined.

MIP-1a is a chemoattractant factor for monocytes/macrophages, and it has been
implicated specifically in osteoarthritis pathology within human joints.266 MIP-1a has
been used as a prognostic indicator of early OA, as its serum detection successfully
differentiated early stage OA patients from controls.262 Additionally, MIP-1a has been
correlated with IL-8 concentrations.262 Apart from the macrophage-depleted group, our
MIP-1a results show similar trends to those of IL-8. As MIP-1a is a primarily
macrophage secreted product, it is logical that its secretion would be reduced under
conditions of macrophage depletion.
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Figure B.9: Summary of MIP-1b concentrations from each OA explant group examined.

MIP-1b is a chemoattractant factor for monocytes/macrophages, and it has been
implicated specifically in osteoarthritis pathology within human joints.266 In fact, MIP-1b
is the only reported cytokine with elevated levels in OA patients compared to rheumatoid
arthritis patients.266 Elevated MIP-1b expression has been correlated with worsened joints
(as evaluated through clinical scoring systems) and local expression of pro-inflammatory
mediators.262 The statistically reduced expression of MIP-1b in the macrophage-depleted
group could explain and/or be explained by the reduction in other pro-inflammatory
mediators observed (see figure B.17 for more information on the inter-relationships of
this cytokine).
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Figure B.10: Summary of INFg concentrations from each OA explant group examined.

INF-g promotes the differentiation of and is secreted by M1 macrophages.256 INFg, VEGF and/or GM-CSF stimulation results in the up-regulation of monokines,
including, IL-1", IL6 and MCP-1.262 Interestingly, INFg expression appears to increase
in stem cell treated cultures. This is counter to our hypotheses and the previously
described IHC M1/M2 macrophage counts described in chapter V. However, as
previously indicated, biochemical mediator quantification is extremely labile.118,255,265
Many markers are involved in numerous complex biochemical cascades. Therefore, there
may be an additional mechanism that is currently not accounted for in our discussions.
Conclusions drawn from this cytokine data alone should be interpreted cautiously.
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Figure B.10: Summary of VEGF concentrations from each OA explant group examined.

VEGF has a complicated and not clearly defined role in OA pathogenesis.
Classically, VEGF is a fibroblastic secretion promoting angiongenesis.132,256 Thus, VEGF
has been associated with blood vessel growth in wound healing as an M2 macrophage
secreted product.256 However, as indicated previously, INF-g, VEGF and/or GM-CSF
stimulation results in the up-regulation of monokines, including, IL-1", IL6 and MCP1.262,267 Our data does not seem to provide clarity into which mechanism is likely
involved in our explant co-culture system.
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Figure B.11: Summary of GM-CSF concentrations from each OA explant group examined.

GM-CSF is only involved in the development of macrophages under
inflammatory conditions (i.e. diseases such as OA) as opposed to normal, homeostatic
conditions.257 GM-CSF is associated with the differentiation and maintenance of M1
macrophages.257 As indicated previously, INF-g, VEGF and/or GM-CSF stimulation
results in the up-regulation of monokines, including, IL-1", IL6 and MCP-1.262,268 In light
of the IHC results described in chapters IV and V, we would have expected levels of
GM-CSF to be highest in OA and hADSC treated cultures. It is surprising to see these
levels so low in OA cultures. However the relationship between high GM-CSF
expression in hADSC treated cultures with low expression in hAMSC treated cultures
seems to corroborate the previously described IHC data.
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Figure B.12: Summary of IL-10 concentrations from each OA explant group examined.

IL-10 is the first of three anti-inflammatory mediators measured through our
analyses (although some prefer to classify IL-10 as a regulatory, as opposed to antiinflammatory, cytokine269). IL-10, IL-13 and IL-4 induce an M2 phenotype within
macrophages.256,257 IL-10 suppresses TNF-#, as it directly inhibits localization of nuclear
NF-$B.267,270 However, IL-10 less reliably suppresses IL-1 synthesis. As previously
indicated, the suppression of both IL-1" and TNF-# are necessary for inflammatory
modulation.150 This could be one mechanistic explanation for the beneficial therapeutic
effects observed with combination IL-4/IL-10 therapies270 as well as reports that IL-10
alone is not an effective immunomodulator.268 IL-10 has also been shown to increase IL1Ra synthesis (IL-1Ra is a competitive inhibitor of IL-1").270
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Figure B.13: Summary of IL-13 concentrations from each OA explant group examined.

IL-13, IL-10 and IL-4 induce an M2 phenotype within macrophages.256,257 IL-13
and IL-4 have demonstrated the ability to mitigate cartilage degradation in vitro.258 While
IL-4 and IL-10 have direct effects on chondroprotection through the down regulation of
ADAMTSs and MMPs, respectively, IL-13 produces an indirect anti-inflammatory effect
through the regulation of PGE2.259 There is limited data providing insight into the relative
efficacy of IL-4 and IL-13 therapeutic strategies. However, this mechanistic insight
seems to offer a potential explanation for the heightened and more rapid mitigation of OA
observed in our data. This is described further in figure B.17.
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Figure B.14: Summary of IL-4 concentrations from each OA explant group examined.

IL-4, IL-10 and IL-13 induce an M2 phenotype within macrophages.256,257 IL-4
suppresses IL-1" and TNF-# expression.258,267,268 This suppression effect can be
enhanced through concomitant expression of IL-10. IL-10 alone is not an effective
suppressor of pro-inflammatory cytokines and does not result in significant
chondroprotection.267 However, IL-4 alone offers both immunomodulatory and
chondroprotective effects.267 hAMSC treatment significantly increases IL-4 expression
(compared to OA cultures and hADSC-treated cultures). This provides mechanistic
insight into a key up-stream anti-inflammatory mediator that could explain the previously
results described results in chapter V. This is described further in figure B.17.
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Figure B.15: Summary of IL-12 concentrations from each OA explant group examined.

IL-12 is classically considered to maintain and regulate inflammation within the
synovium.271 IL-12 is a macrophage secretion associated with the recruitment of helper T
cells (Th1).132 In this activation pathway, IL-12 functions to protect the body against
intracellular pathogens through the up-regulation of INFg and IL-2.272 However, the
trends in our INFg and IL-2 results do not seem to support this activation pathway of IL12. More recently, evidence supports a less significant role for IL-12 in pro-inflammatory
responses, as IL-23 (not IL-12) is necessary for inflammatory reactions.272 For example,
IL-23 and not IL-12 was required for the development of collagen-induced arthritis in
mice.272 Though there is not a consensus within the scientific community, IL-12 is now
hypothesized to play a protective role in immunity.272 IL-12 has also been shown to have
an inhibitory effect on IL-17 (a marker of rejection and diseases characterized by chronic
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inflammation).272 Therefore, the elevated levels of IL-12 observed in macrophage
depleted and amnion stem cell treated groups may represent an under investigated
mechanism of immune-regulation.
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Figure B.16: Summary of IL-2 concentrations from each OA explant group examined.

IL-2 is associated with the recruitment of helper T cells (Th1) and promotion of
inflammation via the stimulation of IL-17.132,272 Interestingly, our IL-2 results do not
follow the stimulatory patterns expected with the classical activation of IL-12. The low
levels of expression observed in most groups support the known auxiliary role of T-cells
in OA. However, the heightened concentrations observed in the macrophage depleted and
indirect hAMSC treated cultures are unexpected results.
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Figure B.17: Simplified Summary of Examined Cytokine Relationships. Red text indicates pro-inflammatory (M1)
macrophage pathway. Green text indicates anti-inflammatory (M2) macrophage pathway. Mixed colors indicate a
multi-functional (pro and anti inflammatory) role in OA. Dashed lines indicate multi-step pathways that are not
pictured for simplicity. Note: PGE2 does not directly stimulate IL-1 and TNF production; it increases expression of
surface TLRs therefore increasing the binding activity of IL-1" and TNF#. PGE primarily acts via the COX-2 pathway.

The observed heightened expression of IL-13 by hADSC treated cultures may
imply an insufficient or delayed anti-inflammatory effect due to its indirect role in
chondroprotection. Primary PGE2 stimulates ADAMTS and MMP production via the
COX-2 pathway, an auxiliary pathway in OA progression.273,274 PGE2 has secondarily
been described as up-regulating the production of TLRs on cell surfaces, ultimately
increasing the production of IL-1" and TNF-#.273 IL-4 has a more direct inhibitory role,
acting

on

the

primary

NF-$B,

MAPK

and

JAK/STAT

pathways

of

OA

progression.258,267,268 The up-regulation of IL-4 by hAMSC-treated cultures may explain
the rapid and more extensive mitigation of disease progression observed.

203

REFERENCES

1.

RH, H. & JD, Z. Prevalence, health care expenditures, and orthopedic surgery
workforce for musculoskeletal conditions. JAMA 302, 1586–1587 (2009).

2.

Woolf, A. D. & Pfleger, B. Burden of major musculoskeletal conditions . Bulletin
of the World Health Organization 81 , 646–656 (2003).

3.

Oreffo, R. O. C. & Triffitt, J. T. Future Potentials for Using Osteogenic Stem Cells
and Biomaterials in Orthopedics. Bone 25, 5–9 (1999).

4.

Lee, E. H. & Hui, J. H. P. The potential of stem cells in orthopaedic surgery. J.
Bone Jt. Surg. 88, 841–851 (2006).

5.

Caplan, A. I. & Ph, D. Mesenchymal Stem Cells&: Cell-Based Reconstructive
Therapy in Orthopedics. Tissue Engineeirng 11, 1198–1211 (2005).

6.

Tapp, Hazel, Hanley Jr., Edward, Patt, Joshua, Gruber, H. Adipose-Derived Stem
Cells&: Characterization and Current Application in Orthopaedic Tissue Repair.
Exp. Biol. Med. 234, 1–9 (2009).

7.

Gir, Phanette, Oni, Geotgette, Brown, Spencer, Mojallal, Ali, Rohrich, R. Human
Adipose Stem Cells&: Current Clinical Applications. Plast. Reconstr. Surg. 129,
1277–1290 (2012).

8.

Huang, J. I. et al. Chondrogenic potential of progenitor cells derived from human
bone marrow and adipose tissue&: A patient-matched comparison. J. Orthop. Res.
23, 1383–1389 (2005).

9.

Bourin, P. et al. Stromal cells from the adipose tissue-derived stromal vascular
fraction and culture expanded adipose tissue-derived stromal / stem cells&: a joint
statement of the International Federation for Adipose Therapeutics and Science (
204

IFATS ) and the International Society for Cellular Therapy ( ISCT ). J.
Cytotherapy 15, 641–648 (2013).
10.

Murphy, J. M. et al. Reduced Chondrogenic and Adipogenic Activity of
Mesenchymal Stem Cells From Patients With Advanced Osteoarthritis. Arthritis
Rheum. 46, 704–713 (2002).

11.

Coleman, C. M., Curtin, C., Barry, F. P., Flatharta, C. O. & Murphy, J. M.
Mesenchymal Stem Cells and Osteoarthritis&: Remedy or Accomplice&? Hum. Gene
Ther. 1250, 1239–1250 (2010).

12.

Wen, W, Wei, C. Treatment of osteoarthritis with mesenchymal stem cells. Sci.
China 57, 586–595 (2014).

13.

Jo, C. H. et al. Intra-Articular Injection of Mesenchymal Stem Cells for the
Treatment of Osteoarthritis of the Knee: A Proof-of-Concept Clinical Trial. Stem
Cells 32, 1254–1266 (2014).

14.

Tanavde, V., Vaz, C., Rao, M. S., Vemuri, M. C. & Pochampally, R. R. Research
using Mesenchymal Stem / Stromal Cells&: quality metric towards developing a
reference material. J. Cytotherapy 17, 1169–1177 (2015).

15.

Bernardo, M. E. et al. Best Practice & Research Clinical Haematology Ex vivo
expansion of mesenchymal stromal cells. Best Pract. Res. Clin. Haematol. 24, 73–
81 (2011).

16.

Ng, P. C. et al. Enhanced ex vivo expansion of adult mesenchymal stem cells by
fetal mesenchymal stem cell ECM. Biomaterials 35, 4046–4057 (2014).

17.

Dos Santos, F. et al. Ex Vivo Expansion of Human Mesenchymal Stem Cells&: A
More Effective Cell Proliferation Kinetics and Metabolism Under Hypoxia. J.

205

Cell. Physiol. 223, 27–35 (2009).
18.

Department of Research & Scientific Affairs, A. A. of O. S. ANNUAL
INCIDENCE OF COMMON MUSCULOSKELETAL PROCEDURES AND
TREATMENT.
http://www.aaos.org/research/stats/CommonProceduresTreatmentsMarch2014.pdf 1–14 (2014).

19.

Burg, K. J. L., Porter, S. & Kellam, J. F. Biomaterial developments for bone tissue
engineering. Biomaterials 21, 2347–2359 (2000).

20.

Alsousou, J., Thompson, M., Hulley, P., Noble, A. & Willett, K. The biology of
platelet-rich plasma and its application in trauma and orthopaedic surgery. Bone
Joint J. 91-B, 987–996 (2009).

21.

Hall, M. P., Band, P. A., Meislin, R. J., Jazrawi, L. M. & Cardone, D. A. Platelet‐
rich Plasma: Current Concepts and Application in Sports Medicine. J. Am. Acad.
Orthop. Surg. 17, (2009).

22.

Nejadnik, H. et al. Autologous Bone Marrow – DerivedMesenchymal Stem Cells
Versus Autologous Chondrocyte Implantation: An Observational Cohort Study.
Am. J. Sports Med. 38, 1110–1116 (2010).

23.

Hui, JH, Chen, F, Thambyah, A, Lee, E. Treatment of Chondral Lesions in
Advanced Osteochondritis dissecans: a comparative study of the efficacy of
chondrocytes, mesenchymal stem cells, periosteal graft, and mosaicplasty
(osteochondral graft) in animal models. J. Pediatr. Orthop. 24, 427–433 (2004).

24.

Bianco, P. et al. The meaning , the sense and the significance&: translating the
science of mesenchymal stem cells into medicine. Nat. Med. 19, 35–42 (2013).

206

25.

Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal
cells . The International Society for Cellular Therapy position statement.
Cytotherapy 8, 315–317 (2006).

26.

Horwitz, E. M. et al. Clarification of the nomenclature for MSC&: The International
Society for Cellular Therapy position statement. Cytotherapy 7, 393–395 (2005).

27.

Bianco, P., Robey, P. G., Saggio, I. & Riminucci, M. ‘“ Mesenchymal ”’ Stem
Cells in Human Bone Marrow of Their Nature , Identity , and Significance. Hum.
Gene Ther. 1066, 1057–1066 (2010).

28.

Cavallo, C. et al. Comparison of alternative mesenchymal stem cell sources for
cell banking and musculoskeletal advanced therapies. J. Cell. Biochem. 112, 1418–
1430 (2011).

29.

Pappa, K. I. & Anagnou, N. P. Novel sources of fetal stem cells: where do they fit
on the developmental continuum? Regen. Med. 4, 423–433 (2009).

30.

Evangelista, M., Soncini, M. & Parolini, O. Placenta-derived stem cells: New hope
for cell therapy? Cytotechnology 58, 33–42 (2008).

31.

Bačenková, D., Rosocha, J., Tóthová, T., Rosocha, L. & Sarisský, M. Isolation and
basic characterization of human term amnion and chorion mesenchymal stromal
cells. Cytotherapy 13, 1047–1056 (2011).

32.

Hass, R., Kasper, C., Böhm, S. & Jacobs, R. Different populations and sources of
human mesenchymal stem cells (MSC): A comparison of adult and neonatal
tissue-derived MSC. Cell Commun. Signal. 9, 12 (2011).

33.

Pasquinelli, G. et al. Ultrastructural characteristics of human mesenchymal stromal
(stem) cells derived from bone marrow and term placenta. Ultrastruct. Pathol. 31,

207

23–31 (2007).
34.

Witkowska-Zimny, M. & Wrobel, E. Perinatal sources of mesenchymal stem cells:
Wharton’s jelly, amnion and chorion. Cell. Mol. Biol. Lett. 16, 493–514 (2011).

35.

Igura, K. et al. Isolation and characterization of mesenchymal progenitor cells
from chorionic villi of human placenta. Cytotherapy 6, 543–553 (2004).

36.

Ilancheran, S. et al. Stem cells derived from human fetal membranes display
multilineage differentiation potential. Biol. Reprod. 77, 577–88 (2007).

37.

Alviano, F. et al. Term Amniotic membrane is a high throughput source for
multipotent Mesenchymal Stem Cells with the ability to differentiate into
endothelial cells in vitro. BMC Dev. Biol. 7, 11 (2007).

38.

Tsai, Ming-Song, Lee, J.L., Chang, Y.J., Hwang, S. M. Isolation of human
multipotent mesenchymal stem cells from second‐trimester amniotic fluid. Hum.
Reprod. 19, 1450–1456 (2004).

39.

Kaviani, A. et al. The placenta as a cell source in fetal tissue engineering. J.
Pediatr. Surg. 37, 995–99999; discussion 995–99999 (2002).

40.

De Coppi, P. et al. Isolation of amniotic stem cell lines with potential for therapy.
Nat. Biotechnol. 25, 100–6 (2007).

41.

Pipino, C. et al. Placenta as a reservoir of stem cells: An underutilized resource?
Br. Med. Bull. 105, 43–67 (2013).

42.

Kern, Susanne, Eichler, Hermann, Stoeve, Johannes, Kluter, Harald, Bieback, K.
Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow , Umbilical
Cord Blood , or Adipose Tissue AND. Stem Cells 24, 1294–1301 (2006).

43.

Lannert, H. et al. Optimizing BM harvesting from normal adult donors. Bone

208

Marrow Transplant. 42, 443–447 (2008).
44.

Wexler, S., Donaldson, C. & Hows, J. Adult bone marrow (BM) is a rich source of
human mesenchymal stem cells but umbilical cord (CB) and adult blood are not.
Bone Marrow Transplant. 29, S144–S144 (2002).

45.

Tamagawa, T., Ishiwata, I., Saito, S. Establishment and characterization of a
pluripotent stem cell line derived from human amniotic membranes and initiation
of germ layers in vitro. Hum. Cell 17, 125–30 (2004).

46.

Nazarov, I. et al. Multipotent Stromal Stem Cells from Human Placenta
Demonstrate High Therapeutic Potential. Stem Cells Transl. Med. 1, 359–372
(2012).

47.

Marongiu, Fabio, Gramignoli, Roberto, Sun, Qian, Tahan, Veysel, Miki, Toshio,
Dorko, Kenneth, Ellis, Ewa, Strom, S. Isolation of Amniotic Mesenchymal Stem
Cells. Stem Cells 44, 1–11 (2007).

48.

Cananzi, M., Atala, A. & De Coppi, P. Stem cells derived from amniotic fluid:
new potentials in regenerative medicine. Reprod. Biomed. Online 18 Suppl 1, 17–
27 (2009).

49.

Bilic, G., Zeisberger, S., Zimmerman, R., Zisch, A. Comparative Characterization
of Cultured Human Term Amnion Epithelial and Mesenchymal Stromal Cells for
Application in Cell Therapy. Cell Transplant. 17, 955–968 (2008).

50.

Cananzi, M. & De Coppi, P. CD117+ amniotic fluid stem cells: State of the art and
future perspectives. Organogenesis 8, 77–88 (2012).

51.

Kunisaki, S. M. Congenital anomalies: Treatment options based on amniotic fluidderived stem cells. Organogenesis 8, 89–95 (2012).

209

52.

Fauza, D. Amniotic fluid and placental stem cells. Best Pract. Res. Clin. Obstet.
Gynaecol. 18, 877–891 (2004).

53.

Casey, M. L. & MacDonald, P. C. Interstitial collagen synthesis and processing in
human amnion: a property of the mesenchymal cells. Biol. Reprod. 55, 1253–1260
(1996).

54.

Parolini, O. et al. Concise review: isolation and characterization of cells from
human term placenta: outcome of the first international Workshop on Placenta
Derived Stem Cells. Stem Cells 26, 300–311 (2008).

55.

Barbati, A., Grazia Mameli, M., Sidoni, A. & Di Renzo, G. C. Amniotic
membrane: separation of amniotic mesoderm from amniotic epithelium and
isolation of their respective mesenchymal stromal and epithelial cells. Curr.
Protoc. Stem Cell Biol. Chapter 1, Unit 1E.8 (2012).

56.

Hass, R., Kasper, C., Böhm, S. & Jacobs, R. Different populations and sources of
human mesenchymal stem cells (MSC): A comparison of adult and neonatal
tissue-derived MSC. Cell Commun. Signal. 9, 12 (2011).

57.

In ’t Anker, P. S. et al. Isolation of mesenchymal stem cells of fetal or maternal
origin from human placenta. Stem Cells 22, 1338–45 (2004).

58.

Miki, T., Lehmann, T., Cai, H., Stolz, D. B. & Strom, S. C. Stem cell
characteristics of amniotic epithelial cells. Stem Cells 23, 1549–59 (2005).

59.

Pittenger, M. F. et al. Multilineage potential of adult human mesenchymal stem
cells. Science 284, 143–147 (1999).

60.

Oedayrajsingh-Varma, Maikel J., van Ham, S.M., Knippenberg, M., Helder, M.N.,
Klein-Nulend, J., Schouten, T.E., Ritt, M.J.P.F., van Milligen, F. J. Adipose tissue

210

derived mesenchymal stem cell yield and growth characteristics.pdf. Cytotherapy
8, 166–177 (2006).
61.

Chung, Michael T., Zimmermann, A.S., Paik, K.J., Morrison, S.D., Hyun, J.S., Lo,
D.D., McArdle, A., Montoro, D.T., Walmsley, G.G, Senarath-Yapa, K., Sorkin,
M., Rennert, R., Chen, H., Chung, A.S., Vistnes, D., Gurtner, G., Longaker, M.T.,
Wan, D. C. Isolation of Human-Adipose-Derived Stromal Cells Using LaserAssisted Liposuction and Their Therapeutic Potential in Regenerative Medicine.
Stem Cells Transl. Med. 2, 808–817 (2013).

62.

Buschmann, J. et al. Yield and proliferation rate of adipose-derived stromal cells
as a function of age, body mass index and harvest site-increasing the yield by use
of adherent and supernatant fractions? Cytotherapy 15, 1098–1105 (2013).

63.

Zuk, P. a et al. Multilineage cells from human adipose tissue: implications for cellbased therapies. Tissue Eng. 7, 211–228 (2001).

64.

Antonucci, I. et al. Isolation of osteogenic progenitors from human amniotic fluid
using a single step culture protocol. BMC Biotechnol. 9, 9 (2009).

65.

Prusa, A.-R. & Hengstschlager, M. Amniotic fluid cells and human stem cell
research: a new connection. Med. Sci. Monit. 8, RA253–A257 (2002).

66.

Ekblad, Å. et al. Amniotic Fluid—A Source for Clinical Therapeutics in the
Newborn? Stem Cells Dev. 00, 150313140935007 (2015).

67.

Phermthai, T. et al. A novel method to derive amniotic fluid stem cells for
therapeutic purposes. BMC Cell Biol. 11, 79 (2010).

68.

Keeley, R., Topoluk, N. & Mercuri, J. Tissues Reborn: Fetal Membrane-Derived
Matrices and Stem Cells in Orthopedic Regenerative Medicine. Crit. Rev. Biomed.

211

Eng. 42, 249–270 (2014).
69.

Bárcena, A. et al. Human placenta and chorion: Potential additional sources of
hematopoietic stem cells for transplantation. Transfusion 51, (2011).

70.

Jones, G. N. et al. Ontological Differences in First Compared to Third Trimester
Human Fetal Placental Chorionic Stem Cells. PLoS One 7, 1–15 (2012).

71.

Soncini, M. et al. Isolation and characterization of mesenchymal cells from human
fetal membranes. J. Tissue Eng. Regen. Med. 1, 296–305 (2007).

72.

Fernandes, R. A. Placental tissues as sources of stem cells—Review. Open J.
Anim. Sci. 02, 166–173 (2012).

73.

Abumaree, M. H. et al. Phenotypic and Functional Characterization of
Mesenchymal Stem Cells from Chorionic Villi of Human Term Placenta. Stem
Cell Rev. Reports 9, 16–31 (2013).

74.

Perin, EC, Borow, KM, Silva, GV, DeMaria, AN, Marroquin, OC, Huang, PP,
Traverse, JH, Krum, H, Skerrett, D, Zheng, Y, Willerson, JT, Itescu, S, Henry, T.
A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in
Patients With Ischemic or Nonischemic Heart Failure. Circ. Res. 117, 576–584
(2015).

75.

Park, K. J. et al. Allogeneic adipose-derived stem cells for the treatment of
perianal fistula in Crohn’s disease: a pilot clinical trial. Color. Dis. n/a–n/a (2015).
doi:10.1111/codi.13223

76.

Yiou, R. et al. Safety of Intracavernous Bone Marrow-Mononuclear Cells for
Postradical Prostatectomy Erectile Dysfunction: An Open Dose-Escalation Pilot
Study. Eur. Urol. doi:http://dx.doi.org/10.1016/j.eururo.2015.09.026

212

77.

Li, J. et al. Factors affecting mesenchymal stromal cells yield from bone marrow
aspiration. Chinese J. Cancer Res. 23, 43–48 (2011).

78.

Baer, P. C. & Geiger, H. Adipose-derived mesenchymal stromal/stem cells: Tissue
localization, characterization, and heterogeneity. Stem Cells Int. 2012, (2012).

79.

Jurgens, W. J. F. M. et al. Effect of tissue-harvesting site on yield of stem cells
derived from adipose tissue: Implications for cell-based therapies. Cell Tissue Res.
332, 415–426 (2008).

80.

Christodoulou, I., Kolisis, F. N., Papaevangeliou, D. & Zoumpourlis, V.
Comparative evaluation of human mesenchymal stem cells of fetal (Wharton’s
Jelly) and adult (adipose tissue) origin during prolonged in vitro expansion:
Considerations for cytotherapy. Stem Cells Int. 2013, (2013).

81.

Zhang, X. et al. Mesenchymal progenitor cells derived from chorionic villi of
human placenta for cartilage tissue engineering. Biochem. Biophys. Res. Commun.
340, 944–52 (2006).

82.

Deasy, B.M., Jankowski, R.J., Payne, T.R., Cao, B., Goff, J.P., Greenberger, J.S.,
Huard, J. Modeling Stem Cell Population Growth: Incorporating Terms for
Proliferative Heterogeneity. Stem Cells 21, 536–545 (2003).

83.

Schallmoser, K. et al. Rapid Large-Scale Expansion of Functional Mesenchymal
Stem Cells from Unmanipulated Bone Marrow Without Animal Serum. Tissue
Engineeirng 14, 185–196 (2008).

84.

Jorgensen, C. Mesenchymal stem cells: uses in osteoarthritis. Joint. Bone. Spine
80, 565–7 (2013).

85.

Murphy, J. M., Fink, D. J., Hunziker, E. B. & Barry, F. P. Stem Cell Therapy in a

213

Caprine Model of Osteoarthritis. Arthritis Rheum. 48, 3464–3474 (2003).
86.

Heng, B. C., Cao, T. & Lee, E. H. Directing Stem Cell Differentiation into the
Chondrogenic Lineage In Vitro. Stem Cells 22, 1152–1167 (2004).

87.

Lo, W.C., Chen WH, Lin TC, Hwang SM, Zeng R, Hsu WC, Chiang YM, Liu
MC, Williams DF, D. W. Preferential therapy for osteoarthritis by cord blood
MSCs through regulation of chondrogenic cytokines. Biomaterials 34, 4739–48
(2013).

88.

Mercuri, J. J. et al. Regenerative Potential of Decellularized Porcine Nucleus
Pulposus Hydrogel Scaffolds: Stem Cell Differentiation, Matrix Remodeling, and
Biocompatibility Studies. Tissue Eng. Part A 19, 952–966 (2012).

89.

Marcus, A. J., Coyne, T. M., Rauch, J., Woodbury, D. & Black, I. B. Isolation ,
characterization , and differentiation of stem cells derived from the rat amniotic
membrane. Differentiation 76, 130–144 (2008).

90.

Guillot, P. V et al. Comparative osteogenic transcription profiling of various fetal
and adult mesenchymal stem cell sources. Differentiation 76, 946–957 (2008).

91.

Lindenmair, A., Nürnberger, S., Stadler, G., Meinl, A., Hackl, C., Eibl, J., Gabriel,
C., Hennerbichler, S., Redl, H., Wolbank, S. Intact human amniotic membrane
differentiated towards the chondrogenic lineage. Cell Tissue Bank. 15, 213–225
(2014).

92.

Stadler, G., Hennerbichler, S., Lindenmair, A., Peterbauer, A., Hofer, K., van
Griensven, M., Gabriel, C., Redl, H., Wolbank, S. Phenotypic Shift of human
amniotic epithelial cells in culture is associated with reduced osteogenic
differentiation in vitro. Cytotherapy 10, 743–52 (2008).

214

93.

Diaz Prado, S., Muinos Lopez, E., Hermida-Gomez, T., Rendal-Vazquez, M.,
Fuentes-Boquete, I., de Toro, F., Blanco, F. Multilineage Differentiation Potential
of Cells Isolated From the Human Amniotic Membrane. J. Cell. Biochem. 857,
846–857 (2010).

94.

Sudo, K. et al. Mesenchymal Progenitors Able to Differentiate into Osteogenic,
Chondrogenic, and/or Adipogenic Cells In Vitro Are Present in Most Primary
Fibroblast-Like Cell Populations. Stem Cells 25, 1610–1617 (2007).

95.

Brady, K. et al. Human fetal and adult bone marrow-derived mesenchymal stem
cells use different signaling pathways for the initiation of chondrogenesis. Stem
Cells Dev. 23, 541–54 (2014).

96.

Wei, J. P. et al. Human amniotic mesenchymal cells differentiate into
chondrocytes. Cloning Stem Cells 11, 19–26 (2009).

97.

Nogami M, Tsuno H, Koike C, Okabe M, Yoshida T, Seki S, Matsui Y, Kimura T,
N. T. Isolation and characterization of human amniotic mesenchymal stem cells
and their chondrogenic differentiation. Transplantation. Transplantation 93, 1221–
8 (2012).

98.

Barboni, B., Russo, V., Curini, V. & Martelli, A. Gestational stage affects amniotic
epithelial cells phenotype , methylation status , immunomodulatory and stemness
properties. Stem Cell Rev. Reports 10, 725–741 (2014).

99.

Lindenmair, A. et al. Osteogenic differentiation of intact human amniotic
membrane. Biomaterials 31, 8659–8665 (2010).

100. Sekiya, I., Vuoristo, J. T., Larson, B. L. & Prockop, D. J. In vitro cartilage
formation by human adult stem cells from bone marrow stroma defines the

215

sequence of cellular and molecular events during chondrogenesis. Proc. Natl.
Acad. Sci. 99 , 4397–4402 (2002).
101. Zhang, L. et al. Chondrogenic differentiation of human mesenchymal stem cells: a
comparison between micromass and pellet culture systems. Biotechnol. Lett. 32,
1339–1346 (2010).
102. de Crombrugghe, B., Lefebvre, V. & Nakashima, K. Regulatory mechanisms in
the pathways of cartilage and bone formation. Curr. Opin. Cell Biol. 13, 721–728
(2001).
103. DeLise, M., Fischer, L. & Tuan, R. S. Cellular interactions and signaling in
cartilage development. Osteoarthritis Cartilage 8, 309–34 (2000).
104. Goldring, M. B. et al. ROLES OF INFLAMMATORY AND ANABOLIC
CYTOKINES IN CARTILAGE METABOLISM&: SIGNALS AND MULTIPLE
EFFECTORS CONVERGE UPON MMP-13 REGULATION IN. Eur. Cells
Mater. 21, 202–220 (2014).
105. Heldin, C., Miyazono, K. & Dijke, P. TGF-beta signalling from cell membrane to
nucleus through SMAD proteins. Nature 390, 465–471 (1997).
106. Keller, B. et al. Interaction of TGFβ and BMP signaling pathways during
chondrogenesis. PLoS One 6, e16421 (2011).
107. Guo, X. & Wang, X. Signaling cross-talk between TGF- β / BMP and other pathways. Cell Res. 19, 71–88 (2009).
108. Houard, X., Goldring, M. B. & Berenbaum, F. Homeostatic mechanisms in
articular cartilage and role of inflammation in osteoarthritis. Curr. Rheumatol. Rep.
15, 375 (2013).

216

109. Fox, AJS, Bedi, A, Rodeo, S. The Basic Science of Articular Cartilage: Structure,
Composition, and Function. Sports Health 1, 461–468 (2009).
110. Sun, L., Wang, X. & Kaplan, D. L. A 3D cartilage – Inflammatory cell culture
system for the modeling of human osteoarthritis. Biomaterials 32, 5581–5589
(2011).
111. DeGroot, J, Verzijl, N, Wenting-van Wijk, MJG, Jacobs, KMG, Van El, B, Van
Roermund, PM, Bank, RA, Bijlsma, JWJ, TeKoppele, JM, Lafeber, F.
Accumulation of advanced glycation end products as a molecular mechanism for
aging as a risk factor in osteoarthritis. Arthritis Rheum. 50, 1207–1215 (2004).
112. Kafienah, W. et al. Three-Dimensional Cartilage Tissue Engineering Using Adult
Stem Cells From Osteoarthritis Patients. 56, 177–187 (2007).
113. Scanzello, C. R. & Goldring, S. R. The role of synovitis in osteoarthritis
pathogenesis

. Bone 51, 249–257 (2012).

114. Chen, W.-H. et al. In vitro stage-specific chondrogenesis of mesenchymal stem
cells committed to chondrocytes. Arthritis Rheum. 60, 450–9 (2009).
115. Blom, A, van Lent, PL, Libregts, S, Holthuysen, AE, van der Kraan, PM, van
Rooijen, V, van den Berg, W. Crucial role of macrophages in matrix
metalloproteinase-mediated cartilage destruction during experimental
osteoarthritis. Arthritis Rheum. 56, 147–157 (2007).
116. Frisbie, D. D., Kisiday, J. D., Kawcak, C. E., Werpy, N. M. & McIlwraith, C. W.
Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived
mesenchymal stem cells for treatment of osteoarthritis. J. Orthop. Res. 27, 1675–
1680 (2009).

217

117. Teeple, E., Jay, G. D., Elsaid, K. A. & Fleming, B. C. Animal Models of
Osteoarthritis: Challenges of Model Selection and Analysis. AAPS J. 15, 438–446
(2013).
118. Kapoor, M., Martel-Pelletier, J., Lajeunesse, D., Pelletier, J.-P. & Fahmi, H. Role
of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev
Rheumatol 7, 33–42 (2011).
119. Benito, MJ, Veale, DJ, FitzGerald, O, van den Berg, WB, Bresnihan, B. Synovial
tissue inflammation in early and late osteoarthritis. Ann. Rheum. Dis. 64, 1263–
1267 (2005).
120. Orozco, L. et al. Treatment of Knee Osteoarthritis With Autologous Mesenchymal
Stem Cells&: A Pilot Study. Transplantation 95, 1535–1541 (2013).
121. Lampropoulou-Adamidou, K. et al. Useful animal models for the research of
osteoarthritis. Eur. J. Orthop. Surg. Traumatol. 24, 263–271 (2013).
122. Hunter, D. J. Pharmacologic therapy for osteoarthritis-the era of disease
modification. Nat Rev Rheumatol 7, 13–22 (2011).
123. Blagojevic, M, Jinks, C, Jeffery, A, Jordan, K. Risk factors for onset of
osteoarthritis of the knee in older adults: a systematic review and meta-analysis.
Osteoarthr. Cartil. 18, 24–33 (2010).
124. Felson, DT, Lawrence, RC, Dieppe, PA, Hirsch, R, Helmick, CG, Jordan, JM,
Kingston, RS, Lane, NE, Nevitt, MC, Zhang, Y, Sowers, M, McAlindon, T,
Spector, TD, Poole, AR, Yanovski, SZ, Ateshian, G, Sharma, L, Buckwalter, JA,
Brandt, KD, Fries, J. Osteoarthritis: new insights. Part 1:the disease and its risk
factors. Ann. Intern. Med. 23, 841–846 (2012).

218

125. Farahat, MN, Yanni, G, Poston, R, Panayi, G. Cytokine expression in synovial
membranes of patients with rheumatoid arthritis and osteoarthritis. Ann. Rheum.
Dis. 52, 870–875 (1993).
126. Colen, S., Bekerom, M. P. J., Mulier, M. & Haverkamp, D. Hyaluronic Acid in the
Treatment of Knee Osteoarthritis. BioDrugs 26, 257–268 (2012).
127. Blom, A. B. et al. Synovial lining macrophages mediate osteophyte formation
during experimental osteoarthritis. Osteoarthr. Cartil. 12, 627–635 (2004).
128. Beekhuizen, M. et al. Osteoarthritic synovial tissue inhibition of proteoglycan
production in human osteoarthritic knee cartilage: establishment and
characterization of a long-term cartilage-synovium coculture. Arthritis Rheum. 63,
1918–27 (2011).
129. Maumus, M. et al. Adipose mesenchymal stem cells protect chondrocytes from
degeneration associated with osteoarthritis. Stem Cell Res. 11, 834–44 (2013).
130. Glasson, S. S. et al. Deletion of active ADAMTS5 prevents cartilage degradation
in a murine model of osteoarthritis. Nature 434, 644–648 (2005).
131. Ryu, J.-S. et al. Co-culture with human synovium-derived mesenchymal stem cells
inhibits inflammatory activity and increases cell proliferation of sodium
nitroprusside-stimulated chondrocytes. Biochem. Biophys. Res. Commun. 447,
715–20 (2014).
132. Sellam, J. & Berenbaum, F. The role of synovitis in pathophysiology and clinical
symptoms of osteoarthritis. Nat Rev Rheumatol 6, 625–635 (2010).
133. de Lange-Brokaar, B. J. E. et al. Synovial inflammation, immune cells and their
cytokines in osteoarthritis: a review. Osteoarthr. Cartil. 20, 1484–1499 (2012).

219

134. Schelbergen, R. F. et al. Treatment efficacy of adipose-derived stem cells in
experimental osteoarthritis is driven by high synovial activation and reflected by
S100A8/A9 serum levels. Osteoarthr. Cartil. 22, 1158–1166 (2014).
135. Sokolove, J. & Lepus, C. M. Role of inflammation in the pathogenesis of
osteoarthritis: latest findings and interpretations. Ther. Adv. Musculoskelet. Dis. 5,
77–94 (2013).
136. Partsch, G, Steiner, G, Leeb, BF, Dunky, A, Broll, H, Smolen, J. Highly increased
levels of tumor necrosis factor-alpha and other proinflammatory cytokines in
psoriatic arthritis syovial fluid.
137. Scanzello, CR, McKeon, B, Swaim, BH, DiCarlo, E, Asomugha, EU, Kanda, V,
Nair, A, Lee, DM, Richmond, JC, Katz, JN, Crow, MK, Goldring, S. Synovial
inflammation in patients undergoing arthroscopic meniscectomy: molecular
characterization and relationship to symptoms. Arthritis Rheum. 63, 391–400
(2011).
138. Ayral, X, Pickering, EW, Woodworth, TG, Mackillop, N, Douglas, M. Synovitis: a
potential predictive factor of structural progression of medial tibiofemoral knee
osteoarthritis - results of a 1 year longitudinal arthroscopic study in 422 patients.
Osteoarthr. Cartil. 13, 361–367 (2005).
139. Conaghan, PG, D’Agostino, MA, Le Bars, M, Baron, G, Schmidely, N, Wakefield,
R, Ravaud, P, Grassi, W, Martin-Mola, E, So, A, Backhaus, M, Malaise, M,
Emery, P, Dougados, M. Clinical and ultrasonographic predictors of joint
replacement for knee osteoarthritis: results from a large, 3-year, prospective
EULAR study. Ann. Rheum. Dis. 38, 644–647 (1995).

220

140. van Buul, G. M. et al. Mesenchymal stem cells secrete factors that inhibit
inflammatory processes in short-term osteoarthritic synovium and cartilage explant
culture. Osteoarthritis Cartilage 20, 1186–96 (2012).
141. Murray, P. J. et al. Macrophage Activation and Polarization: Nomenclature and
Experimental Guidelines. Immunity 41, 14–20 (2014).
142. Mantovani, A, Biswas, SK, Galdiero, MR, Sica, A, Locati, M. Macrophage
plasticity and polarization in tissue repair and remodeling. J. Pathol. 229, 176–185
(2013).
143. Lawrence, T, Natoli, G. Transcriptional regulation of macrophage polarization:
enabling diversity with identity. Nat. Rev. Immunol. 11, 750–761 (2011).
144. Pelegrin, P, Surprenant, A. Dynamics of macrophage polarization reveal new
mechanism to inhibit IL-1B release through pyrophosphates. Eur. Mol. Biol.
Organ. J. 28, 2114–2127 (2009).
145. Fahy N, de Vries-van Melle ML, Lehmann J, Wei W, Grotenhuis N, Farrell E, van
der Kraan PM, Murphy JM, Bastiaansen-Jenniskens YM, van O. G. Human
osteoarthritic synovium impacts chondrogenic differentiation of mesenchymal
stem cells via macrophage polarisation state. Osteoarthr. Cartil. 22, 1167–75
(2014).
146. Tsuneyoshi, Y, Tanaka, M, Sunahara, N, Matsuda, T, Sonoda, T, Ijiri, K, Komiya,
S, Matsuyama, T. Functional folate receptor beta-expressing macrophages in
osteoarthritis synovium and their M1/M2 expression profiles. Scandanavian J.
Rheumatol. 41, 132–140 (2012).
147. Beekhuizen, M, Gierman, LM, van Spil, WE, Van Osch, GJVM, Huizinga, TWJ,

221

Saris, DBF, Creemers, LB, Zuurmond, A. An exploratory study comparing levels
of soluble mediators in control and osteoarthritis synovial fluid. Osteoarthr. Cartil.
21, 918–922 (2013).
148. Mannami, K, Mitsuhashi, T, Takeshita, H, Okada, K. Concentration of interleukin1B in serum and synovial fluid in patients with rheumatoid arthritis and those with
osteoarthritis. Japanese J. Orthop. Assoc. 63, 1343–1352 (1989).
149. Arend, W. P. et al. Binding of IL-1alpha, IL-1beta, and IL-1 Receptor Agaonist by
Soluble IL-1 Receptors and Levels of Souble IL-1 Receptors in Synovial Fluids. J.
Immunol. 4766–4774 (1994).
150. Bondenson, J., Wainwright, S. D., Lauder, S., Amos, N. & Hughes, C. E. The role
of synovial macrophages and macrophage-produced cytokines in driving
aggrecanases, matrix metalloproteinases, and other destructive and inflammatory
responses in osteoarthritis. Arthritis Res. Ther. 8, R187 (2006).
151. Song, R.-H. et al. Aggrecan degradation in human articular cartilage explants is
mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum. 56, 575–585
(2007).
152. Rogerson, FM, Chung, YM, Deutscher, ME, Last, K, Fosang, A. Cytokine-induced
increases in ADAMTS-4 messenger RNA expression do not lead to increased
aggrecanase activity in ADAMTS-5 deficient mice. Arthritis Rheum. 62, 3365–
3373 (2010).
153. Darling, EM, Athanasiou, K. Retaining zonal chondrocyte phenotype by means of
novel growth environments. Tissue Eng. 11, 395–403 (2005).
154. Benya, P. D., Padilla, S. R. & Nimni, M. E. Independent regulation of collagen

222

types by chondrocytes during the loss of differentiated function in culture. Cell 15,
1313–1321 (1978).
155. Steinhagen, J. et al. Perfusion culture system: Synovial fibroblasts modulate
articular chondrocyte matrix synthesis in vitro. Tissue Cell 42, 151–157 (2010).
156. Steinberg, J. J. & Sledge, C. B. Synovial factors and chondrocyte- mediated
breakdown of cartilage: Inhibition by hydrocortisone. J. Orthop. Res. 1, 13–21
(1983).
157. Steinberg, J., Sledge, C. B., Noble, J. & Stirrat, C. R. A tissue-culture model of
cartilage breakdown in rheumatoid arthritis. Quantitative aspects of proteoglycan
release. Biochem. J. 180, 403–412 (1979).
158. Steinberg, James J, Tsukamoto, S, Sledge, C. Breakdown of cartilage proteoglycan
in a tissue culture model of rheumatoid arthritis. Biochim Biophys Acta. 757, 47–
58 (1983).
159. Greenberg, D. D., Stoker, A., Kane, S., Cockrell, M. & Cook, J. L. Biochemical
effects of two different hyaluronic acid products in a co-culture model of
osteoarthritis. Osteoarthr. Cartil. 14, 814–822 (2016).
160. Gregory, M., Capito, N., Kuroki, K., Stoker, A., Cook, J., Sherman, S. A review of
translational animal models for knee osteoarthritis. Arthritis 2012, 14 (2012).
161. Bendele, A. Animal models of osteoarthritis. J. Musculoskelet. Neuron Interact. 1,
363–376 (2001).
162. Lee, KB, Hui, JH, Song, IC, Ardany, L, Lee, E. Injectable mesenchymal stem cell
therapy for large cartilage defects - a porcine model. Stem Cells 25, 2964–2971
(2007).

223

163. Ameye, L. & Young, M. F. Mice deficient in small leucine-rich proteoglycans:
novel in vivo models for osteoporosis, osteoarthritis, Ehlers-Danlos syndrome,
muscular dystrophy, and corneal diseases. Glycobiol. 12 , 107R–116R (2002).
164. Hu, K. et al. Pathogenesis of osteoarthritis-like changes in the joints of mice
deficient in type IX collagen. Arthritis Rheum. 54, 2891–2900 (2006).
165. ter Huurne, M. et al. Antiinflammatory and chondroprotective effects of
intraarticular injection of adipose-derived stem cells in experimental osteoarthritis.
Arthritis Rheum. 64, 3604–3613 (2012).
166. Roberts, M. J. et al. A new approach for assessing early osteoarthritis in the rat.
Anal. Bioanal. Chem. 377, 1003–1006 (2003).
167. Appleton, C. T. G. et al. Forced mobilization accelerates pathogenesis:
characterization of a preclinical surgical model of osteoarthritis. Arthritis Res.
Ther. 9, R13–R13 (2007).
168. Grigolo, B, Lisigno, G, Desando, G, Cavallo, C, Marconi, E, Tscgon, M,
Giavaresi, G, Fini, M, Giardino, R, Facchini, A. Osteoarthritis treated with
mesenchymal stem cells on hyaluronan-based scaffold in rabbit. Tissue
Engineeirng 15, 647–658 (2009).
169. Desando, G, Cavallo, C, Sartoni, f, Martini, L, Parrilli, A, Veronesi, F, Fini, M,
Giardiao, R, Facchini, A, Grigolo, B. Intraarticular delivery of adipose derived
stromal cells attenuates osteoarthritis progression in an experimental rabbit model.
Arthritis Rheum. 15, R22 (2013).
170. Sato, M. et al. Direct transplantation of mesenchymal stem cells into the knee
joints of Hartley strain guinea pigs with spontaneous osteoarthritis. 1–9 (2012).

224

171. Bendele, A., Hulman, J. Effects of Body Weight Restriction on the Development
and Progression of Spontaneous Osteoarthritis in Guinea Pigs. Arthritis Rheum.
34, 1180–1184 (1991).
172. Hyttinen MM, Arokoski JP, Parkkinen JJ, Lammi MJ, Lapveteläinen T, Mauranen
K, Király K, Tammi MI, H. H. Age matters: collagen birefringence of superficial
articular cartilage is increased in young guinea-pigs but decreased in older animals
after identical physiological type of joint loading. Osteoarthr. Cartil. 9, 694–701
(2001).
173. Huebner, J. L., Otterness, I. G., Freund, E. M., Caterson, B. & Kraus, V. B.
Collagenase 1 and collagenase 3 expression in a guinea pig model of osteoarthritis.
Arthritis Rheum. 41, 877–90 (1998).
174. K. S. Santangelo, E. M. Pieczarka, G. J. Nuovo, S. E. & Weisbrode, and A. L. B.
Temporal expression and tissue distribution of interleukin-1β in two strains of
guinea pigs with varying propensity for spontaneous knee osteoarthritis.
Osteoarthr. Cartil. 19, 439–448 (2012).
175. K. S. Santangelo, G. J. N. and A. L. B. In vivo reduction or blockade of
interleukin-1β in primary osteoarthritis influences expression of mediators
implicated in pathogenesis. Osteoarthr. Cartil. 20, 1610–1618 (2013).
176. Meacock, S. C. R., Bodmer, J. L. & Billingham, M. E. J. Experimental
osteoarthritis in guinea-pigs. J. Ecperimental Pathol. 71, 279–293 (1990).
177. Kraus, V. B., Huebner, J. L., Degroot, J. & Bendele, A. The OARSI
histopathology initiative e recommendations for histological assessments of
osteoarthritis in the guinea pig 1. Osteoarthr. Cartil. 18, S35–S52 (2010).

225

178. Sato M, Uchida K, Nakajima H, Miyazaki T, Guerrero AR, Watanabe S, Roberts
S, B. H. Direct transplantation of mesenchymal stem cells into the knee joints of
Hartley strain guinea pigs with spontaneous osteoarthritis. Arthritis Res. Theory
14, (2012).
179. Brown, G. A. AAOS Clinical Practice Guideline: Treatment of Osteoarthritis of
the Knee: Evidence‐Based Guideline, 2nd Edition. J. Am. Acad. Orthop. Surg. 21,
(2013).
180. Katz, J. N. et al. Surgery versus Physical Therapy for a Meniscal Tear and
Osteoarthritis. N. Engl. J. Med. 368, 1675–1684 (2013).
181. Kirkley, A. et al. A Randomized Trial of Arthroscopic Surgery for Osteoarthritis
of the Knee. N. Engl. J. Med. 359, 1097–1107 (2008).
182. Moseley, J. B. et al. A Controlled Trial of Arthroscopic Surgery for Osteoarthritis
of the Knee. N. Engl. J. Med. 347, 81–88 (2002).
183. Buda, R. et al. Osteochondral Lesions of the Knee: A New One-Step Repair
Technique with Bone-Marrow-Derived Cells. J. Bone Jt. Surg. 92, 2–11 (2010).
184. Richmond, J. et al. American Academy of Orthopaedic Surgeons Clinical Practice
Guideline on The Treatment of Osteoarthritis (OA) of the Knee. J. Bone Jt. Surg.
92, 990–993 (2010).
185. Barrera, Pilar, Blom, Arjen, Van Lent, Peter L.E.M., Van Bloois, Louis, Beijnen,
Jos H., Van Rooijen, Nico, De Waal Malefijt, Maarten C., Van De Putte, Leo
B.A., Storm, Gert, Van Den Berg, W. B. Synovial macrophage depletion with
clodronate- containing liposomes in rheumatoid arthritis . Arthritis Rheum. 43,
1951–1959 (2000).

226

186. Schmidt-Weber, C. B. et al. Apoptotic cell death in activated monocytes following
incorporation of clodronate-liposomes. J. Leukoc. Biol. 60, 230–244 (1996).
187. Makkonen, N. et al. Contrasting effects of alendronate and clodronate on RAW
264 macrophages: The role of a bisphosphonate metabolite. Eur. J. Pharm. Sci. 8,
109–118 (1999).
188. Selander, K.S., Monkkonen, J., Karhukorpi, E.K., Harkonen, P., Hannuniemi, R.,
Vaananen, H. K. Characteristics of clodronate-induced apoptosis of osteoclasts and
macrophages. Mol. Pharmacol. 50, 1127–1138 (1996).
189. van Rooijen, N, Sanders, A, Van Den Berg, T. Apoptosis of macrophages induced
by liposome-mediated intracellular delivery of clodronate and propamidine. J.
Immunol. Methods 193, 93–97 (1996).
190. van Rooijen, N. & van Kesteren-Hendrikx, E. CLODRONATE LIPOSOMES:
PERSPECTIVES IN RESEARCH AND THERAPEUTICS. J. Liposome Res. 12,
81–94 (2002).
191. C̆ eponis, A. et al. Effects of low-dose, noncytotoxic, intraarticular liposomal
clodronate on development of erosions and proteoglycan loss in established
antigen-induced arthritis in rabbits. Arthritis Rheum. 44, 1908–1916 (2001).
192. Storm, G, Crommelin, D. Liposomes: quo vadis? Pharmaseutical Sci. Technol.
Today 1, 19–31 (1998).
193. Makkonen, N, Hirvonen, M.R., Teravainen, T, Savolainen, K, Monkkonen, J.
Contrasting effects of three bisphosphonates on nitric oxide production by RAW
264 macrophage-like cells in vitro. J. Pharmacol. Exp. Ther. 277, 1097–1102
(1996).

227

194. Pennanen, Niina, Lapinjoki, Seppo, Urtti, Arto, Monkkonen, J. Effect of
Liposomal and Free Bisphosphonates on the IL-1β, IL-6 and TNFα Secretion from
RAW 264 Cells in Vitro. Pharm. Res. 12, 916–922 (1995).
195. Österman, T. et al. A comparison of clodronate and indomethacin in the treatment
of adjuvant arthritis. Inflamm. Res. 46, 79–85 (1997).
196. van Lent PL, Holthuysen AE, van Rooijen N, van de Loo FA, van de Putte LB,
van den B. W. Phagocytic synovial lining cells regulate acute and chronic joint
inflammation after antigenic exacerbation of smouldering experimental murine
arthritis. J. Rheumatol. 25, 1135–1145 (1998).
197. Kinne, R. W. et al. Long-term amelioration of rat adjuvant arthritis following
systemic elimination of macrophages by clodronate-containing liposomes.
Arthritis Rheum. 38, 1777–1790 (1995).
198. Walsh, D. A. & Chapman, V. Bisphosphonates for osteoarthritis. Arthritis Res.
Ther. 13, 128 (2011).
199. Rossini, M. et al. Intra-articular clodronate for the treatment of knee osteoarthritis:
dose ranging study vs hyaluronic acid. Rheumatol. 48 , 773–778 (2009).
200. Carbone, L. D. et al. The relationship of antiresorptive drug use to structural
findings and symptoms of knee osteoarthritis. Arthritis Rheum. 50, 3516–3525
(2004).
201. Van Lent, P. L. E. M. et al. Crucial role of synovial lining macrophages in the
promotion of transforming growth factor β–mediated osteophyte formation.
Arthritis Rheum. 50, 103–111 (2004).
202. Koh, Y.-G. & Choi, Y.-J. Infrapatellar fat pad-derived mesenchymal stem cell

228

therapy for knee osteoarthritis. Knee 19, 902–907 (2016).
203. Toghraie, F. S. et al. Treatment of osteoarthritis with infrapatellar fat pad derived
mesenchymal stem cells in Rabbit. Knee 18, 71–75 (2011).
204. Centeno, C. J. et al. Regeneration of meniscus cartilage in a knee treated with
percutaneously implanted autologous mesenchymal stem cells. Med. Hypotheses
71, 900–908 (2016).
205. DAVATCHI, F., ABDOLLAHI, B. S., MOHYEDDIN, M., SHAHRAM, F. &
NIKBIN, B. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary
report of four patients. Int. J. Rheum. Dis. 14, 211–215 (2011).
206. Wong, K. L. et al. Injectable Cultured Bone Marrow Derived Mesenchymal Stem
Cells in Varus Knees With Cartilage Defects Undergoing High Tibial Osteotomy:
A Prospective, Randomized Controlled Clinical Trial With 2 Years’ Follow-up.
Arthroscopy 29, 2020–2028 (2016).
207. Koh, Yong-Gon, Jo, Seung-Bae, Kwon, Oh-Ryong, Suh, Dong-Suk, Lee, S., Park,
S. & Choi, Y. Mesenchymal Stem Cell Injections Improve Symptoms of Knee
Osteoarthritis. Arthrosc. J. Arthrosc. Relat. Surg. 29, 748–755 (2013).
208. Vangsness, C. T. et al. Adult Human Mesenchymal Stem Cells Delivered via
Intra-Articular Injection to the Knee Following Partial Medial Meniscectomy. J.
Bone Jt. Surg. 96, 90–98 (2014).
209. CHEN, W. Y. J. & ABATANGELO, G. Functions of hyaluronan in wound repair.
Wound Repair Regen. 7, 79–89 (1999).
210. SELLERS, R. S., PELUSO, D. & MORRIS, E. A. The Effect of Recombinant
Human Bone Morphogenetic Protein-2 (rhBMP-2) on the Healing of Full-

229

Thickness Defects of Articular Cartilage*. J. Bone Jt. Surg. 79, 1452–1463 (1997).
211. Wakitani, S. et al. Mesenchymal cell-based repair of large, full-thickness defects
of articular cartilage. J. Bone Jt. Surg. 76, 579–592 (1994).
212. Németh, K. et al. Bone marrow stromal cells attenuate sepsis via prostaglandin
E(2)—dependent reprogramming of host macrophages to increase their
interleukin-10 production. Nat. Med. 15, 42–49 (2009).
213. Maggini, J. et al. Mouse Bone Marrow-Derived Mesenchymal Stromal Cells Turn
Activated Macrophages into a Regulatory-Like Profile. PLoS One 5, e9252 (2010).
214. Djouad, F. et al. Reversal of the immunosuppressive properties of mesenchymal
stem cells by tumor necrosis factor α in collagen-induced arthritis. Arthritis
Rheum. 52, 1595–1603 (2005).
215. Im, GI, Jung, NH, Tae, S. Chondrogenic differentiation of mesenchymal stem
cellsisolated from patients in late adulthood: the optimal conditions of growth
factors. Tissue Eng. 12, 527–536 (2006).
216. Scharstuhl, A, Schewe, B, Benz, K, Gaissmaier, C, Buhring, HJ, Stoop, R.
Chondrogenic potential of human adult mesenchymal stem cells is independent of
age or osteoarthritis etiology. Stem Cells 25, (2007).
217. Butnariu-Ephrat, M., Robinson, D., Mendes, D. G., Halperin, N. & Nevo, Z.
Resurfacing of Goat Articular Cartilage by Chondrocytes Derived From Bone
Marrow. Clin. Orthop. Relat. Res. 330, (1996).
218. Toda, A., Okabe, M., Yoshida, T. & Nikaido, T. Critical Review The Potential of
Amniotic Membrane / Amnion-Derived Cells for Regeneration of Various Tissues.
228, 215–228 (2007).

230

219. Zhang, X., Hirai, M., Cantero, S., Ciubotariu, R., Dobrila, L., Hirsh, A., Igura, K.,
Satoh, H., Yokomi, I., Nishimura, T., Yamaguchi, S., Yoshimura, K., Rubinstein,
P. and Takahashi, T. A. Isolation and characterization of mesenchymal stem cells
from human umbilical cord blood: Reevaluation of critical factors for successful
isolation and high ability to proliferate and differentiate to chondrocytes as
compared to mesenchymal stem cells fro. J. Cell. Biochem. 112, 1206–1218
(2011).
220. Riboh, J. C., Saltzman, B. M., Yanke, A. B. & Cole, B. J. Human Amniotic
Membrane–Derived Products in Sports Medicine: Basic Science, Early Results,
and Potential Clinical Applications. Am. J. Sports Med. 1–10 (2015).
doi:10.1177/0363546515612750
221. Miki, T. Amnion-derived stem cells: in quest of clinical applications. Stem Cell
Res. Ther. 2, 25 (2011).
222. Jung, K. et al. Science Immunomodulatory effects of human amniotic membranederived mesenchymal stem cells. 13, 23–31 (2012).
223. Magatti,M., De Munari,S., Vertua, E., Gibelli,L., Wengler, G., Parolini, O. Human
amnion mesenchyme harbors cells with allogeneic T-cell suppression and
stimulation capabilities. Stem Cells 26, 182–92 (2008).
224. Wolbank S, Peterbauer A, Fahrner M, Hennerbichler S, van Griensven M, Stadler
G, Redl H, G. C. Dose-dependent immunomodulatory effect of human stem cells
from amniotic membrane: a comparison with human mesenchymal stem cells from
adipose tissue. Tissue Engineeirng 13, 1173–83 (2007).
225. Rossi, D., Pianta, S., Magatti, M., Sedlmayr, P. & Parolini, O. Characterization of

231

the Conditioned Medium from Amniotic Membrane Cells: Prostaglandins as Key
Effectors of Its Immunomodulatory Activity. PLoS One 7, e46956 (2012).
226. Lam, J. et al. Osteochondral defect repair using bilayered hydrogels encapsulating
both chondrogenically and osteogenically pre-differentiated mesenchymal stem
cells in a rabbit model. Osteoarthr. Cartil. 22, 1291–1300 (2014).
227. Filardo, G. et al. Mesenchymal stem cells for the treatment of cartilage lesions:
from preclinical findings to clinical application in orthopaedics. Knee Surgery,
Sport. Traumatol. Arthrosc. 21, 1717–1729 (2013).
228. Ko, J.-Y., Kim, K.-I., Park, S. & Im, G.-I. In vitro chondrogenesis and in vivo
repair of osteochondral defect with human induced pluripotent stem cells.
Biomaterials 35, 3571–3581 (2014).
229. Reyes, R, Pec, MK, Sanchez, E, del Rosario, C, Delgado, A, Evora, C.
COMPARATIVE, OSTEOCHONDRAL DEFECT REPAIR: STEM CELLS
VERSUS CHONDROCYTES VERSUS BONE MORPHOGENETIC PROTEIN2, SOLELY OR IN COMBINATION. Eur. Cells Mater. 25, 351–365 (2013).
230. Jurgens, W. J. F. M. et al. One-Step Surgical Procedure for the Treatment of
Osteochondral Defects with Adipose-Derived Stem Cells in a Caprine Knee
Defect: A Pilot Study. Biores. Open Access 2, 315–325 (2013).
231. Spencer, N. D., Chun, R., Vidal, M. A., Gimble, J. M. & Lopez, M. J. In vitro
expansion and differentiation of fresh and revitalized adult canine bone marrowderived and adipose tissue-derived stromal cells. Vet. J. 191, 231–239 (2012).
232. Mackay, A. M. et al. Chondrogenic Differentiation of Cultured Human
Mesenchymal Stem Cells from Marrow. 4, 415–428 (1998).

232

233. Im, G.-I., Shin, Y.-W. & Lee, K.-B. Do adipose tissue-derived mesenchymal stem
cells have the same osteogenic and chondrogenic potential as bone marrowderived cells? Osteoarthritis Cartilage 13, 845–53 (2005).
234. Ogawa, R. et al. Osteogenic and chondrogenic differentiation by adipose-derived
stem cells harvested from GFP transgenic mice. Biochem. Biophys. Res. Commun.
313, 871–877 (2004).
235. Portmann-Lanz, C. B. et al. Placental mesenchymal stem cells as potential
autologous graft for pre- and perinatal neuroregeneration. Am. J. Obstet. Gynecol.
194, 664–73 (2006).
236. Pratama, G. et al. Changes in Culture Expanded Human Amniotic Epithelial
Cells&: Implications for Potential Therapeutic Applications. PLoS One 6, e26136
(2011).
237. Caruso, M., Evangelista, M., Parolini, O. Human Term Placental Cells: Phenotype,
Properties and New Avenues in Regenerative Medicine. IJMCM 1, 64–74 (2012).
238. Insausti, C. L., Blanquer, M., García-Hernández, A. M., Castellanos, G. &
Moraleda, J. M. Amniotic membrane-derived stem cells: immunomodulatory
properties and potential clinical application. Stem Cells Cloning 7, 53–63 (2014).
239. Miki, T., Marongiu, F., Dorko, K., Ellis, E. C. S. & Strom, S. C. Isolation of
amniotic epithelial stem cells. Curr. Protoc. Stem Cell Biol. Chapter 1, Unit 1E.3
(2010).
240. Winter, A. et al. Cartilage-Like Gene Expression in Differentiated Human Stem
Cell Spheroids A Comparison of Bone Marrow – Derived and Adipose Tissue –
Derived Stromal Cells. 48, 418–429 (2003).

233

241. Chung, D., Hayashi, K., Toupadakis, C. A., Wong, A. & Yellowley, C. E.
Osteogenic proliferation and differentiation of canine bone marrow and adipose
tissue derived mesenchymal stromal cells and the influence of hypoxia. Res. Vet.
Sci. 92, 66–75 (2012).
242. Chu, C. R. & Andriacchi, T. P. The Dance Between Biology, Mechanics, and
Structure: A Systems Based Approach to Developing Osteoarthritis Prevention
Strategies. J. Orthop. Res. n/a–n/a (2015). doi:10.1002/jor.22817
243. Musumeci, G., Aiello, F. C. & Szychlinska, M. A. Osteoarthritis in the XXIst
Century&: Risk Factors and Behaviours that Influence Disease Onset and
Progression. Int. J. Mol. Sci. 6093–6112 (2015). doi:10.3390/ijms16036093
244. Pawan K Gupta, Anjan K Das, A. C. and A. S. M. Mesenchymal stem cells for
cartilage repair in osteoarthritis. Stem Cell Res. Ther. 3, (2012).
245. Matuska, A., O’Shaughnessey, K., King, W. & Woodell-May, J. Autologous
solution protects bovine cartilage explants from IL-1beta- and TNF-alpha-induced
cartilage degradation. J. Orthop. Res. 31, 1929–1935 (2013).
246. Goldring, M. B. & Marcu, K. B. Cartilage homeostasis in health and rheumatic
diseases. Arthritis Res. Ther. 11, 224 (2009).
247. Pritzker, K. P. H. M. D. et al. Osteoarthritis cartilage histopathology&: grading and
staging. Osteoarthr. Cartil. 14, 13–29 (2006).
248. Yelin E, Cisternas M, Foreman A, Pasta D, M. L. H. National and state medical
expenditures and lost earnings attributable to arthritis and other rheumatic
conditions--United States, 2003. Morb. Mortal. Wkly. 56, 4–7 (2007).
249. Lawrence, R. C. Estimates of the prevalence of arthritis and other rheumatic

234

conditions in the United States. Arthritis Rheum. 58, 26–35 (2008).
250. Pelletier, JP, Martel-Pelletier, J, Altman, RD, Ghandur-Mnaymneh, L, Howell,
DS, Wossner Jr., J. Collagenolytic activity and collagen matrix breakdown of the
articular cartilage in the pond-nuki dog model of osteoarthritis. Arthritis Rheum.
26, 866–874 (1983).
251. Van Rooijen, N. & Sanders, a. Liposome mediated depletion of macrophages:
mechanism of action, preparation of liposomes and applications. Journal of
immunological methods 174, 83–93 (1994).
252. Rutgers, M., Saris, D. B. F., Dhert, W. J. A. & Creemers, L. B. Cytokine profile of
autologous conditioned serum for treatment of osteoarthritis, in vitro effects on
cartilage metabolism and intra-articular levels after injection. Arthritis Res. Ther.
12, 1–11 (2010).
253. Schlaak, J.F., Pfers, I., Meyer Zum Buschenfelde, K.H., Marker-Hermann, E.
Differential cytokine profiles in the synovial fluid of patients with osteoarthritis,
rheumatoid arthritis and seronegative spondylarthropathies. Clin. Exp. Rheumatol.
14, 155–162 (1996).
254. de Jager, W., te Velthuis, H., Prakken, B. J., Kuis, W. & Rijkers, G. T.
Simultaneous Detection of 15 Human Cytokines in a Single Sample of Stimulated
Peripheral Blood Mononuclear Cells. Clin. Diagn. Lab. Immunol. 10, 133–139
(2003).
255. Goldring, S. R. & Goldring, M. B. The Role of Cytokines in Cartilage Matrix
Degeneration in Osteoarthritis. Clin. Orthop. Relat. Res. 427, (2004).
256. Roszer, T. Understanding the Mysterious M2 Macrophage through Activation

235

Markers and Effector Mechanisms. Mediators Inflamm. 2015, 1–16 (2015).
257. Italiani, P. & Boraschi, D. From Monocytes to M1/M2 Macrophages: Phenotypical
vs. Functional Differentiation. Front. Immunol. 5, 514 (2014).
258. Silvestri, T., Pulsatelli, L., Dolzani, P., Facchini, A. & Meliconi, R. Elevated
serum levels of soluble interleukin-4 receptor in osteoarthritis. Osteoarthr. Cartil.
14, 717–719 (2006).
259. Wojdasiewicz, P, Poniatowski, L, Szukiewicz, D. The Role of Inflammatory and
Anti-Inflammatory Cytokines in the Pathogenesis of Osteoarthritis. Mediators
Inflamm. 2014, 19 (2014).
260. Scanzello, C. R. & Goldring, S. R. The role of synovitis in osteoarthritis
pathogenesis. Bone 51, 249–257 (2012).
261. Vazquez-Portalatin, N., Breur, G. J., Panitch, A. & Goergen, C. J. Accuracy of
ultrasound-guided intra- articular injections in guinea pig knees. Bone Jt. Res. 4,
1–5 (2015).
262. Attur, M., Krasnokutsky-Samuels, S., Samuels, J. & Abramson, S. B. Prognostic
biomarkers in osteoarthritis. Curr. Opin. Rheumatol. 25, 136–144 (2013).
263. Goldring, M. B. & Goldring, S. R. Articular cartilage and subchondral bone in the
pathogenesis of osteoarthritisTitle. Ann. N. Y. Acad. Sci. 1192, 230–237 (2010).
264. Deshmane, S. L., Kremlev, S., Amini, S. & Sawaya, B. E. Monocyte
Chemoattractant Protein-1 (MCP-1): An Overview. J. Interf. Cytokine Res. 29,
313–326 (2009).
265. Huebner, J. L. & Kraus, V. B. Assessment of the utility of biomarkers of
osteoarthritis in the guinea pig. Osteoarthr. Cartil. 14, 923–930 (2006).

236

266. Koch, A. E. et al. Macrophage Inflammatory Protein-Iβ: A C-C Chemokine in
Osteoarthritis. Clin. Immunol. Immunopathol. 77, 307–314 (1995).
267. van Meegeren, M. E. R. et al. IL-4 alone and in combination with IL-10 protects
against blood-induced cartilage damage. Osteoarthr. Cartil. 20, 764–772 (2012).
268. Dechanet, J., Rissoan, M.-C., Banchereau, J. & Miossec, P. Interleukin 4, but not
Interleukin 10, Regulates the Production of Inflammation Mediators by
Rheumatoid Synoviocytes. Cytokine 7, 176–183 (1995).
269. Singh, Y, Kahn, SA, Mohammad, O, Mazhar, A, Anjum, P, Athar, K. Th1/Th2
profile in patients suffering with osteoarthritis and rheumatoid arthritis: An
analytical observational study. J. Heal. Res. 1, 258–262 (2014).
270. Lubberts, E., Joosten, L. A. B., Helsen, M. M. A. & van den Berg, W. B.
REGULATORY ROLE OF INTERLEUKIN 10 IN JOINT INFLAMMATION
AND CARTILAGE DESTRUCTION IN MURINE STREPTOCOCCAL CELL
WALL (SCW) ARTHRITIS. MORE THERAPEUTIC BENEFIT WITH IL-4/IL10 COMBINATION THERAPY THAN WITH IL-10 TREATMENT ALONE.
Cytokine 10, 361–369 (1998).
271. Sakkas, L. I. & Platsoucas, C. D. The role of T cells in the pathogenesis of
osteoarthritis. Arthritis Rheum. 56, 409–24 (2007).
272. Hoeve, M. A. et al. Divergent effects of IL-12 and IL-23 on the production of IL17 by human T cells. Eur. J. Immunol. 36, 661–670 (2006).
273. Gomez, R., Villalvilla, A., Largo, R., Gualillo, O. & Herrero-Beaumont, G. TLR4
signalling in osteoarthritis[mdash]finding targets for candidate DMOADs. Nat Rev
Rheumatol 11, 159–170 (2015).

237

274. Zweers, M. C. et al. Celecoxib: considerations regarding its potential diseasemodifying properties in osteoarthritis. Arthritis Res. Ther. 13, 1–11 (2011).

238

